Journal of Pharmaceutical Sciences

A publication of the American Pharmaceutical Association

INDEX TO AUTHORS
INDEX TO SUBJECTS

VOLUME 60
JANUARY TO DECEMBER, 1971

Published monthly under the supervision of the Committee on Publications with the approval of the Board of Trustees

EDWARD G. FELDMANN
Editor

MARY H. FERGUSON
Associate Editor

SHELLY ELLIOTT
Production Editor

CHRISTINE L. BAILEY
Contributing Editor

L. LUAN CORRIGAN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

COMMITTEE ON PUBLICATIONS

WARREN E. WEAVER
Chairman
WILLIAM S. APPLE
GROVER C. BOWLES, JR.
CHARLES F. DAHL
JOHN H. NEUMANN

EDITORIAL ADVISORY BOARD

LYNN R. BRADY
EDWARD R. GARRETT
GERHARD LEVY
CARL J. LINTNER, JR.
W. LEWIS NOBLES
G. VICTOR ROSSI

© Copyright 1971 by the American Pharmaceutical Association

AUTHOR INDEX

A

Abbasi, M., *see* Nabih, I., 1251, 1411
Aboul-Enein, M. N., *see* Sam, J., 936, 1370
Abraham, D. J., Trojánek, J., Münzing, H. P., Fong, H. H. S., and Farnsworth, N. R., structure elucidation of maytenonic acid, a new triterpene from *Maytenus senegalensis* (Celastraceae), 1085
Abu-Mustafa, E. A., El-Bay, F. K. A., and Fayez, M. B. E., natural coumarins XII: umbelliprenin, a constituent of *Ammi majus* L. fruits, 788
Aczel, R., *see* Cohen, E. M., 193
Adams, H. J., *see* Caldwell, H. C., 1810
Adams, H. R., Smookler, H. H., Clarke, D. E., Jandhyala, B. S., Dixit, B. N., Ertel, R. J., and Buckley, J. P., clinicopathologic effects of chronic reserpine administration in mongrel dogs, 1134
Affonso, A., and Naik, V. R., microcrystallization methods for aspirin, mebutamate, and quinine sulfate, 1572
Ahmad, Y., Le Quesne, P. W., and Neuss, N., sewarine, a new phenolic akuammicine alkaloid from *Rhazya stricta*, 1581
Alam, A. S., and Parrott, E. L., effect of aging on some physical properties of hydrochlorothiazide tablets, 263
——and Parrott, E. L., effect of dissolution media on disintegration and dissolution of hydrochlorothiazide tablets, 795
Albonico, S. M., *see* Pecca, J. G., 650
Alphin, R. S., and Droppleman, D. A., new method for evaluating topical action of substances on gastric mucosa, 1314
An, R., *see* Ho, B. T., 1761
Anderson, A. D., *see* Erwin, V. G., 77
Anderson, J. C., *see* Foye, W. O., 1095
Araujo, O. E., *see* Warner, D. D., 863
Arora, V., *see* Malik, W. U., 1738
Arret, B., Johnson, D. P., and Kirshbaum, A., outline of details for microbiological assays of antibiotics: second revision, 1689
Arrigoni, E., *see* Benzi, G., 321, 1320
Attia, I. A., *see* Sina, A., 1544
Autian, J., *see* Beyerlein, A. M., 1317
——*see* Lawrence, W. H., 568, 1163
Averhart, V., *see* Kostenbauder, H. B., 1658
Axelson, J. E., *see* Nightingale, C. H., 145
Aynehchi, Y., desoxypodophyllotoxin, the cytotoxic principle of *Callitris columellaris* f. Muell, 121
Azeza, N., *see* Kapoor, A., 956

B

Babb, A. L., *see* Farrell, P. C., 1471
Bafna, S. L., *see* Kamath, B. R., 319
Bagnasco, G., *see* Cometti, A., 1074
Bailey, K., analysis of NMR spectra for rotamer populations of dimethoxyamphetamines, 1232
Balbaa, S. I., *see* Karawya, M. S., 381
Ballard, B. E., and Menczel, E., multiple-dosing drug kinetics: nomographic method of estimating the number of doses needed to approach within a fixed percent of asymptotic minimum drug level, 406
Bandyopadhyay, A., *see* Banerjee, S., 153
Bane, J. M., Jr., *see* Hiestand, E. N., 758
Banerjee, S., Bandyopadhyay, A., Bhattacharjee, R. C., Mukherjee, A. K., and Halder, A. K., serum levels of chloramphenicol in children, rhesus monkeys, and cats after administration of chloramphenicol palmitate suspension, 153
Barfknecht, C. F., Long, J. P., and Benz, F. W., aryl-*n*-methyl-2-pyridiniumketoxime acetylcholinesterase reactivators, 138
——Smith, R. V., Nichols, D. E., Leseney, J. L., Long, J. P., and Engelbrecht, J. A., chemistry and pharmacological evaluation of 1-phenyl-2-propanols and 1-phenyl-2-propanones, 799
Barnard, A. J., Jr., *see* Speights, R. M., 748
Barr, F. S., *see* Driscoll, R. C., 1492
Barr, W. H., *see* Strahl, N. R., 278
Barry, B. W., and Grace, A. J., investigation of semisolid lipophilic preparations by small strain and continuous shear viscometry and their application to texture profile, 814
——and Grace, A. J., rheological and sensory evaluation of work softening and recovery of pharmaceutical white soft paraffins, 1198
——and Saunders, G. M., direct gas chromatographic analysis of long-chain alcohols and alkyltrimethylammonium bromides, 645
Barry, H., III, *see* Jaffe, J. M., 1646
Bartlett, J., *see* Tansy, M. F., 81
Basmadjian, G., and Floss, H. G., microdegradation procedure for radioactive peptide ergot alkaloids, 949
Bates, T. R., *see* De Cato, L., Jr., 140
Beamer, R. L., and Brown, W. D., stereospecific hydrogenations V: hydrogenation rates using palladium-on-poly-*S*-leucine and palladium-on-poly-*S*-valine, 583
Begosh, P. P., *see* Warren, R. J., 801
Beierwaltes, W. H., *see* Holcomb, G. N., 390
Bell, J. H., Hartley, P. S., and Cox, J. S. G., dry powder aerosols I: a new powder inhalation device, 1559
Beltrame, P., *see* Roll, D. B., 484
Bender, A. D., *see* Kormendy, C. G., 167
Benet, L. Z., and Turi, J. S., use of general partial fraction theorem for obtaining inverse Laplace transforms in pharmacokinetic analysis, 1593
——Orr, J. M., Turner, R. H., and Webb, H. S., effect of buffer constituents and time on drug transfer across *in vitro* rat intestine, 234
——*see* Nayak, R. K., 1508
Benney, T. L., and Hamlin, W. E., pharmaceutical sciences—1970: literature review of pharmaceutics, 959
Benz, F. W., *see* Barfknecht, C. F., 138
Benzi, G., Berté, F., Arrigoni, E., Ferrara, A., and Sanguinetti, L., action of antibiotics on respiratory tract IV: tetracyclines and 4-epiderivatives, 321
——Manzo, L., De Bernardi, M., Ferrara, A., Sanguinetti, L., Arrigoni, E., and Berté, F., action of lysergide, ephedrine, and nimergoline on brain metabolizing activity, 1320
——*see* Berté, F., 805
Bernstein, D. F., Higuchi, W. I., and Ho, N. F. H., kinetics of flocculation and/or coalescence of dilute oil-in-water emulsions, 690
Berté, F., Manzo, L., De Bernardi, M., and Benzi, G., distribution of ampicillin administered orally in three different forms in rabbit, 805
——*see* Benzi, G., 321, 1320
Beyer, W. F., and Smith, D. L., unexpected variable in the USP–NF rotating basket dissolution test, 496
——and Smith, E. W., automation of NF method I–USP dissolution-rate test, 1556
Beyerlein, A. M., Sheth, B. S., and Autian, J., use of thermal gravimetric analysis in sorption studies I: interaction of selected liquid compounds with nylon, 1317
Bhacca, N. S., *see* Sharma, R. K., 1677
Bhansali, K. G., Lach, J. L., and Clifton, J. A., MAO activity in normal, cirrhotic, and noncirrhotic abnormal human liver, 611
Bhat, C. V., *see* Kamath, B. R., 319
Bhattacharjee, R. C., *see* Banerjee, S., 153
Bhattacharya, S. K., *see* Ghosal, S., 1209
Biggs, J. D., *see* Wallace, J. E., 1346
Bighley, L. D., *see* Fritz, B., 1617
Biles, J. A., *see* Haleblian, J. K., 1458, 1488
Billman, J. H., and Tonnis, J. A., substituted aralkyl aldehydes: preparation and antitumor evaluation, 1188
Bilous, R., Koehler, E., and Windheuser, J. J., interference in GLC determination of iodoamino acids in hydrolysis products of thyroid extracts, 1270
Bisaillon, S., and Tawashi, R., influence of fluid motion in dissolution-rate determinations, 1874
Bischoff, K. B., Dedrick, R. L., Zaharko, D. S., and Longstreth, J. A., methotrexate pharmacokinetics, 1128
Bittner, S., *see* Schaeffer, H. J., 1184
Blake, M. I., Makris, K., and Hunt, J., determination of sodium *p*-aminosalicylate in the presence of *m*-aminophenol, 1694
——*see* Carlstedt, B. C., 1661
——*see* Hsiao, C. H., 1847
Blakely, J., *see* Castor, G. B., 1578
Boehme, D. H., *see* West, N., 953
Bojarski, J. T., *see* Garrett, E. R., 1145
Boots, M. R., *see* Boots, S. G., 614
Boots, S. G., Boots, M. R., and Guyer, K. E., hypocholesterolemic agents I: 3-methyl-4-phenylbutenoic acids, 614
Bopp, R. J., *see* Nash, J. F., 1062
Borazan, H. N., *see* Goyan, F. M., 117
Boreham, D. R., *see* Dell, D., 1368
Born, G. S., *see* Meeks, M. J., 482
——*see* Rowles, S. G., 725
Borodkin, S., and Sundberg, D. P., polycarboxylic acid ion-exchange resin adsorbates for taste coverage in chewable tablets, 1523
——*see* Farhadieh, B., 209, 212
——*see* Yunker, M. H., 52
Bottari, F., *see* Saski, W., 854
Bowman, F. W., White, M., and Calhoun, M. P., collaborative study of aerobic media for sterility testing by membrane filtration, 1087
——White, M., and Lyles, R. L., microbial contamination of nonsterile antibiotic market samples: a survey, 1099
Boyd, C. M., *see* Holcomb, G. N., 390
Boyes, R. N., *see* Gibaldi, M., 1338
Brady, L. R., *see* Gaylord, M. C., 1503
Braet, W. W., *see* Lewi, P. J., 1079
Breault, G. O., *see* Sinsheimer, J. E., 255
Breunig, H. L., *see* Sampson, C. B., 955
Broadlick, D. E., *see* Sampson, C. B., 955
Brochmann-Hanssen, E., Fu, C.-C., Leung, A. Y., and Zanati, G., opium alkaloids X: biosynthesis of 1-benzylisoquinolines, 1672
——Fu, C.-C., and Misconi, L. Y., opium alkaloids XI: biosynthesis of aporphines in *Papaver somniferum*, 1880
——Fu, C.-C., and Zanati, G., opium alkaloids IX: detection of coreximine in *Papaver somniferum* L. based on its biosynthesis from reticuline, 873
Brockenton, R. E., *see* Demaree, G. E., 1743
Brooks, J. D., *see* Speights, R. M., 748
Brower, J. F., *see* Dow, M. L., 298
Brown, N. H., and Portmann, G. A., analysis of phenylephrine and phenylpropanolamine hydrochlorides in combination, 1229
Brown, Sister J. M., *see* Doorenbos, N. J., 1234
Brown, W. D., *see* Beamer, R. L., 583
Bruce, R. B., Turnbull, L. B., and Newman, J. H., metabolism of methocarbamol in the rat, dog, and human, 104
Bruno, G. A., *see* Holcomb, G. N., 390
Bryan, H., *see* Garth, M. A., 63
Bryant, R., Burger, F. J., Henry, R. L., and Trenk, F. B., semiautomated, simultaneous assay of thiamine, riboflavin, pyridoxine, and niacinamide in multivitamin preparations, 1717
——Burger, F. J., and Trenk, F. B., automated assay of single tablets of chloral betaine, 1721
Buchalter, L., identification of polymeric 5,7,3′,4′-tetrahydroxyflavan-3,4-diol from tannin extract of powdered cassia bark, Saigon, cinnamon USP, *Cinnamomum loureiril* Nees, family Lauraceae, 144
Buckley, J. P., *see* Adams, H. R., 1134
——*see* Cannon, J. G., 1534
——*see* Sofia, R. D., 1240

Buddenhagen, J. D., *see* Farhadieh, B., 209, 212
Bullock, F. J., *see* Coffey, J. J., 1623
Bundgaard, H., kinetic demonstration of a metastable intermediate in isomerization of penicillin to penicillenic acid in aqueous solution, 1273
Burckhalter, J. H., *see* De Leenheer, A., 1238
——*see* Sinsheimer, J. E., 141
Burger, F. J., *see* Bryant, R., 1717, 1721
Burger, J. M., and Nash, R. A., simplified automatic determination of *in vitro* drug dissolution rates using direct concentration recording, 300
Burkman, A. M., *see* Van Tyle, W. K., 1736
Burruss, R. A., *see* Lowenthal, W., 1325
Bylow, A., *see* Warner, C., 1548

C

Cadwallader, D. E., *see* Phillips, J. R., 1033
——*see* Ullah, I., 230, 1496
Caldwell, H. C., Adams, H. J., Jones, R. G., Mann, W. A., Dittert, L. W., Chong, C. W., and Swintosky, J. V., enamine prodrugs, 1810
——Finkelstein, J. A., Goldman, P. P., Groves, W. G., Cinalli, P. J., Long, J. S., and Evers, P. W., spasmolytics IV: azo and azoxy derivatives of 3-tropanyl 2,3-diarylacrylates, 1102
Calhoun, M. P., *see* Bowman, F. W., 1087
Cammarata, A., *see* Peradejordi, F., 576
Campaigne, E., and Knapp, D. R., structural analogs of lysergic acid, 809
Cannon, J. G., Yang, K. W., Rodriguez, M., and Buckley, J. P., bis-quaternary ammonium compounds: derivatives and congeners of bicyclo[2.2.2]octane, 1534
Carbone, J. J., *see* Coutinho, C. B., 1014
Carlstedt, B. C., Crespi, H. L., Blake, M. I., and Katz, J. J., biosynthesis of deuterated benzylpenicillins II: isolation and characterization of a highly deuterated benzylpenicillin, 1661
Carrano, R. A., *see* Heindel, N. D., 703
Carstensen, J. T., and Su, K. S. E., nature of bonding in montmorillonite adsorbates I: surface adsorption, 733
Castor, G. B., Kantor, N., Knoll, E., Blakely, J., Nielsen, J. K., Randolph, J. O., and Kirshbaum, A., characteristics of a highly purified pyrogenic lipopolysaccharide, 1578
Casy, A. F., Hassan, M. M. A., and Wu, E. C., conformation of some acetylcholine analogs as solutes in deuterium oxide and other solvents, 67
Ceprini, M. Q., *see* Stefanovich, V., 781
Chafetz, L., specificity of spectrophotometric determination of ephedrine and other phenalkanolamine drugs as benzaldehydes after periodate oxidation, 291
——stability-indicating assay methods for drugs and their dosage forms, 335
——Daly, R. E., Schriftman, H., and Lomner, J. J., selective colorimetric determination of acetaminophen, 463
——Gaglia, C. A., Jr., Chen, T., and Moran, C., facile isolation of phenylephrine from syrups, 314
——*see* Penner, M. H., 1388
Chandra, D., *see* Sharma, V. N., 1262
Chang, C. T., *see* Huang, C. L., 1895
Chang, Y., and Malone, M. H., anti-inflammatory and liver sulfhydryl content-altering effects of certain nonsteroids in the rat, 416
Chappelow, C. C., Jr., and Rost, W. J., *N*-phenylacetylsulfamide: sulfone analog of anticonvulsant acylureas, 620
Chatten, L. G., and Krause, S. I., colorimetric assay of tetracycline antibiotics, 107
——Locock, R. A., and Krause, R. D., use of ceric sulfate and cupric perchlorate for titrimetric analyses of phenothiazine derivatives, 588
——Myers, G. E., Khullar, K. K., and Yager, G. A., antibacterial activity of certain bases against *Escherichia coli* and *Staphylococcus aureus*, 316
Chawdry, I., *see* Weiner, N. D., 425
Chen, C.-H., Soine, T. O., and Lee, K.-H., total synthesis of (±)-bisnorargemonine, 1634
Chen, F., *see* Johnson, B. J., 330
Chen, T., *see* Chafetz, L., 314
Cheng, C. C., structure and antimalarial activity of aminoalcohols and 2-(*p*-chlorophenyl) - 2 - (4 - piperidyl)tetrahydrofuran, 1596
Cheripko, J. A., *see* Coutinho, C. B., 1014
Chernov, H. I., *see* Yeh, S. Y., 469
Chiou, W. L., mechanism of increased rates of dissolution and oral absorption of chloramphenicol from chloramphenicol–urea solid dispersion system, 1406
——and Niazi, S., phase diagram and dissolution-rate studies on sulfathiazole–urea solid dispersions, 1333
——and Riegelman, S., absorption characteristics of solid dispersed and micronized griseofulvin in man, 1376
——and Riegelman, S., increased dissolution rates of water-insoluble cardiac glycosides and steroids *via* solid dispersions in polyethylene glycol 6000, 1569
——and Riegelman, S., pharmaceutical applications of solid dispersion systems, 1281
——and Smith, L. D., solid dispersion approach to the formulation of organic liquid drugs using polyethylene glycol 6000 as a carrier, 125
Cho, M. J., Mitchell, A. G., and Pernarowski M., interaction of bishydroxycoumarin with human serum albumin, 196
——Mitchell, A. G., and Pernarowski, M., interaction of bishydroxycoumarin with polyvinylpyrrolidone, 720
Chong, C. W., *see* Caldwell, H. C., 1810
Choulis, N. H., and Harrell, W. B., TLC analysis of Mannich bases derived from indolizines, 486
Christian, J. E., *see* Morris, C. H., 790
——*see* Rowles, S. G., 725
Christian, R. P., *see* Coutinho, C. B., 1014
Christiansen, R. G., *see* Singh, B., 491
Christopherson, J., *see* Haleblian, J., 541
Chu, R. S. F., *see* Foye, W. O., 1839
Cinalli, P. J., *see* Caldwell, H. C., 1102
Clarke, D. E., *see* Adams, H. R., 1134
Clayton, J. D., *see* Shealy, Y. F., 1426
Clifton, J. A., *see* Bhansali, K. G., 611
Cochran, T. G., Wareham, D. V., and Huitric, A. C., absolute configuration of *cis*- and *trans*-2-(*o*-bromophenyl)cyclohexanols and (+)-*cis*-2-(*o*-bromophenyl)-cyclohexylamine, 180
Cocolas, G. H., Robinson, E. C., Dewey, W. L., and Spaulding, T. C., preparation and activity of β-substituted acetylcholine iodides, 1749
Coffey, J. J., Bullock, F. J., and Schoenemann, P. T., numerical solution of nonlinear pharmacokinetic equations: effects of plasma protein binding on drug distribution and elimination, 1623
Cohen, A. I., *see* Dreyfuss, J., 826
Cohen, E. M., polarographic determination of ethacrynic acid, 1702
——and Aczel, R., reactions of germine-3,16-diacetate in aqueous solution, 193
Cohen, S. D., Nicholas, B. A., and Jenkins, H. J., classification of nicotine block at neuromuscular junction, 1740
Colaizzi, J. L., *see* Jaffe, J. M., 1646
Combs, G., *see* Glasser, A. C., 126
Comer, J. P., *see* Sampson, C. B., 955
Cometti, A., Bagnasco, G., and Maggi, N., GLC analysis of multicomponent suppository formulations, 1074
Conard, G. J., Haavik, C. O., and Finger, K. F., binding of 5,5-diphenylhydantoin and its major metabolite to human and rat plasma proteins, 1642
Conway, M. W., *see* Kaul, P. N., 93
Counsell, R. E., *see* Holcomb, G. N., 390
Coutinho, C. B., Spiegel, H. E., Kaplan, S. A., Yu, M., Christian, R. P., Carbone, J. J., Symington, J., Cheripko, J. A., Lewis, M., Tonchen, A., and Crews, T., kinetics of absorption and excretion of levodopa in dogs, 1014
Coutts, R. T., Hubbard, J. W., Midha, K. K., and Prasad, K., synthesis and properties of some hypotensive *N*-alkylaminopropionic esters and *N,N*-dialkylaminopropionic esters and their hydroxamic acids, 28
Cox, J. S. G., Woodard, G. D., and McCrone, W. C., solid-state chemistry of cromolyn sodium (disodium cromoglycate), 1458
——*see* Bell, J. H., 1559
Cox, R. H., *see* Zia, H., 45, 89
Coyne, E., *see* Lowary, L. R., 638
Crawford, R. R., and Esmerian, O. K., effect of plasticizers on some physical properties of cellulose acetate phthalate films, 312
Crescuolo, P., *see* Watson, J. R., 454
Crespi, H. L., *see* Carlstedt, B. C., 1661
Cressman, W. A., and Sumner, D., the dog as a quantitative model for evaluation of nondisintegrating sustained-release tablets, 132
Crew, M. C., *see* Leinweber, F.-J., 1512
Crews, T., *see* Coutinho, C. B., 1014
Crochet, R. A., *see* Saenz, R. V., 1266
Crouthamel, W. G., Tan, G. H., Dittert, L. W., and Doluisio, J. T., drug absorption IV: influence of pH on absorption kinetics of weakly acidic drugs, 1160
Cummings, B., *see* Rao, K. V., 1725
Cummins, L. M., Martin, Y. C., and Scherfling, E. E., serum and urine levels of ethchlorvynol in man, 261

D

Daly, R. E., *see* Chafetz, L., 463
Danish, F. Q., and Parrott, E. L., effect of concentration and size of lubricant on flow rate of granules, 752
——and Parrott, E. L., flow rates of solid particulate pharmaceuticals, 548
Danowski, T. S., Folkers, K., Wissinger, H. A., Hohmann, T. C., Gerneth, J. A., and Vester, J. W., hexahydrocoenzyme Q_4 in pseudohypertrophic muscular dystrophy, 640
Darby, T. D., *see* Fakouhi, T., 1045
D'Arcy, P. F., Griffin, J. P., Jenkins, J. S., Kirk, W. F., and Peacock, A. W. C., sustained-release formulation of prednisolone administered orally to man, 1028
Darling, C. M., and Jenkins, H., aminotetrahydrofuranol derivatives, 1107
Davidson, I. W. F., Miller, H. S., Jr., and Di Carlo, F. J., pharmacodynamics and biotransformation of pentaerythritol tetranitrate in man, 274
Davies, W. L., and Gloor, W. T., Jr., batch production of pharmaceutical granulations in a fluidized bed I: effects of process variables on physical properties of final granulation, 1869
Davis, R. E., Hartman, C. W., and Fincher, J. H., dialysis of ephedrine and pentobarbital from whole human saliva and simulated saliva, 429
Davis, S. S., viscoelastic properties of pharmaceutical semisolids IV: destructive oscillatory testing, 1356
——viscoelastic properties of pharmaceutical semisolids III: nondestructive oscillatory testing, 1351
Davis, W. W., and Kreutler, C. J., normal and promoted GI absorption of water-soluble substances II: absorption of vitamin B_{12} from ligated stomach and intact intestine of the rat, 1651
——*see* Kreutler, C. J., 1835
Dearden, J. C., and Tomlinson, E., correction for effect of dilution on diffusion through a membrane, 1278
De Bernardi, M., *see* Benzi, G., 1320
——*see* Berté, F., 805
De Cato, L., Jr., Stoll, R. G., Bates, T. R., and Malone, M. H., further investigation of reserpine and deoxycholic acid potentiation, 140
Dedrick, R. L., *see* Bischoff, K. B., 1128
De Leenheer, A., and Heyndrickx, A., identification of a major metabolite of nortriptyline in human urine, 1403
——Shum, Y. Y., Sinsheimer, J. E., and Burckhalter, J. H., unexpected formation of thioacridone and its spectral properties, 1238
Dell, D., Boreham, D. R., and Martin, B. K., estimation of 4-butoxyphenylacetohydroxamic acid utilizing the Lossen rearrangement, 1368
DeLuca, P. P., instrumented pilot plant lyophilizer: its versatility in developing and programming production cycles, 774
De Marchi, F., Tamagnone, G. F., and Torrielli, M. V., synthesis and pharmacological evaluation of 1,4-dihydro-2*H*-3,1-benzoxazin-2-one derivatives, 1757
Demarco, P. V., *see* Thakkar, A. L., 652
Demaree, G. E., Brockenton, R. E., Heiffer, M. H., and Rothe, W. E., antagonism of norepinephrine responses of isolated

rabbit aorta by aliphatic sulfur-containing amines, 1743
de Silva, J. A. F., and Strojny, N., determination of flurazepam and its major biotransformation products in blood and urine by spectrophotofluorometry and spectrophotometry, 1303
Dewey, W. L., *see* Cocolas, G. H., 1749
Diamond, L., *see* Glasser, A. C., 127
DiBernardo, F., *see* Warner, C., 1548
Di Carlo, F. J., *see* Davidson, I. W. F., 274
——*see* Leinweber, F.-J., 1512, 1516
Diliberto, J. J., *see* Wojtowicz, P. F., 1385
Discher, C. A., *see* Janssen, R. W., 798
Dittert, L. W., *see* Caldwell, H. C., 1810
——*see* Crouthamel, W. G., 1160
——*see* Doluisio, J. T., 715
Dixit, B. N., *see* Adams, H. R., 1134
Dobrecky, J., *see* Pecca, J. G., 650
Doluisio, J. T., LaPiana, J. C., and Dittert, L. W., pharmacokinetics of ampicillin trihydrate, sodium ampicillin, and sodium dicloxacillin following intramuscular injection, 715
——*see* Crouthamel, W. G., 1160
——*see* Kojima, S., 1639
Donahue, J. J., *see* Oliveri-Vigh, S., 1851
Doorenbos, N. J., and Brown, Sister J. M., 4,17α-dimethyl-4-aza-5α-androstan-17β-acetate and related azasteroids, 1234
——Scott, J., and Vaidya, S. S., derivatives of 17a-aza-D-homo-5-androsten-3β-ol, 1236
——*see* Fetterman, P. S., 1246
——*see* Sharma, R. K., 1677
——*see* Slatkin, D. J., 1891
Dorsey, W. S., and Easterly, W. D., Jr., synthesis and anti-inflammatory activity of fluorinated benzamides, 1723
Doukas, P. H., and Speaker, T. J., azulene analogs of pharmacologic agents I: amides, 184
——and Speaker, T. J., azulene analogs of pharmacologic agents II: amides, 479
Dow, M. L., Kirchhoefer, R. D., and Brower, J. F., rapid identification and estimation of gitoxin in digitoxin and digoxin tablets by TLC, 298
Dreyfuss, J., and Cohen, A. I., identification of 7-hydroxyfluphenazine as major metabolite of fluphenazine-^{14}C in the dog, 826
——Ross, J. J., Jr., and Schreiber, E. C., biological disposition and metabolic fate of fluphenazine-^{14}C in the dog and rhesus monkey, 821
——Ross, J. J., Jr., and Schreiber, E. C., excretion and biotransformation of the enanthate ester of fluphenazine-^{14}C by the dog, 829
Driscoll, R. C., Barr, F. S., Gragg, B. J., and Moore, G. W., determination of therapeutic blood levels of methamphetamine and pentobarbital by GC, 1492
Droppleman, D. A., *see* Alphin, R. S., 1314
Dunham, N. W., *see* Lowary, L. R., 638
Duvall, R. N., *see* Gold, G., 922

E

Easterly, W. D., Jr., *see* Dorsey, W. S., 1723
Eide, G. J., *see* Erwin, V. G., 77
Eisen, H., *see* Sunwoo, C., 238
Eksborg, S., Persson, B., Vessman, J., and Enell, B., determination of a quaternary ammonium compound, emepronium bromide, in human urine by an ion-pair extraction method, 475
El-Bassiouni, E. A., *see* Kudla, R. M., 1065
——*see* Mattocks, A. M., 1767
El-Bay, F. K. A., *see* Abu-Mustafa, E. A., 788
Eldawy, M. A., *see* Oauf, A. A. A., 158
Elison, C., Lien, E. J., Zinger, A. P., Hussain, M., Tong, G. L., and Golden, M., CNS activities of lactam derivatives, 1058
Ellis, C. A., *see* Villani, F. J., 1586
Ellis, M., *see* Skinner, W. A., 643
Elveback, L., *see* Kennedy, C. C., 1139
Enell, B., *see* Eksborg, S., 475
Engelbrecht, J. A., *see* Barfknecht, C. F., 799
Englert, L. F., *see* Ho, B. T., 1761
Ernst, R. R., *see* Mogenhan, J. A., 222
Ertel, R. J., *see* Adams, H. R., 1134
Erwin, V. G., Anderson, A. D., and Eide, G. J., enhancement of fatty acid oxidation and medium-chain fatty acyl coenzyme A synthetase by adenine nucleotides in rat heart homogenates, 77
Esmerian, O. K., *see* Crawford, R. R., 312
Ethier, J. C., *see* Neville, G. A., 497
Evers, P. W., *see* Caldwell, H. C., 1102

F

Fakouhi, T., Darby, T. D., and McCutcheon, R. S., cardiovascular effects of bulbocapnine, 1045
Farag, H. H., *see* Oauf, A. A. A., 158
Farber, P., *see* Tansy, M. F., 81
Farhadieh, B., Borodkin, S., and Buddenhagen, J. D., drug release from methyl acrylate–methyl methacrylate copolymer matrix I: kinetics of release, 209
——Borodkin, S., and Buddenhagen, J. D., drug release from methyl acrylate–methyl methacrylate copolymer matrix II: control of release rate by exposure to acetone vapor, 212
Farnsworth, N. R., *see* Abraham, D. J., 1085
——*see* Sofia, R. D., 1240
Farrell, P. C., Popovich, R. P., and Babb, A. L., *in vitro* dynamic dialysis technique to determine solute–protein binding interactions, 1471
Fayez, M. B. E., *see* Abu-Mustafa, E. A., 788
Feeter, D. K., Jacobs, M. F., and Rawlings, H. W., assay for vitamins D_2 and D_3 in the presence of tocopherols (vitamin E) and vitamin A, 913
Feldman, J. A., and Patel, V. U., colorimetric determination of acetyl sulfisoxazole in the presence of its hydrolysis products, sulfisoxazole and acetic acid, 1696
——Frank, S. G., and Holmes, T. J., Jr., determination of di-(2-ethylhexyl) sodium sulfosuccinate and related dialkyl esters in aqueous solutions by the ferric hydroxamate procedure, 920
Feldman, S., Gibaldi, M., and Reinhard, M., estimation of diffusion coefficients and molecular weights of interacting colloids from dissolution-rate data, 1105
——*see* Gibaldi, M., 1338
Fell, J. T., and Newton, J. M., assessment of compression characteristics of powders, 1428
——and Newton, J. M., effect of particle size and speed of compaction on density changes in tablets of crystalline and spray-dried lactose, 1866
Felmeister, A., *see* Lordi, N. G., 933
——*see* Weiner, N. D., 425
Ferguson, G. G., *see* Stull, R. E., 1221
Ferguson, N. M., *see* Stull, R. E., 1221
Ferrara, A., *see* Benzi, G., 321, 1320
Fetterman, P. S., Keith, E. S., Waller, C. W., Guerrero, O., Doorenbos, N. J., and Quimby, M. W., Mississippi-grown *Cannabis sativa* L.: preliminary observation on chemical definition of phenotype and variations in tetrahydrocannabinol content *versus* age, sex, and plant part, 1246
Fincher, J. H., *see* Davis, R. E., 429
——*see* Javaid, K. A., 1709
——*see* Miller, L. G., 1733
——*see* Sadik, F., 916
——*see* Waggoner, W. G., 1830
Finger, K. F., *see* Conard, G. J., 1642
Fink, M. L., *see* Sinsheimer, J. E., 141
Finkelstein, J. A., *see* Caldwell, H. C., 1102
Fives, W. P., *see* Heindel, N. D., 703
Floss, H. G., *see* Basmadjian, G., 949
Flynn, G. L., structural approach to partitioning: estimation of steroid partition coefficients based upon molecular constitution, 345
——and Roseman, T. J., membrane diffusion II: influence of physical adsorption on molecular flux through heterogeneous dimethylpolysiloxane barriers, 1788
——and Smith, E. W., membrane diffusion I: design and testing of a new multifeatured diffusion cell, 1713
Folkers, K., *see* Danowski, T. S., 640
Foltz, E. L., *see* Kwan, K. C., 678
Fong, H. H. S., *see* Abraham, D. J., 1085
Forcier, G. A., Mushinsky, R. F., and Wagner, R. L., Jr., spectrophotometric determination of pyrantel in pyrantel pamoate bulk samples and pharmaceutical formulations, 111
Forist, A. A., and Judy, R. W., comparative pharmacokinetics of chlorphenesin carbamate and methocarbamol in man, 1686
Forlano, A. J., sterically hindered esters of vitamin A III: biological availability of vitamin A from sterically hindered esters, 616
Foye, W. O., and Kim, C. M., metal-binding abilities of radioprotective organic thiosulfates, 151
——Anderson, J. C., and Sane, J. N., sulfur-containing derivatives of β-phenethylamine: methanesulfonamides, 1095
——Chu, R. S. F., Shah, K. A., and Parsons, W. H., metabolism of the radioprotective agent triammonium 2-dithiocarbamyl-3-dithiocarbonylthiopropanoate in the mouse, 1839
Frank, S. G., *see* Feldman, J. A., 920
Free, S. M., *see* Rosen, E., 1900
French, W. N., *see* Matsui, F., 287
Friberg, S., Rydhag, L., and Jederström, G., liquid crystalline phases in aerosol formulations I: phase equilibria in propellant compositions, 1883
Fritchie, G. E., *see* Ho, B. T., 634, 1761
Fritz, B., Lach, J. L., and Bighley, L. D., solubility analysis of multicomponent systems capable of interacting in solution, 1617
Fu, C.-C., *see* Brochmann-Hanssen, E., 873, 1672, 1880
Fujita, T., *see* Naito, S., 1257
Fukui, K., *see* Naito, S., 249
Fung, H.-L., and Higuchi, T., molecular interactions and solubilities of polar nonelectrolytes in nonpolar solvents, 1782

G

Gaglia, C. A., Jr., *see* Chafetz, L., 314
Gardner, J. O., *see* Solo, A. J., 1089
Garg, B. D., *see* Kovacs, K., 1576
Garg, H. G., and Prakash, C., potential antidiabetics VIII: 4-arylhydrazone-*N'*-guanylnitrate-3-methyl-2-pyrazolin-5-ones, 4-arylazo-*N'*-guanylnitrate-3,5-dimethylpyrazoles, and 4-arylazo-*N'*-guanylnitrate-3,5-diphenylpyrazoles, 323
——*see* Malik, W. U., 1738
Garg, L. C., pH-dependent hydrolysis of 4,4'-diformamidodiphenylsulfone, 606
Garner, D. D., *see* Garson, L. R., 1083
Garrett, E. R., and Schnelle, K., separation and spectrofluorometric assay of the β-adrenergic blocker sotalol from blood and urine, 833
——and Weber, D. J., metal complexes of thiouracils II: solubility analyses and spectrophotometric investigations, 845
——and Won, C. M., prediction of stability in pharmaceutical preparations XVI: kinetics of hydrolysis of canrenone and lactonization of canrenoic acid, 1801
——Bojarski, J. T., and Yakatan, G. J., kinetics of hydrolysis of barbituric acid derivatives, 1145
——Lippold, B. C., and Mielck, J. B., kinetics and mechanisms of lactonization of coumarinic acids and hydrolysis of coumarins I, 396
——*see* Lippold, B. C., 1019
Garrett, R. D., *see* Sullivan, G., 1727
Garson, L. R., and Garner, D. D., unsymmetrical carbonates as potential long-lasting insect repellents, 1083
——and Kirchner, L. K., organosilicon entities as prophylactic and therapeutic agents, 1113
Garth, M. A., Bryant, H., Kramer, J., and Kirshbaum, A., survey of a laboratory building for airborne antibiotics, 63
Gaut, Z. N., and Solomon, H. M., inhibition of nicotinate phosphoribosyl transferase by nonsteroidal anti-inflammatory drugs: a possible mechanism of action, 1887
——*see* Schwartz, M. A., 1500
Gautieri, R. F., *see* Iuliucci, J. D., 420
——*see* O'Hara, G. P., 473
——*see* Mitala, J. J., 1878
Gaylord, M. C., and Brady, L. R., comparison of pigments in carpophores and saprophytic cultures of *Paxillus panuoides* and *Paxillus atrotomentosus*, 1503
German, V. F., N^{α},N^{α}-dimethylhistamine, the hypotensive principle of the sponge *Ianthella* sp., 495

——isolation and characterization of cytotoxic principles from *Hyptis verticillata* Jacq., 649
Gerneth, J. A., *see* Danowski, T. S., 640
Gerraughty, R. J., *see* Lausier, J. M., 1906
——*see* Needham, T. E., Jr., 258, 565
Ghosal, S., Mazumder, U. K., and Bhattacharya, S. K., chemical and pharmacological evaluation of *Banistereopsis argentea* Spring ex Juss, 1209
Giaquinto, A. R., *see* Welles, H. L., 1212
Gibaldi, M., and Weintraub, H., some considerations as to the determination and significance of biologic half-life, 624
——Boyes, R. N., and Feldman, S., influence of first-pass effect on availability of drugs on oral administration, 1338
——*see* Feldman, S., 1105
——*see* Mayersohn, M., 225, 326, 1813
——*see* Nightingale, C. H., 145, 1360
Gibson, C. A., *see* LaRocca, J. P., 74
Gisvold, O., *see* Kriesel, D. C., 1250
Glasser, A. C., and Triplett, J., 3-substituted-2-thiohydrothymines as potential antitumor agents, 122
——Diamond, L., and Combs, G., synthesis and anticonvulsant activity of substituted 2-thioquinazolin-4-ones I: preliminary studies, 127
Gloor, W. T., Jr., *see* Davies, W. L., 1869
Gold, G., Duvall, R. N., Palermo, B. T., and Hurtle, R. L., granule strength as a formulation factor I: instrumentation, 922
Gold, S., *see* West, N., 953
Golden, M., *see* Elison, C., 1058
Golder, R. H., *see* Hohenleitner, F. J., 471
Goldman, P. P., *see* Caldwell, H. C., 1102
Govan, H. K., *see* Mollica, J. A., 1380
Goyan, F. M., Johnson, R. D., and Borazan, H. N., improved thermoelectric osmometer, 117
Grace, A. J., *see* Barry, B. W., 814, 1198
Grady, L. T., *see* Hays, S. E., 295
——*see* Zimmerer, R. O., Jr., 493
Gragg, B. J., *see* Driscoll, R. C., 1492
Greenough, R. C., *see* Leinweber, F.-J., 1516
Griffin, J. P., *see* D'Arcy, P. F., 1028
Griffiths, R. V., and Mitchell, A. G., surface transformation during dissolution of aspirin, 267
Groff, W. A., *see* Sidell, F. R., 860, 1224
Groves, W. G., *see* Caldwell, H. C., 1102
Gruber, C. M., *see* Rubin, A., 1797
Grundhofer, B., *see* Mayersohn, M., 1813
Guerrero, O., *see* Fetterman, P. S., 1246
Guin, H. W., *see* Shealy, Y. F., 1192
Gupta, V. D., stoichiometric balances and stability constants of amine–bromthymol blue complexes, 1584
Guttman, D., and Higuchi, T., NMR evidence for self-association of theophylline in aqueous solution: a response, 1269
Guyer, K. E., *see* Boots, S. G., 614

H

Haavik, C. O., *see* Conard, G. J., 1642
Haddad, H. M., *see* Loucas, S. P., 1109
Halder, A. K., *see* Banerjee, S., 153
Haleblian, J. K., Koda, R. T., and Biles, J. A., comparison of dissolution rates of different crystalline phases of fluprednisolone by *in vitro* and *in vivo* methods, 1488
——Koda, R. T., and Biles, J. A., isolation and characterization of some solid phases of fluprednisolone, 1485
——Runkel, R., Mueller, N., Christopherson, J., and Ng, K., steroid release from silicone elastomer containing excess drug in suspension, 541
Ham, N. S., solution conformations of antihistamines, 1764
Hamid, I. A., and Parrott, E. L., effect of temperature on solubilization and hydrolytic degradation of solubilized benzocaine and homatropine, 901
Hamlin, W. E., *see* Benney, T. L., 959
Hammer, R. H., Wilder, B. J., Streiff, R. R., and Mayersdorf, A., flash methylation and GLC of diphenylhydantoin and 5-(*p*-hydroxyphenyl)-5-phenylhydantoin, 327
Hammouda, Y., and Khalafallah, N., stability of tecomine, the major antidiabetic factor of *Tecoma stans* (Juss.) f. Bignoniaceae, 1142
Hamor, G. H., and Watson, L. D., Schiff base derivatives of anti-inflammatory *O*-substituted hydroxylamines, 925
Hansen, W. G., *see* Morris, C. H., 790
Haque, R.-U., *see* Javidan, S., 1825
Harrell, W. B., *see* Choulis, N. H., 486
Harris, L. S., *see* Slatkin, D. J., 1891
Hartley, P. S., *see* Bell, J. H., 1559
Hartman, C. W., *see* Davis, R. E., 429
——*see* Javaid, K. A., 1709
——*see* Sadik, F., 916
Harwood, C. F., compaction effect on flow property indexes for powders, 161
Hasan, M., Theimer, E. E., and Jain, V. K., colorimetric determination of eriodictyol and its glycoside, eriocitrin, 451
Hassan, M. M. A., *see* Casy, A. F., 67
Havemeyer, R. N., *see* Pelzmann, K. S., 331
Haynes, J. D., worldwide virtual temperatures for product stability testing, 927
Haynes, L. J., *see* Leinweber, F.-J., 1512, 1516
Hays, S. E., and Grady, L. T., inclusion compounds in pharmaceutical analysis II: assay of a cream following chemical dehydration, 295
Heiffer, M. H., *see* Demaree, G. E., 1743
Heil, G. C., *see* Rosen, E., 1900
Heindel, N. D., Fives, W. P., Lemke, T. F., and Carrano, R. A., synthesis and selected pharmacology of anthranilamides, 703
Henry, E. D., *see* Sullivan, G., 1097
Henry, R. L., *see* Bryant, R., 1717
Herzog, K. A., and Swarbrick, J., drug permeation through thin-model membranes II: permeation characteristics of a polymeric model biomembrane, 393
——and Swarbrick, J., drug permeation through thin-model membranes III: correlations between *in vitro* transfer, *in vivo* absorption, and physicochemical parameters of substituted benzoic acids, 1666
Heveran, J. E., *see* Jones, B. C., 1036
——*see* Oliveri-Vigh, S., 1851
Hewitt, R. R., and Levy, G., effect of viscosity on thiamine and riboflavin absorption in man, 784
Heyd, A., polymer–drug interaction: stability of aqueous gels containing neomycin sulfate, 1343
Heyndrickx, A., *see* De Leenheer, A., 1403
Hiestand, E. N., Bane, J. M., Jr., and Strzelinski, E. P., impact test for hardness of compressed powder compacts, 758
Hifnawy, M. S., *see* Karawya, M. S., 381
Higuchi, T., *see* Fung, H.-L., 1782
——*see* Guttman, D., 1269
——*see* Rasmussen, C. E., 1608
——*see* Repta, A., 1465
Higuchi, W. I., *see* Bernstein, D. F., 690
——*see* Ho, N. F. H., 537
Himel, C. M., *see* Jun, H. W., 1821
Hirschorn, J. O., and Kornblum, S. S., dissolution of poorly water-soluble drugs II: excipient dilution and force of compression effects on tablets of a quinazolinone compound, 445
Hi[illegible], G., *see* Lokhandwala, M., 685
——*see* Patel, H., 1905
——*see* Suh, S.-H. K., 930
Hiyama, T., *see* Ishida, Y., 896
Ho, B. T., An, R., Fritchie, G. E., Englert, L. F., McIsaac, W. M., MacKay, B., and Ho, D. H. W., marijuana: some pharmacological studies, 1761
——Fritchie, G. E., Noel, M. B., and McIsaac, W. M., hydroxyindole-*O*-methyltransferase V: effects of substituents on hydrolysis of *N*-acyltryptamines in rats, 634
——Noel, M. B., and Tansey, L. W., hydroxyindole-*O*-methyltransferase VI: inhibitory activities of substituted benzoyltryptamines and benzenesulfonyltryptamines, 636
Ho, D. H. W., *see* Ho, B. T., 1761
Ho, N. F. H., and Higuchi, W. I., quantitative interpretation of *in vivo* buccal absorption of *n*-alkanoic acids by the physical model approach, 537
——*see* Bernstein, D. F., 690
Ho, T. C., *see* Kornet, M. J., 803
Hochberg, A., *see* Hucker, H. B., 1053
Hoffman, E. A., *see* Hucker, H. B., 1049, 1053
Hohenleitner, F. J., Tansy, M. F., and Golder, R. H., effect of vagal stimulation on duodenal serotonin in the guinea pig, 471
——*see* Tansy, M. F., 81
Hohmann, T. C., *see* Danowski, T. S., 640
Holcomb, G. N., Boyd, C. M., Counsell, R. E., Beierwaltes, W. H., Szczesniak, R. A., Murty, D. R. K., and Bruno, G. A., tumor-localizing agents X: radioiodinated hypoglycemic agents, 390
Holmes, T. J., Jr., *see* Feldman, J. A., 920
Hom, F. S., *see* Veresh, S. A., 1092
Hong, D. D., *see* Sinsheimer, J. E., 141
Horbaly, W. R., *see* Kanter, S. L., 1898
Hou, J. P., and Poole, J. W., β-lactam antibiotics: their physicochemical properties and biological activities in relation to structure, 503
Hsiao, C. H., Rhodes, H. J., and Blake, M. I., nonaqueous titration of barbiturates in tetramethylurea, 1847
Huang, C. L., and Chang, C. T., physical properties of quaternary ammonium salts of phenothiazine derivatives, 1895
——and Mir, G. N., pharmacological properties of hypobranchial gland of *Thais haemastoma* (Clench), 1842
——and Mir, G. N., toxicological and pharmacological properties of sea pansy, *Renilla mulleri*, 1620
Huang, J.-H., removal of ferrous ions by *N*,*N'*-ethylenediaminetetraacetic acid in microbiological assay of pyridoxine, 1481
Hubbard, J. W., *see* Coutts, R. T., 28
Hucker, H. B., and Hoffman, E. A., physiologic disposition and metabolic fate of indomethacin analogs I: 1-(*p*-chlorobenzyl-idenyl-5-methoxy-2-methylindene-3-acetic acid, 1049
——Hochberg, A., and Hoffman, E. A., physiologic disposition and metabolic fate of indomethacin analogs II: 1-(*p*-chlorobenzoyl)-5-dimethylamino-2-methylindole-3-acetic acid, 1053
Huitric, A. C., McGraw, N. P., and Lowry, B. R., absolute configuration of (±)-*trans*-2-*o*-tolyl-*trans*-5-hydroxycyclohexanol: metabolite of racemic *trans*-2-*o*-tolylcyclohexanol, 302
——*see* Cochran, T. G., 180
——*see* Lowry, B. R., 632
Hunt, J., *see* Blake, M. I., 1694
Hurtle, R. L., *see* Gold, G., 922
Hussain, A., possible reaction pathway for acylation of coenzyme A, 1276
——*see* Warner, C., 1548
Hussain, M., *see* Elison, C., 1058

I

Idsvoog, P., *see* Perrin, J. H., 602
Indindoli, L., *see* Weinstein, S. H., 1567
Irwin, G. M., *see* Poole, J. W., 1850
Isenberg, L., *see* Kornet, M. J., 803
Ishida, Y., Onishi, M., Hiyama, T., and Yabuuchi, Y., antagonistic activities of derivatives of cystinyl-tyrosyl-tyrosine to actions of oxytocin, 896
Itoh, K., *see* Lawrence, W. H., 1163
Iuliucci, J. D., and Gautieri, R. F., morphine-induced fetal malformations II: influence of histamine and diphenhydramine, 420

J

Jacobs, M. F., *see* Feeter, D. K., 913
Jacobson, M., *see* Sonnet, P. E., 1254
Jaffe, J. M., Colaizzi, J. L., and Barry, H., III, effects of dietary components on GI absorption of acetaminophen tablets in man, 1646
Jain, V. K., *see* Hasan, M., 451
Jandhyala, B. S., *see* Adams, H. R., 1134
Janssen, R. W., and Discher, C. A., controlled potential coulometric analysis of amine-oxides of pharmaceutical interest, 798
Javaid, K. A., Fincher, J. H., and Hartman, C. W., timed-release tablets employing lipase–lipid–sulfamethizole systems prepared by spray congealing, 1709
Javidan, S., Haque, R.-U., and Mrtek, R. G., microbiologic determination of drug partitioning I: gelatin–acacia complex coacervate system, 1825
Jawad, M. J., *see* Kostenbauder, H. B., 1658
Jederström, G., *see* Friberg, S., 1883
Jeffery, D. A., and Noujaim, A. A., radioassay of cortisol and corticosterone by

a modified competitive protein-binding method, 1476
Jenkins, H., *see* Darling, C. M., 1107
Jenkins, H. J., *see* Cohen, S. D., 1740
Jenkins, J. S., *see* D'Arcy, P. F., 1028
Johnson, B. J., immunochemical studies on linear antigenic polypeptides of a known sequence of amino acids, 332
——and Chen, F., linear polypeptide of a known sequence of amino acids: poly-(L-phenylalanyl-L-glutamyl-L-alanylglycyl)-glycine methyl ester, 330
Johnson, C. L., *see* Neal, J. M., 477
Johnson, D. P., *see* Arret, B., 1689
Johnson, H. L., *see* Skinner, W. A., 643
——*see* Tsakotellis, P., 84
Johnson, R. D., *see* Goyan, F. M., 117
Jones, B. C., Heveran, J. E., and Senkowski, B. Z., determination of organically bound fluorine using sodium biphenyl reagent and a fluoride-specific ion electrode, 1036
Jones, R. G., *see* Caldwell, H. C., 1810
Judy, R. W., *see* Forist, A. A., 1686
Jun, H. W., and Luzzi, L. A., fluorescence techniques in drug–plasma protein binding, 1430
——Mayer, R. T., Himel, C. M., and Luzzi, L. A., binding study of *p*-hydroxybenzoic acid esters to bovine serum albumin by fluorescent probe technique, 1821
Jurd, L., Stevens, K. L., King, A. D., Jr., and Mihara, K., antimicrobial properties of natural phenols and related compounds II: cinnamylated phenols and their hydrogenation products, 1753
Jusko, W. J., fluorometric analysis of ampicillin in biological fluids, 728
——pharmacodynamics of chemotherapeutic effects: dose–time–response relationships for phase-nonspecific agents, 892

K

Kabadi, B. N., semiautomated fluorometric determination of rauwolfia alkaloids, 1862
Kaldy, L., *see* Weber, D. J., 467
Kamath, B. R., Bhat, C. V., Vyas, A. H., Shah, R. S., Kanhere, S. S., and Bafna, S. L., ion-exchange resins on cinchona alkaloids IV: effect of resin particle size on equilibrium exchange and column studies, 319
Kanhere, S. S., *see* Kamath, B. R., 319
Kanter, S. L., and Horbaly, W. R., direct measurement of aspirin, 1898
Kantor, N., *see* Castor, G. B., 1578
Kaplan, S. A., *see* Coutinho, C. B., 1014
Kapoor, A., Azeza, N., Somaiya, N. H., and Trimboli, M. A., enzyme-active sites: importance of aspartic acid in peptide esterase models, 956
Karawya, M. S., Balbaa, S. I., and Hifnawy, M. S., peel oils of different types of *Citrus sinensis* L. and *C. aurantium* L. growing in Egypt, 381
Karim, A., Ranney, R. E., and Maibach, H. I., pharmacokinetic and metabolic fate of potassium canrenoate (SC-14266) in man, 708
Kassem, A. A., *see* Sina, A., 1544
Katz, J. J., *see* Carlstedt, B. C., 1661
Kaul, P. N., and Conway, M. W., induction and inhibition of *in vivo* glucuronidation of apomorphine in mice, 93
Kavanagh, F. W., automated system for analytical microbiology III: computer interpolation of potency, 1858
——*see* Kuzel, N. R., 764, 767
Kay, A. I., and Simon, T. H., use of an analog computer to simulate and interpret data obtained from linear nonisothermal stability studies, 205
Kazmi, S. J. A., and Mitchell, A. G., dialysis method for determining preservative distribution in emulsions, 1422
Kehl, H., vasomotor and α-block negating actions of a hydroxamic acid, 839
Keith, E. S., *see* Fetterman, P. S., 1246
Kennedy, C. C., Spiekerman, R. E., and Elveback, L., antihypertensive properties of cryptenamine used with reserpine and methyclothiazide, 1139
Kenner, C. T., *see* Tolbert, C. E., 596
Kessler, W. V., *see* McDowell, R. W., 695
——*see* Meeks, M. J., 482
——*see* Rowles, S. G., 725
Khalafallah, N., *see* Hammouda, Y., 1142
Khalil, S. A., *see* Miller, G. H., 33
Khalil, S. K. W., and Patterson, B. D., colorimetric determination of physostigmine in pharmaceuticals, 1387
Khandekar, J. D., *see* Kovacs, K., 1576
Kho, B. T., *see* Warner, C., 1548
Khullar, K. K., *see* Chatten, L. G., 316
Kildsig, D. O., *see* Smolen, V. F., 130
Kim, C. M., *see* Foye, W. O., 151
King, A. D., Jr., *see* Jurd, L., 1753
Kirchhoefer, R. D., *see* Dow, M. L., 298
Kirchner, L. K., *see* Garson, L. R., 1113
Kirk, W. F., *see* D'Arcy, P. F., 1028
Kirshbaum, A., *see* Arret, B., 1689
——*see* Castor, G. B., 1578
——*see* Garth, M. A., 63
Kiryu, S., crystal structure of a 1:1 aminopyrine–barbital complex, 699
Kitao, K., *see* Naito, S., 1257
Kitaura, M., *see* Naito, S., 1257
Klaassen, C. D., *see* Sabih, K., 745
Klein, H. R., and Mader, W. J., TLC identification of sulfonamides, 448
Knapp, D. R., *see* Campaigne, E., 809
Knapp, J. E., and Schiff, P. L., Jr., isolation and identification of constituents from *Cudrania javanesis*, 1729
Knevel, A. M., *see* Sharp, R. A., 458
Knoll, E., *see* Castor, G. B., 1578
Knowles, B., *see* Zatz, J. L., 1731
Koda, R. T., *see* Haleblian, J. K., 1485, 1488
Koehler, E., *see* Bilous, R., 1270
Kojima, S., Smith, R. B., and Doluisio, J. T., drug absorption V: influence of food on oral absorption of phenobarbital in rats, 1639
Kolis, S. J., *see* Schwartz, M. A., 438
Kormendy, C. G., and Bender, A. D., experimental modification of the chemistry and biology of the aging process, 167
Kornblum, S. S., *see* Hirschorn, J. O., 445
Kornet, M. J., Ho, T. C., and Isenberg, L., new compounds: 2,4-dinitrobenzenesulfenamides, 803
Korol, B., influence of pentobarbital on some cardiovascular effects of cryptenamine in dogs, 488
Kosersky, D. S., and Malone, M. H., evaluation of cryogenine in rat sympathetic ganglia, 952
Kostenbauder, H. B., Jawad, M. J., Perrin, J. H., and Averhart, V., dialysis and circular dichroism study of the binding of sulfaethidole to crystalline and fraction V bovine serum albumin, 1658
Kovacs, K., Garg, B. D., and Khandekar, J. D., hepatic injury caused by *N*-γ-phenylpropyl-*N*-benzyloxyacetamide: a light and electron microscopic study, 1576
Kramer, J., *see* Garth, M. A., 63
Krause, R. D., *see* Chatten, L. G., 588
Krause, S. I., *see* Chatten, L. G., 107
Krauth, C. A., *see* Shealy, Y. F., 1192, 1426
Kreutler, C. J., and Davis, W. W., normal and promoted GI absorption of water-soluble substances III: absorption of antibiotics from stomach and intestine of the rat, 1835
——*see* Davis, W. W., 1651
Kriesel, D. C., and Gisvold, O., analgesics: synthesis of 1-dioxolanoalkylnormeperidines and 1-dioxanoalkylnormeperidines, 1250
Kudla, R. M., El-Bassiouni, E. A., and Mattocks, A. M., accelerated peritoneal dialysis of barbiturates, diphenylhydantoin, and salicylate, 1065
Kuzel, N. R., and Kavanagh, F. W., automated system for analytical microbiology I: theory and design considerations, 764
——and Kavanagh, F. W., automated system for analytical microbiology II: construction of system and evaluation of antibiotics and vitamins, 767
Kwan, K. C., Wadke, D. A., and Foltz, E. L., pharmacokinetics of phosphonomycin in man I: intravenous administration, 678

L

Lach, J. L., *see* Bhansali, K. G., 611
——*see* Fritz, B., 1617
——*see* Yeh, S. Y., 793
Lambert, J. P. F., *see* Margosis, M., 592, 1550
Landolt, R. R., *see* McDowell, R. W., 695
——*see* Meeks, M. J., 482
LaPiana, J. C., *see* Doluisio, J. T., 715
LaRocca, J. P., Gibson, C. A., and Thompson, B. B., synthesis and characterization of some 3-nitroso-2-arylimidazo(1,2-*a*)-pyrimidines, 74
Laster, W. R., Jr., *see* Shealy, Y. F., 1192
Lausier, J. M., Gerraughty, R. J., and Paruta, A. N., efficient deoxygenation of water by gas permeation, 1906
Lawrence, W. H., Itoh, K., Turner, J. E., and Autian, J., toxicity of ethylene chlorohydrin II: subacute toxicity and special tests, 1163
——Turner, J. E., and Autian, J., toxicity of ethylene chlorohydrin I: acute toxicity studies, 568
Lee, K.-H., *see* Chen, C.-H., 1634
Lee, K. P., *see* Wagner, J. G., 666
——*see* Welling, P. G., 1629
Leinweber, F.-J., Greenough, R. C., Schwender, C. F., Haynes, L. J., and Di Carlo, F. J., bunolol metabolism by dogs: isolation and identification of two acidic metabolites, 1516
——Haynes, L. J., Crew, M. C., and Di Carlo, F. J., absorption, tissue distribution, and excretion of bunolol-^{14}C by dogs, 1512
Lemke, T. F., *see* Heindel, N. D., 703
Lenehan, R. F., *see* Sullivan, G., 1727
Le Quesne, P. W., *see* Ahmad, Y., 1581
Leseney, J. L., *see* Barfknecht, C. F., 799
Leung, A. Y., *see* Brochmann-Hanssen, E., 1672
Levinton, R., *see* Walenrod, L., 1856
Levy, G., comparative systemic availability of acetaminophen when administered orally as such and as acetophenetidin, 499
——and Regardh, C., drug biotransformation interactions in man V: acetaminophen and salicylic acid, 608
——and Yamada, H., drug biotransformation interactions in man III: acetaminophen and salicylamide, 215
——*see* Hewitt, R. R., 784
Levy, R. H., and Rowland, M., dissociation constants of sparingly soluble substances: nonlogarithmic linear titration curves, 1155
Lewi, P. J., and Braet, W. W., kinetic simulation by digital computer using graphic display techniques, 1079
Lewis, M., *see* Coutinho, C. B., 1014
Lewis, R. J., assay of warfarin, 1271
Lien, E. J., *see* Elison, C., 1058
Lin, M. C. H., *see* Urbányi, T., 755
Lindstrom, R. E., *see* Welles, H. L., 1212
Lippold, B. C., and Garrett, E. R., kinetics and mechanisms of lactonization of coumarinic acids and hydrolysis of coumarins II, 1019
——*see* Garrett, E. R., 396
Litchfield, M. H., aspects of nitrate ester metabolism, 1599
Litterio, F. R., and Sandoval, A., specific colorimetric reaction for quantitative determination of 3-hydroxy-$\Delta^{1,5}$-diene grouping in steroids, 1542
Locock, R. A., *see* Chatten, L. G., 588
Lokhandwala, M., Patel, D. B., Patel, H., Merker, P. C., Shafi'ee, A., and Hite, G., stereochemical investigations of local anesthetic action, 685
Lomner, J. J., *see* Chafetz, L., 463
Long, J. P., *see* Barfknecht, C. F., 138, 799
Long, J. S., *see* Caldwell, H. C., 1102
Longstreth, J. A., *see* Bischoff, K. B., 1128
Lordi, N. G., Felmeister, A., and Weiner, N. D., inhibitory effect of cholesteryl nitrate on interaction of nitrogen dioxide with cholesterol in monomolecular films, 933
Lotti, D. M., *see* Stewart, J. T., 461
Loucas, S. P., Yeh, K. C., and Haddad, H. M., effect of calcium ions on the scattering of light by heparin, 1109
Lowary, L. R., Smith, F. A., Coyne, E., and Dunham, N. W., comparative neutralization of lung- and mucosal-derived heparin by protamine sulfate using *in vitro* and *in vivo* methods, 638
Lowenthal, W., and Burruss, R. A., mechanism of action of starch as a tablet disintegrant IV: effect of medicaments and disintegrants on mean pore diameter and porosity, 1325

Lowry, B. R., and Huitric, A. C., *cis*- and *trans* - 2 - (3,4,5 - trimethoxyphenyl)cyclohexylamines: *N*-methyl and *N,N*-dimethyl derivatives, 632
——*see* Huitric, A. C., 302
Luders, R., O'Brien, P., and Tishler, F., GLC determination of new antiarrhythmic drug, 627
Luts, H. A., new compounds: anils, 1903
——structure–activity studies of new potential depressants 3,4,5-trimethoxybenzamides II, 1409
Luzzi, L. A., *see* Jun, H. W., 1430, 1821
——*see* Zia, H., 45, 89
Lyle, R. E., *see* Wu, M. T., 1904
Lyles, R. L., *see* Bowman, F. W., 1099

M

MacKay, B., *see* Ho, B. T., 1761
Mader, W. J., *see* Klein, H. R., 448
Maggi, N., *see* Cometti, A., 1074
Mahony, D. E., *see* Yung, D. K., 386
Maibach, H. I., *see* Karim, A., 708
——*see* Tsakotellis, P., 84
Mainville, C. A., *see* Mattok, G. L., 561
Makris, K., *see* Blake, M. I., 1694
Malik, W. U., Garg, H. G., and Arora, V., synthesis and biological evaluation of some 4-arylazopyrazoles, 1738
Malone, M. H., *see* Chang, Y., 416
——*see* De Cato, L., Jr., 140
——*see* Kosersky, D. S., 952
——*see* Sklar, S., 304
Mancott, A., *see* Tietjen, J., 460
Mann, D. E., Jr., *see* O'Hara, G. P., 473
Mann, T. A., *see* Villani, F. J., 1586
Mann, W. A., *see* Caldwell, H. C., 1810
Mannelli, M., *see* Saski, W., 854
Manzo, L., *see* Benzi, G., 1320
——*see* Berté, F., 805
Margosis, M., and Lambert, J. P. F., determination of zinc in pharmaceutical products by neutron activation analysis, 592
——Tanner, J. T., and Lambert, J. P. F., neutron activation analysis of halogens in drugs, 1550
Martin, A. N., *see* Miller, G. H., 33
——*see* Peradejordi, F., 576
Martin, A. R., *see* Pai, V. S., 201
Martin, B. K., *see* Dell, D., 1368
Martin, C. F., *see* Moon, B. H., 618
Martin, Y. C., *see* Cummins, L. M., 261
Mary, N. Y., free and bound water in crude drugs: effect of extraction method on subsequent analysis by GLC, 1417
Mason, W. D., Needham, T. E., and Price, J. C., monitoring tablet dissolution with a sodium ion-selective glass electrode, 1756
Masoud, A. N., *see* Slatkin, D. J., 1891
Matsui, F., and French, W. N., analysis of binary mixtures of pharmaceutical amines by the acid dye technique, 287
——*see* Watson, J. R., 454
Mattocks, A. M., and El-Bassiouni, E. A., peritoneal dialysis: a review, 1767
——*see* Kudla, R. M., 1065
——*see* Penzotti, S. C., 1520
Mattok, G. L., McGilveray, I. J., and Mainville, C. A., acetaminophen III: dissolution studies of commercial tablets of acetaminophen and comparison with *in vivo* absorption parameters, 561
Mauger, J. W., *see* Paruta, A. N., 432
Maulding, H. V., and Zoglio, M. A., hydrolytic degradation of itobarbital, 40
——and Zoglio, M. A., pKa determinations utilizing solutions of 7-(2-hydroxypropyl)-theophylline, 309
Mayer, R. T., *see* Jun, H. W., 1821
Mayersdorf, A., *see* Hammer, R. H., 327
Mayersohn, M., and Gibaldi, M., drug transport III: influence of various sugars on passive transfer of several drugs across the everted rat intestine, 225
——and Gibaldi, M., drug transport IV: influence of hypotonic and hypertonic solutions on passive drug transfer across the everted rat intestine, 326
——Gibaldi, M., and Grundhofer, B., drug transport V: mechanism of potassium-ion inhibition of passive transfer of solutes across everted rat intestine, 1813
Mazumder, U. K., *see* Ghosal, S., 1209
McCrone, W. C., *see* Cox, J. S. G., 1458
McCutcheon, R. S., *see* Fakouhi, T., 1045
McDowell, R. W., Landolt, R. R., Kessler, W. V., and Shaw, S. M., placental transfer of 2,3,5-triiodobenzoic acid in the rat, 695
McGavock, W. C., *see* Zachariades, C., 918
McGilveray, I. J., *see* Mattok, G. L., 561
McGraw, N. P., *see* Huitric, A. C., 302
McIsaac, W. M., *see* Ho, B. T., 634, 1761
McLaughlin, J. L., *see* Neal, J. M., 477
McShefferty, J., *see* Sawardeker, J. S., 1591
Meeks, M. J., Landolt, R. R., Kessler, W. V., and Born, G. S., effect of vanadium on metabolism of glucose in the rat, 482
Menczel, E., *see* Ballard, B. E., 406
Merker, P. C., *see* Lokhandwala, M., 685
Merrill, E. J., synthesis of ^{14}C-labeled bunolol, 1589
Metri, J., *see* Nabih, I., 1242
Midha, K. K., *see* Coutts, R. T., 28
Mielck, J. B., *see* Garrett, E. R., 396
Mihara, K., *see* Jurd, L., 1753
Miller, G. H., Khalil, S. A., and Martin, A. N., structure–activity relationships of tetracyclines I: inhibition of cell division and protein and nucleic acid syntheses in *Escherichia coli* W, 33
Miller, H. S., Jr., *see* Davidson, I. W. F., 274
Miller, L. G., and Fincher, J. H., influence of drug particle size after intramuscular dosage of phenobarbital to dogs, 1733
Mintz, M., *see* Weinstein, S. H., 1567
Mir, G. N., *see* Huang, C. L., 1620, 1842
Misconi, L. Y., *see* Brochmann-Hanssen, E., 1880
Miskel, J. J., *see* Veresh, S. A., 1092
Mital, R. L., *see* Sharma, V. N., 1262
Mitala, J. J., and Gautieri, R. F., apparent enzyme inhibition through enzyme-induction studies as a possible mode of action of certain cobalt compounds, 1878
Mitchell, A. G., *see* Cho, M. J., 196, 720
——*see* Griffiths, R. V., 267
——*see* Kazmi, S. J. A., 1422
Mitchner, H., *see* Weber, D. J., 467
Mogenhan, J. A., Whitbourne, J. E., and Ernst, R. R., determination of ethylene oxide in surgical materials by vacuum extraction and gas chromatography, 222
Mollica, J. A., Rehm, C. R., Smith, J. B., and Govan, H. K., hydrolysis of benzothiadiazines, 1380
Moon, B. H., and Martin, C. F., 3-aminopiperidones V: 2-ethoxy and 2-carbethoxy derivatives of 2-*p*-methoxyphenylglutarimide, 618
Moore, G. W., *see* Driscoll, R. C., 1492
Moran, C., *see* Chafetz, L., 314
Morris, C. H., Christian, J. E., and Hansen, W. G., effects of aspirin on gastric mucosae of albino rat and Mongolian gerbil (*Meriones unguiculatus*), 790
Mrtek, R. G., *see* Javidan, S., 1825
Mueller, N., *see* Haleblian, J., 541
Mukerjee, P., analysis of distribution model for micellar solubilization using thermodynamics of small systems: nonideality of solubilization of benzoic acid derivatives in nonionic surfactants, 1531
——solubilization of benzoic acid derivatives by nonionic surfactants: location of solubilizates in hydrocarbon core of micelles and polyoxyethylene mantle, 1528
Mukherjee, A. K., *see* Banerjee, S., 153
Münzing, H. P., *see* Abraham, D. J., 1085
Murty, D. R. K., *see* Holcomb, G. N., 390
Mushinsky, R. F., *see* Forcier, G. A., 111
Mutha, S. C., detection of CL-912, a 1,3-dioxalane, in collapsible tube liner by attenuated total reflection spectroscopy, 1264
Myers, G. E., *see* Chatten, L. G., 316

N

Nabih, I., and Abbasi, M., aromatic amines condensed with aminothiazoles, directly and with isatoic anhydride, for schistosomiasis treatment I, 1251
——and Abbasi, M., condensed *p*-toluidines with aminothiazoles as schistosomicidal agents II, 1411
——and Metri, J., structure and activity in molluscicides III: enzymatic peroxidation of the molluscicidal agent pentachlorophenol, 1242
——and Zayed, A., new schistosomicidal and carcinostatic agents of the thiaxanthone type (I), 1747
Negwekar, J. B., and Unnikrishnan, A., Michaelis–Menten kinetics of renal tubular secretion of D-(−)-*p*-methyl mandelic acid and D-(−)-*p*-ethyl mandelic acid in rats, 375
Naik, V. R., *see* Affonso, A., 1572
Naito, S., and Fukui, K., biopharmaceutical studies on aminoethanesulfonylphenetidine and related compounds II, 249
——Osumi, S., Kitao, K., Tetsuo, M., Kitaura, M., and Fujita, T., synthesis of compounds related to metabolites of trimetazidine in rabbits, 1257
——Ueno, Y., Yamaguchi, H., and Nakai, T., biopharmaceutical studies on 4-(aminoethanesulfonylamino)antipyrine and related compounds I, 245
Nakai, T., *see* Naito, S., 245
Nakano, M., effects of interaction with surfactants, adsorbents, and other substances on the permeation of chlorpromazine through a dimethylpolysiloxane membrane, 571
Nash, J. F., Bopp, R. J., and Rubin, A., GLC determination of *dl*-2-(3-phenoxyphenyl)propionic acid (fenoprofen) in human plasma, 1062
Nash, R. A., *see* Burger, J. M., 300
Nayak, R. K., and Benet, L. Z., drug transfer across rat intestinal musculature after edetic acid treatment, 1508
Neal, J. M., Sato, P. T., Johnson, C. L., and McLaughlin, J. L., cactus alkaloids X: isolation of hordenine and *N*-methyltyramine from *Ariocarpus kotschoubeyanus*, 477
Needham, T. E., *see* Mason, W. D., 1756
Needham, T. E., Jr., Paruta, A. N., and Gerraughty, R. J., solubility of amino acids in mixed solvent systems, 258
——Paruta, A. N., and Gerraughty, R. J., solubility of amino acids in pure solvent systems, 565
Nematollahi, J., *see* Shihab, F., 622
Nessen, M. A., *see* Smith, R. V., 907
Neumeyer, J. L., and Shagoury, R. A., chemistry and pharmacology of marijuana, 1433
Neuss, N., *see* Ahmad, Y., 1581
Neville, G. A., and Ethier, J. C., preparation and characterization of lincomycin cyclamate, 497
Newman, J. H., *see* Bruce, R. B., 104
Newton, J. M., *see* Fell, J. T., 1428, 1866
Ng, K., *see* Haleblian, J. K., 541
Niazi, S., *see* Chiou, W. L., 1333
Nicholas, B. A., *see* Cohen, S. D., 1740
Nichols, D. E., *see* Barfknecht, C. F., 799
Niebergall, P. J., Schnaare, R. L., and Sugita, E. T., nonlinear regression applied to non-Newtonian flow, 1393
——Sugita, E. T., and Schnaare, R. L., dissolution rates under sink conditions, 1575
Nieforth, K. A., *see* Sklar, S., 304
Nielsen, J. K., *see* Castor, G. B., 1578
Nightingale, C. H., drug concentration in goldfish at the pharmacologic end-point, 1762
——and Gibaldi, M., kinetics of drug absorption in goldfish, 1360
——Axelson, J. E., and Gibaldi, M., physiologic surface-active agents and drug absorption VIII: effect of bile flow on sulfadiazine absorption in the rat, 145
Noel, M. B., *see* Ho, B. T., 634, 636
Noujaim, A. A., *see* Jeffery, D. A., 1496

O

Ouaf, A. A. A., Eldawy, M. A., and Farag, H. H., new compounds: synthesis of certain *p*-alkoxyphenylaceta nide derivatives as potential analgesic agents, 158
O'Brien, P., *see* Luders, R., 627
O'Dell, C. A., *see* Shealy, Y. F., 554, 1426
O'Dell, R. G., *see* Prosky, L., 1341
Odin, E., *see* Schaeffer, H. J., 1184
O'Hara, G. P., Mann, D. E., Jr., and Gautieri, R. F., effect of cobalt chloride and sodium cobaltinitrite on the growth of established epithelial tumors induced by methylcholanthrene, 473

Oliveri-Vigh, S., Donahue, J. J., Heveran, J. E., and Senkowski, B. Z., coulometric titration of *N*-isopropyl-α-(2-methylhydrazino)-*p*-toluamide hydrochloride, 1851
Onishi, M., *see* Ishida, Y., 896
Opliger, C. E., *see* Shealy, Y. F., 1192
Orr, J. M., *see* Benet, L. Z., 234
Ostrenga, J., Steinmetz, C., and Poulsen, B., significance of vehicle composition I: relationship between topical vehicle composition, skin penetrability, and clinical efficacy, 1175
——Steinmetz, C., Poulsen, B., and Yett, S., significance of vehicle composition II: prediction of optimal vehicle composition, 1180
Osumi, S., *see* Naito, S., 1257

P

Pai, V. S., Parulkar, A. P., Martin, A. R., and White, A. I., substituted tetralins III: synthesis and analgesic activities of some substituted 2-methyl- and 2-benzyl-4,4-dimethyl-2-aminotetralins, 201
Palermo, B. T., *see* Gold, G., 922
Pancholi, N. S., *see* Sharma, V. N., 1262
Parkhurst, R. M., *see* Skinner, W. A., 643
Parrott, E. L., salicylate absorption from rectal suppositories, 867
——*see* Alam, A. S., 263, 795
——*see* Danish, F. Q., 548, 752
——*see* Hamid, I. A., 901
Parsons, W. H., *see* Foye, W. O., 1839
Parulkar, A. P., *see* Pai, V. S., 201
Paruta, A. N., and Mauger, J. W., solubility of sodium salicylate in mixed solvent systems, 432
——*see* Lausier, J. M., 1906
——*see* Needham, T. E., Jr., 258, 565
Patel, D. B., *see* Lokhandwala, M., 685
Patel, H., Soares, J., and Hite, G., novel behavior of *N*-methyl-3-benzoyl-3-hydroxypiperidine under conditions of Von Braun demethylation, 1905
——*see* Lokhandwala, M., 685
Patel, J. A., *see* Welling, P. G., 1629
Patel, V. K., *see* Washkuhn, R. J., 736
Patel, V. U., *see* Feldman, J. A., 1696
Patterson, B. D., *see* Khalil, S. K. W., 1387
Peacock, A. W. C., *see* D'Arcy, P. F., 1028
Pecca, J. G., Dobrecky, J., and Albonico, S. M., synthesis and antibacterial activity of 5-nitro-2-furaldehyde phenylhydrazones, 650
Pelzmann, K. S., and Havemeyer, R. N., portal vein blood sampling in intestinal drug absorption studies, 331
Penner, M. H., Tsilifonis, D. C., and Chafetz, L., separation of quingestanol acetate from sesame oil solution and its determination in combinations with ethinyl estradiol or quinestrol, 1388
Penzotti, S. C., and Mattocks, A. M., effects of dwell time, volume of dialysis fluid, and added accelerators on peritoneal dialysis of urea, 1520
Peradejordi, F., Martin, A. N., and Cammarata, A., quantum chemical approach to structure–activity relationships of tetracycline antibiotics, 576
Pernarowski, M., *see* Cho, M. J., 196, 720
Perrin, J. H., and Idsvoog, P., extrinsic cotton effects of bishydroxycoumarin when bound to bovine serum albumin, 602
——*see* Kostenbauder, H. B., 1658
Persson, B., *see* Eksborg, S., 475
Pfeffer, M., *see* Weinstein, S. H., 1567
Phillips, J. R., and Cadwallader, D. E., behavior of erythrocytes in phosphate buffer systems, 1033
Piccolo, J., and Tawashi, R., inhibited dissolution of drug crystals by certified water-soluble dyes II, 59
——and Tawashi, R., inhibited dissolution of drug crystals by certified water-soluble dyes III, 1818
Platt, D. S., pharmacokinetics of fenclozic acid in animals and man, 366
Poole, J. W., Irwin, G. M., and Young, S., colorimetric assay procedure for dissolution studies of meprobamate formulations, 1850
——*see* Hou, J. P., 503
Popovich, R. P., *see* Farrell, P. C., 1471
Portmann, G. A., *see* Brown, N. H., 1229
Portoghese, P. S., translocation of ligand conformational free energy in receptor activation: a possible functional role of conformational isomerism in drug action, 806
Postma, E., *see* Schwartz, M. A., 438, 1500
Poulsen, B., *see* Ostrenga, J., 1175, 1180
Poust, R. I., *see* Smolen, V. F., 1745
Powers, L. J., photolysis of 5-nitrofuramides in methanol, 1425
Prakash, C., *see* Garg, H. C., 323
Prasad, K., *see* Coutts, R. T., 28
Price, J. C., *see* Mason, W. D., 1756
Prosky, L., and O'Dell, R. G., *in vivo* conversion of ^{14}C-labeled cyclamate to cyclohexylamine, 1341
Prosser, A. R., and Sheppard, A. J., GLC of trimethylsilyl derivatives of pantothenyl alcohol and pantothenates, 909

Q

Quimby, M. W., *see* Fetterman, P. S., 1246
——*see* Slatkin, D. J., 1891

R

Randolph, J. O., *see* Castor, G. B., 1578
Ranney, R. E., *see* Karim, A., 708
Rao, G. S., and Sinsheimer, J. E., constituents from *Gymnema sylvestre* leaves VIII: isolation, chemistry, and derivatives of gymnemagenin and gymnestrogenin, 190
Rao, K. V., Wilson, R. A., and Cummings, B., alkaloids of tylophora III: new alkaloids of *Tylophora indica* (Burm) Merrill and *Tylophora dalzelli* Hook. f., 1725
Rasero, L. J., Jr., *see* Simon, R. K., 1111
Rasmussen, C. E., and Higuchi, T., spectropolarimetric and circular dichroism methods for determining the activity of penicillin, 1608
Ravin, L. J., and Warren, R. J., micelle formation and its significance in interpretation of NMR spectra of phenothiazine derivatives, 329
——*see* Warren, R. J., 801
Rawlings, H. W., *see* Feeter, D. K., 913
Rees, J. E., and Shotton, E., effects of moisture in compaction of particulate material, 1704
Regardh, C., *see* Levy, G., 608
Rehm, C. R., *see* Mollica, J. A., 1380
Reinhard, M., *see* Feldman, S., 1105
Repta, A., and Higuchi, T., quantitative analysis of microgram quantities of pilocarpine in aqueous solution, 1465
Rhodes, H. J., *see* Hsiao, C. H., 1847
Rice, L. M., Sheth, B. S., and Zalucky, T. B., new compounds: symmetrically substituted tetraalkyl methanes, 1760
Ridolfo, A., *see* Rubin, A., 1797
Riegelman, S., *see* Chiou, W. L., 1281, 1376, 1569
Rietta, M. S., *see* Schulman, S. G., 1762
Rippie, E. G., *see* Zoglio, M. A., 411
Ritschel, W. A., influence of formulating factors on drug safety of timed-release nitroglycerin tablets, 1683
Robinson, E. C., *see* Cocolas, G. H., 1749
Robinson, E. P., *Pseudomonas aeruginosa* contamination of liquid antacids: a survey, 604
Robinson, J. R., *see* Washkuhn, R. J., 736, 1168
Rodda, B. E., *see* Rubin, A., 1797
Rodriguez, M., *see* Cannon, J. G., 1534
Roll, D. B., and Beltrame, P., assignment of configuration of dehydrochlorination products of mitotane, 484
Roseman, T. J., *see* Flynn, G. L., 1788
Rosen, E., Free, S. M., and Heil, G. C., reduced side effects following administration of new anorectic agent, 4′-chloro-2-(ethylamino)propiophenone, in timed-release form, 1900
Ross, J. J., Jr., *see* Dreyfuss, J., 821, 829
Rost, W. J., *see* Chappelow, C. C., Jr., 620
Rothe, W. E., *see* Demaree, G. E., 1743
Rothman, G., *see* Tansy, M. F., 81
Rowland, M., *see* Levy, R. H., 1155
Rowles, S. G., Born, G. S., Russell, H. T., Kessler, W. V., and Christian, J. E., biological disposition of pentylenetetrazol-10-^{14}C in rats and humans, 725
Rubin, A., Rodda, B. E., Warrick, P., Ridolfo, A., and Gruber, C. M., physiological disposition of fenoprofen in man I: pharmacokinetic comparison of calcium and sodium salts administered orally, 1797
——*see* Nash, J. F., 1062
Runkel, R., *see* Haleblian, J. K., 541
Russell, H. T., *see* Rowles, S. G., 725
Rydhag, L., *see* Friberg, S., 1883

S

Sabih, K., and Sabih, K., combined GLC and high-resolution mass spectroscopic analysis of diphenylhydantoin, 1216
——Klaassen, C. D., and Sabih, K., combined GC and high resolution mass spectrometric determination of probenecid, 745
Sackman, P., *see* Shefter, E., 282
Sadee, W., and Van Der Kleijn, E., thermolysis of 1,4-benzodiazepines during gas chromatography and mass spectroscopy, 135
Sadik, F., Fincher, J. H., and Hartman, C. W., X-ray diffraction analysis for identification of kaolin NF and bentonite USP, 916
Saenz, R. V., and Crochet, R. A., new compounds: preparation of oxime esters from 1-azabicyclo[4.4.0]decane-4-one, 1266
Saettone, M. F., *see* Saski, W., 854
Saheb, S. E., and Sanassian, M. A., color reaction of thyroxine and its derivatives with nitrous acid, 1259
Sam, J., Vacik, D. N., and Aboul-Enein, M. N., aryl-2-piperidylcarbinols: potential cardiovascular agents, 936
——Valentine, J. L., and Aboul-Enein, M. N., reaction of 3-(chloroalkyl)-2-benzoxazolinones with amines: formation of 3-(aminoalkyl)-2-benzoxazolinones and 5-substituted-2,3,4,5-tetrahydro-1, 5-benzoxazepines, 1370
Sampson, C. B., Breunig, H. L., Comer, J. P., and Broadlick, D. E., characterization of USP XVIII content uniformity plan, 955
Sanassian, M. A., *see* Saheb, S. E., 1259
Sandoval, A., *see* Litterio, F. R., 1542
Sane, J. N., *see* Foye, W. O., 1095
Sanguinetti, L., *see* Benzi, G., 321, 1320
Santoro, R. S., and Warren, R. J., isolation and identification of 8-(2-diphenylmethoxy-*N*-methylethylamine)-1,3-dimethylxanthine from dimenhydrinate, 791
Saski, W., Mannelli, M., Saettone, M. F., and Bottari, F., relative toxicity of three homologous series of nonionic surfactants in the planarian, 854
Sato, P. T., *see* Neal, J. M., 477
Saunders, G. M., *see* Barry, B. W., 645
Sawardeker, J. S., and McShefferty, J., effect of formulation of anagestone acetate on progestational proliferation of rabbit uterus after oral administration, 1591
Schaeffer, H. J., and Schwender, C. F., enzyme inhibitors XXIV: bridging hydrophobic and hydrophilic regions on adenosine deaminase, 1204
——Odin, E., and Bittner, S., enzyme inhibitors XXIII: syntheses of 9-(substituted aralkyl)-6-substituted purines as inhibitors of adenosine deaminase, 1184
Scherfling, E. E., *see* Cummins, L. M., 261
Schertel, M. E., and Sheppard, A. J., cathode ray polarography of riboflavin, thiamine hydrochloride, and niacinamide content of pharmaceutical preparations, 1070
Schiff, P. L., Jr., *see* Knapp, J. E., 1729
——*see* Slatkin, D. J., 1891
Schnaare, R. L., *see* Niebergall, P. J., 1393, 1575
Schnelle, K., *see* Garrett, E. R., 833
Schoenemann, P. T., *see* Coffey, J. J., 1623
Schoenwald, R. D., and Smolen, V. F., drug-absorption analysis from pharmacological data II: transcorneal biophasic availability of tropicamide, 1039
——*see* Smolen, V. F., 96
Schor, J. M., *see* Weinstein, S. H., 1567
Schott, H., algebraic extrapolation of tie lines in ternary phase diagrams, 160
——are there spherical micelles?, 1594

——contact angles and wettability of human skin, 1893
——hydrophilic–lipophilic balance and distribution coefficients of nonionic surfactants, 648
Schreiber, E. C., *see* Dreyfuss, J., 821, 829
Schriftman, H., *see* Chafetz, L., 463
Schulman, S. G., dissociation constants of some isomeric aminoquinolines: determination of the site of protonation from shifts in electronic absorption spectra, 371
——octahedral hybridization of hydrogenic orbitals in molecular orbital and ligand field calculations, 647
——pH dependence of fluorescence of riboflavin and related isoalloxazine derivatives, 628
——and Rietta, M. S., formation of coordinate covalent complex between lithium and 8-quinolinol, 1762
Schwartz, M. A., Postma, E., and Gaut, Z. N., biological half-life of chlordiazepoxide and its metabolite, demoxepam, in man, 1500
——Postma, E., and Kolis, S. J., metabolism of demoxepam, a chlordiazepoxide metabolite, in the dog, 438
Schwender, C. F., *see* Leinweber, F.-J., 1516
——*see* Schaeffer, H. J., 1204
Scott, J., *see* Doorenbos, N. J., 1236
Segelman, A. B., *see* Sofia, R. D., 1240
Selye, H., hormones and resistance, 1
Senkowski, B. Z., *see* Jones, B. C., 1036
——*see* Oliveri-Vigh, S., 1851
Sennello, L. T., GLC determination of methamphetamine hydrochloride in methyl acrylate–methyl methacrylate sustained-release tablets, 595
Shafi'ee, A., *see* Lokhandwala, M., 685
Shagoury, R. A., *see* Neumeyer, J. L., 1433
Shah, A. C., automated *in vitro* dissolution-rate technique for acidic and basic drugs, 1564
Shah, K. A., *see* Foye, W. O., 1839
Shah, R. S., *see* Kamath, B. R., 139
Shami, E. G., *see* Warren, R. J., 801
Shane, N., and Stillman, R., fluorometric determination of salicylic acid in buffered aspirin products, 114
Shangraw, R. F., and Walkling, W. D., effect of vehicle dielectric properties on rectal absorption of acetaminophen, 600
Sharma, H. L., *see* Sharma, V. N., 1262
Sharma, R. K., Doorenbos, N. J., and Bhacca, N. S., potential aldosterone antagonists: spiro-[androstane-17-yl-5′-oxazolidine] derivatives and their NMR spectra, 1677
Sharma, V. N., Pancholi, N. S., Sharma, H. L., Mital, R. L., and Chandra, D., phenothiazines as anticholinergics, 1262
Sharp, R. A., and Knevel, A. M., analysis of barium in barium sulfate and diagnostic meals containing barium sulfate using atomic absorption spectroscopy, 458
Shaw, S. M., *see* McDowell, R. W., 695
Shaw, S. R., *see* Wickramasinghe, J. A. F., 1669
Shealy, Y. F., and O'Dell, C. A., synthesis, antileukemic activity, and stability of 3 - (substituted - triazeno)pyrazole - 4 - carboxylic acid esters and 3-(substituted-triazeno)pyrazole-4-carboxamides, 554
——Krauth, C. A., Opliger, C. E., Guin, H. W., and Laster, W. R., Jr., triazenes of phenylbutyric, hydrocinnamic, phenoxyacetic, and benzoylglutamic acid derivatives, 1192
——O'Dell, C. A., Clayton, J. D., and Krauth, C. A., benzene analogs of triazenoimidazoles, 1426
Shefter, E., and Sackman, P., structural studies on molecular complexes V: crystal structures of sulfathiazole–sulfanilamide and sulfathiazole–theophylline complexes, 282
——and Smissman, E. E., conformation of a *trans*-diaxial decalin analog of acetylcholine, 1364
Sheppard, A. J., *see* Prosser, A. R., 909
——*see* Schertel, M. E., 1070
Sheth, B. S., *see* Beyerlein, A. M., 1317
——*see* Rice, L. M., 1760
Shih, I. K., analytical applications of *p*-nitrosobenzoic acid I: specific colorimetric determination of *m*-aminophenol in *p*-aminosalicylic acid and sodium *p*-aminosalicylate, 1853
——degradation products of chloramphenicol, 786
——identity of a major chromogen in *p*-aminosalicylic acid and sodium *p*-aminosalicylate dosage forms, 1886
——photodegradation products of chloramphenicol in aqueous solution, 1889
Shihab, F., Sprowls, J., and Nematollahi, J., solubility of alkyl benzoates II: effect of dielectric constant on the solubility of substituted alkyl benzoates, 56
——Sprowls, J., and Nematollahi, J., solubility of alkyl benzoates III: hydrogen bonding and solubility—a theoretical approach, 622
Shotton, E., *see* Rees, J. E., 1704
Shum, Y. Y., *see* De Leenheer, A., 1238
Sidell, F. R., and Groff, W. A., intramuscular and intravenous administration of small doses of 2-pyridinium aldoxime methochloride to man, 1224
——and Groff, W. A., toxogonin: oral administration to man, 860
Simon, R. K., and Rasero, L. J., Jr., tablet absorption in the rat, 1111
Simon, T. H., *see* Kay, A. I., 205
Sina, A., Youssef, M. K., Kassem, A. A., and Attia, I. A., paper chromatographic determination of oxytetracycline, 1544
Singh, B., and Christiansen, R. G., new compounds: steroidal spiroethers, 491
Sinsheimer, J. E., and Breault, G. O., chromatographic determination of benzoic acid derivatives for application to metabolism studies, 255
——Hong, D. D., Stewart, J. T., Fink, M. L., and Burckhalter, J. H., fluorescent analysis of primary aliphatic amines by reaction with 9-isothiocyanatoacridine, 141
——*see* De Leenheer, A., 1238
——*see* Rao, G. S., 190
Skidmore, D., *see* Tsakotellis, P., 84
Skinner, W. A., Johnson, H. L., Ellis, M., and Parkhurst, R. M., relationship between antioxidant and antihemolytic activities of vitamin E derivatives *in vitro*, 643
——*see* Tsakotellis, P., 84
Sklar, S., Nieforth, K. A., and Malone, M., synthesis and preliminary screening of *N*-ethyltryptamine derivatives related to reserpine and lysergic acid, 304
Slatkin, D. J., Doorenbos, N. J., Harris, L. S., Masoud, A. N., Quimby, M. W., and Schiff, P. L., Jr., chemical constituents of *Cannabis sativa* L. root, 1891
Smissman, E. E., *see* Shefter, E., 1364
Smith, D. L., *see* Beyer, W. F., 496
Smith, E. W., *see* Beyer, W. F., 1556
——*see* Flynn, G. L., 1713
Smith, F. A., *see* Lowary, L. R., 638
Smith, J. B., *see* Mollica, J. A., 1380
Smith, L. D., *see* Chiou, W. L., 125
Smith, R. B., *see* Kojima, S., 1639
Smith, R. V., and Nessen, M. A., atomic absorption analysis of sodium, potassium, and calcium in Ringer's solution, 907
——and Sood, S. P., *in vitro* metabolism of certain nornuciferine derivatives, 1654
——*see* Barfknecht, C. F., 799
Smolen, V. F., determination of time course of *in vivo* pharmacological effects from *in vitro* drug-release testing, 878
——quantitative determination of drug bioavailability and biokinetic behavior from pharmacological data for ophthalmic and oral administrations of a mydriatic drug, 354
——and Kildsig, D. O., entropic factor in the solubility of small particles, 130
——and Poust, R. I., hexachlorophene-induced changes in electrical response specificity of human finger epidermis for sodium and potassium ions, 1745
——and Schoenwald, R. D., drug-absorption analysis from pharmacological data I: method and confirmation exemplified for the mydriatic drug tropicamide, 96
——*see* Schoenwald, R. D., 1039
Smookler, H. H., *see* Adams, H. R., 1134
Soares, J., *see* Patel, H., 1905
Sofia, R. D., Segelman, A. B., Farnsworth, N. R., and Buckley, J. P., pharmacological evaluation of 3,4-dimethoxyphenylacetamide, 1240
Soine, T. O., *see* Chen, C.-H., 1634
——*see* Zoglio, M. A., 411
Solo, A. J., and Gardner, J. O., agents for alkylating steroid hormone receptors III: ω-substituted esters of 17α-hydroxyprogesterone, 1089
Solomon, H. M., *see* Gaut, Z. N., 1887
Somaiya, N. H., *see* Kapoor, A., 956
Sonnett, P. E., and Jacobson, M., tumor inhibitors II: cytotoxic alkaloids from *Annona purpurea*, 1254
Sood, S. P., *see* Smith, R. V., 1654
Spaulding, T. C., *see* Cocolas, G. H., 1749
Speaker, T. J., *see* Doukas, P. H., 184, 479
Speights, R. M., Brooks, J. D., and Barnard, A. J., Jr., determination of chloride in aluminum hydroxide gels by use of a chloride-selective electrode, 748
Spiegel, H. E., *see* Coutinho, C. B., 1014
Spiekerman, R. E., *see* Kennedy, C. C., 1139
Spitz, H. D., and Weinberger, J., determination of ethylene oxide, ethylene chlorohydrin, and ethylene glycol by gas chromatography, 271
Sprowls, J., *see* Shihab, F., 56, 622
Stefanovich, V., and Ceprini, M. Q., spectrophotometric determination of anthramycin, 781
Steinmetz, C., *see* Ostrenga, J., 1175, 1180
Stephenson, R. E., *see* Whitworth, C. W., 48
Stevens, K. L., *see* Jurd, L., 1753
Stewart, J. T., synthesis and biological evaluation of substituted α-phenylcinnamonitriles, 1244
——and Lotti, D. M., fluorometric determination of amphetamines with 3-carboxy-7-hydroxycoumarin, 461
——*see* Sinsheimer, J. E., 141
Stillman, R., *see* Shane, N., 114
Stoll, R. G., *see* De Cato, L., Jr., 140
Stone, J. C., and Wright, J., GLC analysis of the trimethylsilyl derivative of 2,4-dihydroxy - 3,3 - dimethylbutyric acid γ-lactone in pantothenyl alcohol, 163
Strahl, M. S., *see* Wells, J. N., 533
Strahl, N. R., and Barr, W. H., intestinal drug absorption and metabolism III: glycine conjugation and accumulation of benzoic acid in rat intestinal tissue, 278
Streiff, R. R., *see* Hammer, R. H., 327
Strojny, N., *see* de Silva, J. A. F., 1303
Strzelinski, E. P., *see* Hiestand, E. N., 758
Stull, R. E., Ferguson, N. M., and Ferguson, G. G., selected pharmacological studies of an alkaloidal extract of *Banisteriopsis quitensis*, 1221
Su, K. S. E., *see* Carstensen, J. T., 733
Sugita, E. T., *see* Niebergall, P. J., 1393, 1575
Suh, S.-H. K., and Hite, G., absolute configuration of antipodes of γ-chloro-β-carboxy-β-hydroxybutyric acid, chlorocitramalic acid, 930
Sullivan, G., and Henry, E. D., occurrence and distribution of phenoxazinone pigments in the genus *Pycnoporus*, 1097
——Garrett, R. D., and Lenehan, R. F., occurrence of atromentin and thelephoric acid in cultures of *Clitocybe subilludens*, 1727
Sumner, D., *see* Cressman, W. A., 132
Sundberg, D. P., *see* Borodkin, S., 1523
Sunwoo, C., and Eisen, H., solubility parameter of selected sulfonamides, 238
Svoboda, G. H., Sweeney, M. J., and Walkling, W. D., antitumor activity of an acronycine–polyvinylpyrrolidone coprecipitate, 333
Swarbrick, J., *see* Herzog, K. A., 393, 1666
Sweeney, M. J., *see* Svoboda, G. H., 333
Swintosky, J. V., *see* Caldwell, H. C., 1810
Symington, J., *see* Coutinho, C. B., 1014
Szczesniak, R. A., *see* Holcomb, G. N., 390

T

Tamagnone, G. F., *see* De Marchi, F., 1757
Tan, G. H., *see* Crouthamel, W. G., 1160
Tanner, J. T., *see* Margosis, M., 1550
Tansey, L. W., *see* Ho, B. T., 636
Tansy, M. F., Rothman, G., Bartlett, J., Farber, P., and Hohenleitner, F. J., vagal adrenergic degranulation of enterochromaffin cell system in guinea pig duodenum, 81
——*see* Hohenleitner, F. J., 471

Taraszka, M. J., relative enzymatic hydrolysis rates of lincomycin esters I: soluble esters, 1414
——transfer of clindamycin and 1′-demethyl - 4′ - depropyl - 4′ - pentylclindamycin by the cannulated-everted rat gut, 946
Tarwater, O. R., *see* Wells, J. N., 156
Tawashi, R., microscope observations of aspirin crystallization from ethanol, 1420
——*see* Bisaillon, S., 1874
——*see* Piccolo, J., 59, 1818
Tensmeyer, L. G., *see* Thakkar, A. L., 1267
Tetsuo, M., *see* Naito, S., 1257
Thakkar, A. L., and Demarco, P. V., cycloheptaamylose inclusion complexes of barbiturates: correlation between proton magnetic resonance and solubility studies, 652
——Tensmeyer, L. G., and Wilham, W. L., NMR evidence for self-association of theophylline in aqueous solution, 1267
Theimer, E. E., *see* Hasan, M., 451
Thompson, B. B., *see* LaRocca, J. P., 74
Tietjen, J., and Mancott, A., rapid assay of hydrogen peroxide solution (USP XVIII) *via* UV spectrophotometry, 460
Tishler, F., *see* Luders, R., 627
Tolbert, C. E., and Kenner, C. T., determination of lactate in parenterals containing reducing sugars, 596
Tomlinson, E., *see* Dearden, J. C., 1278
Tonchen, A., *see* Coutinho, C. B., 1014
Tong, G. L., *see* Elison, C., 1058
Tonnis, J. A., *see* Billman, J. G., 1188
Torrielli, M. V., *see* De Marchi, F., 1757
Trenk, F. B., *see* Bryant, R., 1717, 1721
Trimboli, M. A., *see* Kapoor, A., 956
Triplett, J., *see* Glasser, A. C., 122
Trojánek, J., *see* Abraham, D. J., 1085
Tsakotellis, P., Johnson, H. L., Skinner, W. A., Skidmore, D., and Maibach, H. I., topical mosquito repellents III: carboxamide acetals and ketals and related carbonyl addition derivatives, 84
Tsilifonis, D. C., *see* Penner, M. H., 1388
Tsubouchi, M., spectrophotometric determination of organic cations by solvent extraction with tetrabromophenolphthalein ethyl ester, 943
Tsuji, K., *see* Van Giessen, B., 1068
Turi, J. S., *see* Benet, L. Z., 1593
Turnball, L. B., *see* Bruce, R. B., 104
Turner, J. E., *see* Lawrence, W. H., 568, 1163
Turner, R. H., *see* Benet, L. Z., 234

U

Ueno, Y., *see* Naito, S., 245
Ullah, I., and Cadwallader, D. E., dissolution of slightly soluble powders under sink conditions II: griseofulvin powders, 230
——and Cadwallader, D. E., dissolution of slightly soluble powders under sink conditions III: transport of drug solution across screens and membrane barriers, 1496
Unnikrishnan, A., *see* Nagwekar, J. B., 375
Urbányi, T., and Lin, M. C. H., automated IR technique for determination of methylphenidate hydrochloride in tablet formulation, 755
——and Walter, A., IR determination of trace quantities of dicyandiamide and cyanamide in guanidine sulfate, 1699

V

Vacik, D. N., *see* Sam, J., 936
Vaidhyanathan, V. S., influence of complex formation on membrane transport, 886
Vaidya, S. S., *see* Doorenbos, N. J., 1236
Valentine, J. L., *see* Sam, J., 1370
Van Der Kleijn, E., *see* Sadee, W., 135
Van Giessen, B., and Tsuji, K., GLC assay method for neomycin in petrolatum-based ointments, 1068
Van Tyle, W. K., and Burkman, A. M., spectrofluorometric assay of apomorphine in brain tissue, 1736
Veresh, S. A., Hom, F. S., and Miskel, J. J., spectrophotofluorometric determination of salicylamide in blood serum and urine, 1092
Vessman, J., *see* Eksborg, S., 475
Vester, J. W., *see* Danowski, T. S., 640
Villani, F. J., Ellis, C. A., and Mann, T. A., derivatives of 10,11-dihydro-5*H*-dibenzo-[*a*,*d*]cycloheptene and related compounds V: homologous 4-azaketones and derivatives, 1586
Vogel, W. H., *see* West, N., 953
Vyas, A. H., *see* Kamath, B. R., 319

W

Wadke, D. A., *see* Kwan, K. C., 678
Waggoner, W. G., and Fincher, J. H., influence of HLB values of surfactants on ephedrine release from emulsified liquid systems, 1830
Wagner, J. G., assay of warfarin: a rebuttal, 1272
——Welling, P. G., Lee, K. P., and Walker, J. E., *in vivo* and *in vitro* availability of commercial warfarin tablets, 666
——*see* Welling, P. G., 1629
Wagner, R. L., Jr., *see* Forcier, G. A., 111
Walenrod, L., and Levinton, R., elimination of choline interference in microbiological assay of inositol in pharmaceutical products, 1856
Walker, J. E., *see* Wagner, J. G., 666
——*see* Welling, P. G., 1629
Walkling, W. D., *see* Shangraw, R. F., 600
——*see* Svoboda, G. H., 333
Wallace, J. E., and Biggs, J. D., determination of phenothiazine compounds in biologic specimens by UV spectrophotometry, 1346
Waller, C. W., *see* Fetterman, P. S., 1246
Walter, A., *see* Urbányi, T., 1699
Wan, L. S. C., stability of salicylic acid and cetrimide system in the presence of additives, 939
Wareham, D. V., *see* Cochran, T. G., 180
Warner, C., DiBernardo, F., Bylow, A., Hussain, A., and Kho, B. T., modified iodimetric determination of echothiophate iodide, 1548
Warner, D. D., and Araujo, O. E., kinetics of rheological properties of acacia solutions, 863
Warren, R. J., and Zarembo, J. E., NMR studies on acyl migration in diglyceride solutions, 307
——Ravin, L. J., Begosh, P. P., Shami, E. G., and Zarembo, J. E., NMR studies on enolization of 1-*p*-chlorophenyl-1-hydroxy-2-propanone, 801
——*see* Ravin, L. J., 329
——*see* Santoro, R. S., 791
Warrick, P., *see* Rubin, A., 1797
Washkuhn, R. J., and Robinson, J. R., relative substituent effects on alkaline solvolysis of β-lactams (2-azetidinones) and amides, 1168
——Patel, V. K., and Robinson, J. R., linear free energy models for ester solvolysis with a critical examination of the alcohol and phenol dissociation model, 736
Watson, J. R., Crescuolo, P., and Matsui, F., rapid simultaneous determination of salicylic acid and aspirin by GC I: analysis of synthetic aspirin–salicylic acid mixtures and of single-component aspirin tablets, 454
Watson, L. D., *see* Hamor, G. H., 925
Webb, H. S., *see* Benet, L. Z., 234
Weber, D. J., Mitchner, H., Kaldy, L., and Yasaki, K., content uniformity test for esterified estrogen tablets, 467
——*see* Garrett, E. R., 845
Weinberger, J., GLC determination of ethylene chlorohydrin following Co-sweep extraction, 545
——*see* Spitz, H. D., 271
Weiner, N. D., Chawdry, I., and Felmeister, A., interaction of 3-methylcholanthrene with lecithin–cholesterol mixed films, 425
——*see* Lordi, N. G., 933
Weinstein, S. H., Pfeffer, M., Schor, J. M., Indindoli, L., and Mintz, M., metabolites of naloxone in human urine, 1567
Weintraub, H., *see* Gibaldi, M., 624
Welles, H. L., Giaquinto, A. R., and Lindstrom, R. E., degradation of urea in concentrated aqueous solution, 1212
Welling, P. G., Lee, K. P., Patel, J. A., Walker, J. E., and Wagner, J. G., urinary excretion of ephedrine in man without pH control following oral administration of three commercial ephedrine sulfate preparations, 1629
——*see* Wagner, J. G., 666
Wells, J. N., and Strahl, M. S., synthesis of 3′-aminopteroic acid, 533
——and Tarwater, O. R., synthesis of azetidines, 156
West, N., Vogel, W. H., Boehme, D. H., and Gold, S., urinary excretion of chlorpromazine and chlorpromazine sulfoxide in four patients on different days, 953
Westlake, W. J., problems associated with analysis of pharmacokinetic models, 882
Whitbourne, J. E., *see* Mogenhan, J. A., 222
White, A. I., *see* Pai, V. S., 201
White, M., *see* Bowman, F. W., 1087, 1099
Whitehouse, L. W., *see* Yung, D. K., 386
Whitworth, C. W., and Stephenson, R. E., effect of three liquid additives on diffusion of atropine from ointment bases, 48
Wickramasinghe, J. A. F., and Shaw, S. R., GC determination of tolazamide in plasma, 1669
Wilder, B. J., *see* Hammer, R. H., 327
Wilham, W. L., *see* Thakkar, A. L., 1267
Wilson, R. A., *see* Rai, K. V., 1725
Windheuser, J. J., *see* Bilous, R., 1270
Wissinger, H. A., *see* Danowski, T. S., 640
Wojtowicz, P. F., and Diliberto, J. J., separation and quantitative assay of furazolidone and nifuroxime in suppositories by magnesium silicate adsorption column chromatography, 1385
Won, C. M., *see* Garrett, E. R., 1801
Woodard, G. D., *see* Cox, J. S. G., 1458
Woods, L. A., *see* Yeh, S. Y., 148, 469
Woodson, A. L., 2,4-dinitrophenylhydrazine: a sensitive quantitative reagent for determining microgram quantities of prednisone, 1538
Wright, J., *see* Stone, J. C., 163
Wu, E. C., *see* Casy, A. F., 67
Wu, M. T., and Lyle, R. E., new compounds: synthesis of dimethyl *N*,*N*′-bis(2-amino-3-oxophenoxazine-4,6-dimethyl-1,9-dicarbonyl)-*dl*-dialaninate, 1904

X

Y

Yabuuchi, Y., *see* Ishida, Y., 986
Yager, G. A., *see* Chatten, L. G., 316
Yakatan, G. L., *see* Garrett, E. R., 1145
Yamada, H., *see* Levy, G., 215
Yamaguchi, H., *see* Naito, S., 245
Yang, K. W., *see* Cannon, J. G., 1534
Yasaki, K., *see* Weber, D. J., 467
Yeh, K. C., *see* Loucas, S. P., 1109
Yeh, S. Y., and Lach, J. L., stability of morphine in aqueous solution IV: isolation of morphine and sodium bisulfite interaction product, 793
——and Woods, L. A., isolation and characterization of urinary metabolites of nalorphine in dogs and cats, 148
——Chernov, H. I., and Woods, L. A., metabolism of morphine by cats, 469
Yett, S., *see* Ostrenga, J., 1180
Young, S., *see* Poole, J. W., 1850
Youssef, M. K., *see* Sina, A., 1544
Yu, M., *see* Coutinho, C. B., 1014
Yung, D. K., Mahony, D. E., and Whitehouse, L. W., synthesis and *in vivo* antimicrobial evaluation of hydrazones of 1-phenyl-, 1-benzyl-, and 1-benzhydryl-4-aminopiperazines, 386
Yunker, M. H., and Borodkin, S., determination of rate constants for *in vitro* three-compartment transfer using a two-phase system, 52

Z

Zachariades, C., and McGavock, W. C., spectrophotometric determination of Fe (II), Fe (III), and total Fe, 918
Zaharko, D. S., *see* Bischoff, K. B., 1128
Zalucky, T. B., *see* Rice, L. M., 1760
Zanati, G., *see* Brochmann-Hanssen, E., 873, 1672

Zarembo, J. E., *see* Warren, R. J., 307, 801
Zatz, J. L., and Knowles, B., monolayers of polyvinylpyrrolidone copolymers, 1731
Zayed, A., *see* Nabih, I., 1747
Zia, H., Cox, R. H., and Luzzi, L. A., competitive binding of two sulfas and penicillin G to bovine serum albumin using NMR techniques, 45
——Cox, R. H., and Luzzi, L. A., *in vitro* binding study of epinephrine and bovine serum albumin, 89
Zimmerer, R. O., Jr., and Grady, L. T., GLC assay of sodium thyroxine, 493
Zinger, A. P., *see* Elison, C., 1058
Zoglio, M. A., Soine, T. O., and Rippie, E. G., esters of bicyclic aminoalcohols V: duration of corneal anesthesia *versus* enzymatic hydrolytic rate of benzoates of 1-, 2-, and 3-methyl-2-hydroxyquinolizidines, 411
——*see* Maulding, H. V., 40, 309

SUBJECT INDEX

A

Absolute configuration—cyclohexanol and cyclohexylamine derivatives, 180
—methyl and ethyl mandelic acids, 375
Absorption analysis, drug—theoretical considerations, 878
half-life—ethchlorvynol, 261
kinetics, buccal—saliva dilution effect, 1278
kinetics—bunolol-^{14}C, dogs, 1512
kinetics, GI—acetaminophen tablets, effect of foods, man, 1646
kinetics, GI—*dl*-2-(3-phenoxyphenyl)propionic acid (fenoprofen), man, 1797
kinetics, *in vitro*—salicylate and acetanilide through denuded intestinal musculature, rat, 1508
kinetics, labeled levodopa—oral, intravenous administration, 1014
kinetics, oral—griseofulvin solid dispersion, man, 1376
kinetics—oral phenobarbital, effect of food, rats, 1639
kinetics, oral—plasma level data, first-pass effect, 1338
kinetics—solid dispersion systems, review, 1281
oral, fast release—polyethylene glycol–insoluble drug dispersions, 1569
rates, buccal—*n*-alkanoic acids, 537
rates, half-lives, intramuscular injection—penicillins, 715
soluble antibiotics—role of surfactants in doubly ligated stomach, ligated small intestine, intact GI tract, rats, 1835
stomach and GI—vitamin B_{12}, rats, 1651
sulfadiazine—effect of bile flow, rats, 145
sustained-, nonsustained-release dosage forms—rate, extent studied in man, dog, comparison, 132
toxogonin—oral administration, 860
Absorption–dissolution parameters, comparison—acetaminophen, 561
Absorption-rate constants—warfarin tablets, 666
Acacia solutions—rheological properties, 863
Acetamidocinnamic acid, α-methylcinnamic acid hydrogenation rates—palladium-on-poly-*S*-valine, 583
Acetaminophen in dosage forms—analysis, 463
—influence of salicylic acid, man, 608
—rectal absorption from aqueous suspension, propylene glycol suspension, theobroma oil suppository, relationship to dielectric constants, 600
salicylamide—biotransformation interaction, human, 215
systemic availability—acetaminophen, acetophenetidin administration, 499
tablets—dissolution, 561
tablets—effect of foods on GI absorption, man, 1646
Acetone dimethyl acetal—dehydration agent, 295
vapor effect—drug release rates, copolymer matrix, 212
Acetylcholine analogs—conformation determination in deuterium oxide, 67
iodides, β-substituted—preparation, activity, 1749
Acetylcholinesterase reactivators—synthesis, potency relationship, *syn*-, *anti*-phenyl-*N*-methyl-2-pyridiniumketoximes, 138
Acetyl β-ethylcholine iodide, enantiomers—preparation, absolute configuration, activity, 1749
Acetyl sulfisoxazole—colorimetric determination in the presence of sulfisoxazole, 1696
Acid, base addition effects—amino acid solubility, pure solvents
Acronycine–polyvinylpyrrolidone coprecipitate—antitumor activity, 333
Activation energy, desorption—liquids from nylon, 1317
parameters—alkaline hydrolysis, benzoate esters, 736
Acyl migration—in diglycerides, effect of temperature, 307
Acyl coenzyme A synthetase—rat heart nucleotide effect, 77
***N*-Acyltryptamines,** substituted—effect on hydroxyindole-*O*-methyltransferase hydrolysis, rats, 634
Acylureas—synthesis of sulfone analog, 620
Additives—effect on stability of salicylic acid–cetrimide system, 939
Adenine nucleotides—rat heart homogenates, 77
Adenosine deaminase inhibitors—9-(1-hydroxy-2-alkyl)adenines, single binding site–bridging mechanism, theoretical, 1204
inhibitors, irreversible—9-(substituted aralkyl)-6-substituted purines, 1184
α-Adrenergic blockage—sulfur-containing aliphatic amines, antagonism of norepinephrine responses, rabbit aorta, 1743
Adrenocortical suppression—prednisolone phosphate dosage form comparison, 1028
Adsorbents, surfactants, interaction with chlorpromazine—membrane permeation effect, 571
Adsorption, physical—influence on molecular flux, lag time relationships, dimethylpolysiloxane heterogeneous barriers, 1788
Aerobic media for membrane filtration sterility testing—collaborative study, 1087
Aerosol dry powder—cromolyn sodium, crystallography, 1458
powder drugs—portable inhaler, 1559
Aging effect, emulsions—particle number, particle-size distribution, 690
effects—acetaminophen tablet dissolution, 561
hydrochlorothiazide tablets—accelerated physical stability, 263
process modification—biology, chemistry, 167
Air sampling—vacuum collection through membrane, 63
Akuammicine alkaloids—elucidation of sewarine structure by mass spectroscopy and NMR, 1581
Alcohol, phenol dissociation models, Hammett relationship—structure–reactivity relationship, benzoate esters, 736
Alcoholic, aqueous systems—amino acid solubility, 565
Alcohols, acetone, dioxane–water mixtures—sodium salicylate solubility, 432
long-chain—analysis, 645
Aldosterone antagonists, potential—spiro[androstane-17-yl-5′-oxazolidine] derivatives, 1677
Alkaloids, from benzylisoquinolines—synthesis, structure identification, (±)-bisnorargemonine, 1634
***n*-Alkanoic acids,** absorption—theoretical consideration, 537
***p*-Alkoxyphenylacetamide** derivatives—synthesized as potential analgesic agents, 158
3-(*N*-Alkylamino)propionic esters and hydroxamic acids—synthesis, 28
1-Alkyl-3-benzoyl-3-acyloxypiperidines—synthesis, 685
Alkyl *p*-hydroxybenzoates—solubility, hydrogen bonding, theoretical aspects, 622
Alkyltrimethylammonium bromides—analysis, 645
1-Amido-3-acetyl azulenes (lidocaine analogs)—synthesis, 479
Amine binary mixtures—analysis, 287
prodrugs—enamine derivatives of phenylpropanolamine, 1810
Amine–bromthymol blue complexes—stoichiometric balances, stability constants, 1584
Amine-oxides—quantitative analysis by controlled potential coulometry, 798
Amines, 2,4-dinitrobenzenesulfenamide derivatives—description, compilation, 803
primary aliphatic—fluorescent analysis using 9-isothiocyanatoacridine, 141
Amino acid solubility—hydroalcoholic solvent systems, 258
solubility—pure solvent systems, 565
9-Aminoacridine and *n*-butylisothiocyanate—isolation, characterization of thioacridone as a reaction product, 1238
Aminoalcohol esters, bicyclic—synthesis, 411
Aminoalcohols—structure–antimalarial activity relationships, 1596
3-(Aminoalkyl)-2-benzoxazolinones—preparation from 3-(chloroalkyl)-2-benzoxazolinones, 1370
4-Aminoantipyrine, absorption–exsorption kinetics—goldfish, 1360
—goldfish overturn as a function of bathing fluid concentration, 1762
ω-Amino carboxylic acid group domination—amino acid solubility, 258
4 - (Aminoethanesulfonylamino)antipyrine—biopharmaceutical studies, 245
Aminoethanesulfonylphenetidine, related compounds—biopharmaceutical studies, 249
2-Aminoethyl diphenylborate—color reagent, 451
***m*-Aminophenol**—colorimetric analysis (*p*-nitrosobenzoic acid) in *p*-aminosalicylic acid and sodium *p*-aminosalicylate, 1853
9-(*p*-Aminophenyl)acridine with acridine, aniline, and sulfur—isolation, characterization of thioacridone as a reaction product, 1238
3-Aminopiperidones—2-ethoxy, 2-carbethoxy derivatives of 2-*p*-methoxyphenylglutarimide synthesized for structure–activity studies, 618
3′-Aminopteroic acid—synthesis, 533
Aminopyrine–barbital complex—crystal structure, 699
Aminoquinolines, isomeric—dissolution constants, 371
***p*-Aminosalicylic acid**—determination in *m*-aminophenol mixtures, ion-exchange chromatography, 1694
sodium *p*-aminosalicylate—colorimetric determination of *m*-aminophenol, 1853
sodium *p*-aminosalicylate dosage form—identification of major chromogen, 3,3′-dihydroxyazoxybenzene, 1886
Aminotetrahydrofuranol derivatives—synthesis, pharmacological screening as possible anticholinergic agents, 1107
Aminothiazoles, condensation with aromatic amines—synthesis of oral schistosomiasis agents, 1251
Amphetamines—analysis, 461
dimethoxy-, rotamers—NMR spectroscopy, analysis, 1232
Ampicillin analysis—biological fluids, 728
distribution—rabbit, 805
sodium and trihydrate—pharmacokinetics, 715
Anagestone acetate—formulation effects of progestational proliferation, rabbit uterus, oral administration, 1591
Analgesic activity—substituted tetralins, 201
agents, potential—*p*-alkoxyphenylacetamide derivatives synthesized, 158
agents, potential—synthesis, pharmacological evaluation of 1-dioxolanoalkylnormeperidines, 1-dioxanoalkylnormeperidines, 1250
Analog computer simulation—stability studies, 205
Analytical methods, drugs, dosage forms—stability indicating, 335
Anesthesia, pentobarbital—influence on cryptenamine cardiovascular effects, dogs, 488
Anesthetics, local—conformation–activity relationship, 685
sparingly soluble—dissociation constants, determination, 1155
Anhydride intermediates—coenzyme A acylation, 1276
Anils, potential antianxiety agents—synthesis by condensation of ketone with amines, preliminary screening, 1903
Annona purpurea—isolation, characterization of four aporphine alkaloids, 1254

Anorectic agent, 4′-chloro-2-(ethylamino)-propiophenone—reduction of side effects found using timed-release dosage form, 1900
Antacids, liquid—contamination by *Pseudomonas aeruginosa*, survey, 604
Anthramycin—spectrophotometric determination, 781
Anthranilamides—synthesis from isatoic anhydrides, 703
Anthranilic acid and *N*-myristyl-β-aminopropionic acid—peritoneal dialysis acceleration, 1065
Antianxiety agents—synthesis of new anils, preliminary screening, 1903
Antibacterial activity—5-nitro-2-furaldehyde phenylhydrazones, 650
Antibiotics, airborne dissemination—laboratory building, 63
—effects of tetracyclines on respiratory tract, 321
β-lactams—review, 503
nonsterile market samples—microbial contamination, survey, 1099
—outline of 83 microbiological assays, 1689
—pharmaceutical aspects, 959
soluble—comparison of doubly ligated stomach, ligated small intestine, and intact GI tract absorption, rats, effect of surfactants, 1835
vitamins—automated analysis procedures, 767
Antibodies, polypeptide produced—specificity, 332
Anticholinergic agents, potential—synthesis of aminotetrahydrofuranol derivatives, pharmacological evaluation, 1107
agents, potential—synthesis, pharmacological evaluation of oxime esters from 1-azabicyclo[4.4.0]decane - 4 - one, 1266
agents, potential—synthesis, pharmacological evaluation of quaternary oximes of 10-*N*-substituted phenothiazines, 1262
Anticholinesterase poisoning—administration of 2-pyridinium aldoxime methochloride, 1224
Anticonvulsant acylureas—synthesis of the sulfone analog *N*-phenylacetylsulfamide, 620
Anticonvulsants, potential—synthesis and pharmacological screening of 1,4-dihydro - 2*H* - 3,1 - benzoxazin - 2 - one derivatives, structure–activity relationships, 1757
synthesized, evaluated—substituted 2-thioquinazolin-4-ones, 127
Antidiabetics, potential—pyrazole congeners synthesized, screened, 323
Antiestrogenics—synthesis, steroidal spiroethers, 491
Antihemolytic effects, vitamin E derivatives—correlated with antioxidant activities, 643
Antihistamine effect—β-hydroxylamine cinnamonyl hydroxamic acid action, 839
Antihistamines—activity–conformation relationships, 1764
Antihypertensive activity and side effects—cryptenamine, methyclothiazide, reserpine combinations, 1139
agents—chronic reserpine administration, myocardial surveillance, 1134
agents, potential—synthesis, evaluation of *N*-methanesulfonyl derivatives of β-phenethylamine, 1095
Anti-inflammatory action—nonsteroids, 416
agents, potential—1-(*p*-chlorobenzoyl)-5-dimethylamino - 2 - methylindole - 3-acetic acid, pharmacological evaluation, 1053
agents, potential—synthesis and pharmacological evaluation of six fluorine-containing *N*-substituted benzamides, 1723
analgesic potential—anthranilamides, 703
hydroxylamines—synthesis, pharmacological screening of Schiff base derivatives, 925
Antileukemic activity—*p*-dialkyltriazene derivatives, 1192
activity—triazeno derivatives of pyrazole esters, amides, 554
activity—triazenoimidazoles, benzene analogs, 1426
Antimalarial agents—structure–activity relationships of aminoalcohols and 2-(*p*-chlorophenyl) - 2 - (4 - piperidyl)tetrahydrofuran, 1596
Antimicrobial activity—hydrazones, 386
activity—Mannich bases tested, *Staphylococcus aureus*, *Escherichia coli*, 316
activity—neomycin in petrolatum-based ointments, 1068
activity—3-nitroso - 2 - arylimidazo(1,2 - *a*)-pyrimidines, 74
agents—determination of drug partitioning using coacervate systems, 1825
agents, potential—synthesis and biological evaluation of 4-arylazopyrazoles, 1738
agents, potential—synthesis of cinnamylphenols and hydrogenation products, pharmacological screening, 1753
agents, potential—synthesis, pharmacological screening, 17a-aza-D-homo-5-androsten-3β-ol derivatives, 1236
agents, potential—synthesis, screening, 4,17α-dimethyl-4-aza-5α-androstan-17α-ol acetate, esters, 1234
Antimitotic activity—*H. verticillata* extracts, 649
Antioxidants, vitamin E derivatives—*in vitro* evaluation of antihemolytic activities, correlation, 643
Antipodes of γ-chloro-β-carboxy-β-hydroxybutyric acid, chlorocitramalic acid—absolute configuration, 930
Antipyretic drug assay, suppositories—GLC, 1074
Antitremor activity—anthranilamides, 703
Antitumor activity—acronycine–polyvinylpyrrolidone coprecipitate, 333
activity evaluation—substituted aralkyl aldehydes, 1188
agents, potential—2-thiohydrothymines synthesized, screened, 122
Apomorphine glucuronidation—induction, inhibition, 93
—spectrofluorometric analysis of submicrogram quantities in brain, 1736
Aporphine alkaloids, *Annona purpurea*—potential tumor inhibitors, 1254
biotransformations—nornuciferine metabolism, 1654
Aporphines—biosynthesis of *Papaver somniferum*, 1880
Ariocarpus kotschoubeyanus—isolation hordenine, *N*-methyltyramine, 477
Aromatic amines, condensation with aminothiazoles—synthesis of oral schistosomiasis agents, 1251
Arthritic subjects—fenclozic acid serum level relation, activity, 366
Arylamine—determined as degradation product in chloramphenicol, 786
4-Arylazopyrazoles—synthesis and biological evaluation as antimicrobial agents, 1738
Aryl-2-piperidylcarbinols, substituted—synthesis, pharmacological screening, 936
Ascorbic acid—color formation, Fe (III) determination, 918
Aspirin, crystallization, spherulites—saturated aspirin in ethanol, 1420
dissolution—surface transformation, 267
—effect on gastric mucosae, albino rat, Mongolian gerbil, 790
—fluorometric determination, elimination of interference by salicylic acid, 1898
—gastrotoxic effects, cats, 1314
hydrolysis—salicylic acid assay effect, 114
—inducing development of gastric erosions and bleeding, albino rat, Mongolian gerbil, 790
mixture—determination of phenylephrine and phenylpropanolamine, 1229
—preparation of microcrystalline form, effect on serum levels, 1572
sodium salicylate absorption, suppositories—comparison, 867
tablets—analysis, 454
Association-, dissociation-rate constants—computation methods, 886
theophylline—aqueous solution, 1267, 1269
Atomic absorption spectroscopy—analysis, 458, 907
Atromentic acid, *Paxillus* cultures—isolation, identification, 1503
Atromentin—occurrence in 30- and 45-day-old *Clitocybe subilludens* cultures, 1727
Paxillus carpophores—isolation, identification, 1503
Atropine diffusion—ointment bases, 48
Attenuated total internal reflection—migration of CL-912 from urological jelly to collapsible tube lining, 1264
total reflectance—aspirin crystals, 267
Automated analysis—esterified estrogen tablets, content uniformity, 467
analysis, microbiological—theory, design, 764
microbiological methods—use of digital computer to minimize errors introduced by manual interpolation of potencies, 1858
procedure—methylphenidate HCl determination in tablets, 755
system—*in vitro* dissolution rates, 300
system—photometric microbiological analysis, 767
Autoradiograms, TLC—analysis, 725
17a-Aza-D-homo-5-androsten-3β-ol derivatives—synthesis, screening as possible antimicrobial agents, 1236
4-Azaketones and derivatives—synthesis, screened for biological activity, 1586
Azasteroids—synthesis, antimicrobial activity evaluation, 1234
—synthesis, pharmacological evaluation of 17a-aza-D-homo-5-androsten-3β-ol derivatives, 1236
Azetidines (3-amino-2-phenylazetidine, *p*-chloro analog)—synthesis, monoamine oxidase inhibitory activity evaluation *in vitro*, 156
2-Azetidinones and linear amides—solvolysis mechanism, substituent effects, 1168
Azomethine (Schiff base) derivatives—synthesis, pharmacological screening, 925
Azulene analogs, procainamide—synthesis, 184
1-Azulyl amides (lidocaine analogs)—synthesis, 479

B

Bacterial protein growth inhibition hypothesis—tetracyclines, 576
pyrogens—isolation and purification of lipopolysaccharide from *Klebsiella pneumoniae*, determination of constituents and pyrogen activity, 1578
Banistereopsis argentea Spring ex Juss—isolation, identification, pharmacological evaluation of seven indole alkaloids, 1209
Banistereiopsis quitensis, alkaloid extract—pharmacological screening, mice, rats, 1221
Barbiturate absorption—effect of food, rats, 1639
poisoning—treatment with peritoneal dialysis, 1767
Barbiturates, diphenylhydantoin, and salicylate—accelerated peritoneal dialysis, 1065
—nonaqueous titration in tetramethylurea, 1847
Barbituric acid and 5,5-disubstituted barbiturates—hydrolysis kinetics, pH effect, 1145
Barium—determination, 458
Bentonite—identification, 916
Benzamides, fluorinated—synthesized as potential anti-inflammatory agents, physical constants determined, screened using rat-paw edema test, 1723
Benzoate esters, *p*-substituted—alkaline hydrolysis, 736
Benzocaine, solubilization, hydrolysis—temperature effect, 901
1,4-Benzodiazepines, thermolysis, rearrangement—during GC, mass spectroscopy analysis, 135
Benzoic acid adsorption—montmorillonite, 733
(carboxyl-^{14}C) absorption, metabolism—intestinal, 278
derivatives—determination as metabolites, 255
derivatives—solubilization in nonionic surfactant micelles, distribution, 1528
derivatives—solubilization in nonionic surfactants, thermodynamic nonideality, 1531
membrane permeation—correlations between *in vitro* transfer, *in vitro* absorption, physicochemical parameters, 1666
Benzothiadiazines—hydrolysis, mechanism, pH–rate profiles, 1380
3,1-Benzoxazin-2-one derivatives—synthesis and pharmacological screening as possible anticonvulsants, structure–activity relationships, 1757
***S*-Benzyl-cysteinyl-tyrosyl-tyrosine** derivatives—synthesis, oxytocin antagonists, 896

1-Benzylisoquinolines—proposed biosynthesis in *P. somniferum*, 1672
Benzylpenicillin, deuterated—biosynthesis, isolation, PMR characterization, 1661
methyl ester, isomerization—metastable intermediate kinetics, 1273
Bicyclo[2.2.2]octane derivatives—interquaternary distances correlated with hypotensive effects, 1534
Bile—role in sulfadiazine absorption, rats, 145
salt solutions—diffusion coefficients, molecular weight estimations, from dissolution-rate data, 1105
Biliary, urinary, fecal excretion—fluphenazine-^{14}C and metabolites, 821
urinary, fecal excretion—fluphenazine-^{14}C enanthate, 829
Binding-site competition—drug–plasma, two-compartment model, 1623
Bioavailability—calcium and sodium salts of fenoprofen, man, 1797
—chewable tablets, coating effect, 1523
—effect of phenobarbital particle size, intramuscular administration, beagle dogs, 1733
estimate calculations—from plasma levels, first-pass effect, 1338
evaluation—application of spectrophotofluorometric salicylamide determination, 1092
time course determination—pharmacological data, 878
—timed-release nitroglycerin tablets, 1683
—warfarin tablets, 666
Biokinetics, mydriatic drug—pharmacological response data, 354
Biologic half-life—theoretical considerations of determination, significance, 624
membrane permeation—surfactants, 854
Biological activity, effects—phenethylamines, 655
activity–structure relationships—β-lactam antibiotics, 503
assay—comparison of vitamin A esters, 616
availability—penicillins, 715
availability—vitamin A from sterically hindered esters, 616
consequences—cellular system aging, 167
fluids—ampicillin and degradation product, analysis, 728
fluids—probenecid determination, 745
Biomembrane model, polymeric—*in vitro–in vivo*, drug-absorption correlations, 1666
polymeric—permeation characteristics, 393
Biopharmaceutics—drug properties, absorption, pharmacokinetics, 959
Biosynthesis—1-benzylisoquinolines in *P. somniferum*, proposed, 1672
deuterated benzylpenicillin—*P. chrysogenum* cultures, ^{2}H-substrates, 1661
synthesis—psychotomimetic phenethylamines, 655
Biotransformation interaction—acetaminophen, salicylamide, 215
man—acetaminophen–salicylic acid interaction, 608
metabolite formation, excretion—demoxepam, 438
pharmacodynamics—pentaerythritol tetranitrate, 274
3,6 - Bis(*p* - chlorophenyl) - 1,4 - dimethyl-2,5,7 - trioxabicyclo[2.2.1]heptane—isolation, identification from enolization of 1-*p*-chlorophenyl-1-hydroxy-2-propanone, 801
Bishydroxycoumarin—extrinsic cotton effects when bound to bovine serum albumin, 602
–human serum albumin—interaction, 196
polyvinylpyrrolidone—interaction, 720
(±)-Bisnorargemonine—synthesis, structure identification, 1634
Bis-quaternary ammonium compounds—interquaternary distance correlated with hypotensive effects, 1534
Blood levels, dogs—effect of phenobarbital particle size after intramuscular administration, 1733
drugs—parameter predictions, 882
—methocarbamol, 104
Blue tetrazolium, isonicotinic acid procedures—analysis, 345
Bonding nature—montmorillonite adsorbates, 733
Books
Advances in Drug Research, Vol. 5, 958
Alkaloid-Bearing Plants and Their Contained Alkaloids, 1957–1968, Supplement of Lloydia—The Journal of Natural Products, 958
Alzheimer's Disease, 1280
AMA Drug Evaluations 1971, 1766
Animal Experiments in Pharmacological Analysis, 1279
Antibiotic and Chemotherapy, 1908
Antibiotika-Chemotherapeutika, 334
Antimicrobial Agents and Chemotherapy—1970, 1908
Antitussive Agents, Volumes I, II, and III, 957
Bacteriophage Biochemistry, 1280
Basic Biochemistry, 1112
Basic Laser Raman Spectroscopy, 166
The Biochemical Basis of Neuropharmacology, 502
Bio-Medical Telemetry, 2nd Edition, 166
Breathing: Hering-Breuer Centenary Symposium. A Ciba Foundation Symposium, 166
British Medical Bulletin: Drugs: Development and Use, Vol. 26, No. 3, 165
British Pharmaceutical Codex 1968—Supplement 1971, 1908
British Pharmacopoeia 1968, Addendum 1971, 1432
British Veterinary Codex, 958
Cavitation, 502
Chemical Influences on Behaviour, 1432
Chromatographic and Microscopic Analysis of Drugs, 808
Clinical Cancer Chemotherapy Including Ambulatory Infusion, 166
Clinical Guide to Undesirable Drug Interactions and Interferences, 1280
Common Sense Lives Here: A Community Guide to Drug Abuse Action, 165
Control Processes in Multicellular Organisms. A Ciba Foundation Symposium, 166
Crystals and the Polarising Microscope, 502
The Dating of Pharmaceuticals, 165
Dependence Liability of "Non-Narcotic" Drugs, 1280
The Determination of Hydrazino-Hydrazide Groups, 166
A Documented Cross-Indexed Manual to Human Drug Interactions (Second Edition), 1908
Drug Abuse and What We Can Do About It, 958
1971 Drug Abuse Reference, 1280
The Economics of Drug Innovation, 334
Encyclopedia of Industrial Chemical Analysis, Vol. 9, Casein to Chromium, 334
Encyclopedia of Industrial Chemical Analysis, Vol. 10, 958
Encyclopedia of Industrial Chemical Analysis, Vol. 11, Corn Products to Drycleaning Agents, 1432
Encyclopedia of Industrial Chemical Analysis, Vol. 12, Dyes to Flour, 1766
Energy Metabolism in Trauma. A Ciba Foundation Symposium, 1766
Essentials of Molecular Pharmacology, 502
Experimental and Clinical Effects of *L*-Asparaginase, 334
The Family and Its Future. A Ciba Foundation Symposium, 1766
The Fate of Drugs in the Organism, Volumes I and II, 502
Flame Emission and Atomic Absorption Spectrometry, 1908
Formulation and Function of Cosmetics, 502
The Frozen Cell. A Ciba Foundation Symposium, 166
A Guide to Drugs in Current Use, 1112
Hagers Handbuch Der Pharmazeutischen Praxis, 1432
Handbook of Drug Interactions, 334
Handbook of Drug Interactions, 1766
Handbook of Experimental Pharmacology, 1432
Handbook of Experimental Pharmacology, Volume 28, Part 1, Concepts in Biochemical Pharmacology, 1765
Hexoprenalin: Pharmakologie und Therapeutische Anwendung Beim Asthmatischen Formendreis, 958
Hormones and the Immune Response. Ciba Foundation Group No. 36, 1766
The Human Body and the Law: A Medico Legal Study, 1280
6-Hydroxydopamine and Catecholamine Neurons, 1908
Hypertrophic Obstructive Cardiomyopathy. Ciba Foundation Study Group No. 37, 1766
Identifizierung Von Arzneistoffen, 1766
Index Nominum 1970/71, 1908
Inflammation Biochemistry and Drug Interaction, 501
Infrared Analysis of Essential Oils, 1432
Infrared Vapour Spectra, 166
An Introduction to ^{19}F NMR Spectroscopy, 166
Late Effects of Radiation, 958
Lehbuch der Pharmazeutischen Chemie, 958
Lewis's Pharmacology, 501
Lidocaine in the Treatment of Ventricular Arrhythmias, 1908
Mechanisms of Molecular Migrations (Vol. 3), 1280
Medicaments Organiques De Synthese III, 958
Methadone Maintenance, 1112
Methods of Biochemical Analysis, Vol. 19, 1432
Micromethods for the Clinical and Biochemical Laboratory, 166
Molecular Orbital Studies in Chemical Pharmacology, 808
Molecular Properties of Drug Receptors. A Ciba Foundation Symposium, 1908
Molecular Radiation Biology, 653
Nucleoside Antibiotics, 334
Official Methods of Analysis of the Association of Official Analytical Chemists, 334
Organic Solvents, Third Edition (Techniques of Chemistry, Volume 2), 1112
Permeability and Function of Biological Membranes, 958
Pesticides in the Environment (Volume 1, Part I), 1908
Pharmacie, 334
Pharmacognosy, 6th Edition, 653
Pharmacognosy and Phytochemistry, 1432
Pharmacological Experiments on Intact Preparations, 1432
Pharmacological Experiments on Isolated Preparations, 1432
Pharmacology and Therapeutics in Dentistry, 958
The Pharmacopeia of Korea—Second Edition, Part II, 1432
The Pineal Gland. A Ciba Foundation Symposium, 1766
Prescription Pharmacy: Dosage Formulation and Pharmaceutical Adjuncts, 654
Principles of Aerosol Technology, 654
Principles of Physical Chemistry for Biology and Pharmacy, Second (SI) Edition, 1432
Probit Analysis, 3rd ed., 1432
Problems Actuels de Biochimie Appliquee, 334
Progesterone: Its Regulatory Effect on the Myometrium. A Ciba Foundation Study Group, 166
Pyrogens and Fever. A Ciba Foundation Symposium, 1766
Remington's Pharmaceutical Sciences, 14th Edition, 165
Rodd's Chemistry of Carbon Compounds, Second Edition, Vol. II, Part E–Steroids, 1432
Sensorineural Hearing Loss, 1280
Short-term Changes in Neural Activity and Behavior, 502
Snake Venoms and Envenomatin (Clinical Toxicology, Vol. 3, No. 3, Sept. 1970), 334
Symposium Sur Les Progres Des Techniques Nucleaires En Pharmacodynamie, 1280
Synthetic Methods of Organic Chemistry, 166
Synthetic Peptides, Vol. I, 502
Synthetic Polymeric Membranes, 1280
Taste and Smell in Vertebrates, 1280
Teamwork for World Health. A Ciba Foundation Symposium, 1766
Teeanalyse, 958
Textbook of Pharmacognosy, Fifth Edition, 165
Ultramicro Elemental Analysis, 1112
WHO Expert Committee on Drug De-

pendence: World Health Organization Technical Report Series, 1112
Bovine serum albumin, acetylated bovine serum albumin—epinephrine binding, 89
—bound bishydroxycoumarin, extrinsic cotton effects, 602
–parabens binding — determination, fluorescent probe technique, 1821
—sulfonamide displacement, bound penicillin, 45
Bromcresol purple—less-polar amine determination, 287
***cis*- and *trans*-2-(*o*-Bromophenyl)cyclohexanols** and (+)-*cis*-2-(*o*-bromophenyl)-cyclohexylamine—synthesis, absolute configuration, 180
Bromthymol blue—total amine determination, 287
Bromthymol blue–amine complexes—stoichiometric balances, stability constants, 1584
Buccal absorption, *n*-alkanoic acids—quantitative interpretation, 537
Bufexamac—Lossen rearrangement, GLC analysis, plasma, urine, 1368
Buffer effects—coumarinate lactonization, 396
time, effects—drug transfer, rat intestine, 234
Bulbocapnine—cardiovascular effects, dogs, 1045
Bunolol, ^{14}C-labeled—synthesis, 1589
metabolites—isolation, identification, dog urine, 1516
Bunolol-^{14}C, metabolites—absorption, excretion, tissue distribution, dogs, 1512
4-Butoxyphenylacetohydroxamic acid—Lossen rearrangement, GLC analysis, plasma, urine, 1368
***dl* - 5 - [3 - (*tert* - Butylamino) - 2 - hydroxypropoxy] - 3,4 - dihydro - 1(2*H*) - naphthalenone - 1 - ^{14}C** (bunolol)—synthesis, 1589
***N* - *n* - Butyl[(5 - dimethylamino) - 1 - naphthalene]sulfonamide**—as a fluorescent probe, parabens–bovine serum albumin binding, 1821
***N* - Butyl - 5 - methoxy - 2 - furamide**—identification as photolysis product, 1425

C

Calcium—as lipase accelerator, effect on drug release from timed-release tablets, 1709
Calcium $^{+2}$—effect on heparin light scattering, 1109
Callitris columellaris—isolation of cytotoxic principle, desoxypodophyllotoxin, evaluation, 121
***Cannabis sativa* L.**—isolation and identification of chemical constituents, 1891
nine strains—phenotype definition, tetrahydrocannabinol content *versus* age, sex, plant part, 1246
Cannabinoids—chemistry and pharmacology review, 1433
Cannulation method—portal vein, 331
Canrenoate-^{3}H, potassium (SC-14266)—pharmacokinetic, metabolic fate, human, 708
Canrenone, canrenoic acid—hydrolysis–lactonization kinetics, pH effect, appropriate pharmaceutical preparations, 1801
Carbonates, unsymmetrical, 1,3-dihydroxy-2-propanone—insect repellents, potential, 1083
Carboxamide acetals, ketals—synthesis, 84
3-Carboxy-7-hydroxycoumarin-cyclic amine reaction—fluorescence, 461
Cardiovascular agents, potential—synthesis, pharmacological screening, aryl-2-piperidylcarbinols, 936
Carrageenin-induced pedal edema, rats—anti-inflammatory testing, 416
Catalyst surface-active sites—inhibition studies, 583
Catatoxic, syntoxic steroids—classification, 1
Catecholamine cardiovascular activity—bulbocapnine effect, 1045
Cell culture growth inhibition—ethylene chlorohydrin, 568
Cellular systems—aging changes, 167
Cellulose acetate phthalate films, physical properties—effect of plasticizers, 312
Ceric sulfate—phenothiazine titration, 588
Cetrimide–salicylic acid interaction, stability—effect of additives, 939
Chemotherapeutic agents, phase nonspecific—pharmacodynamic model, 892
Chloral betaine tablets—automated colorimetric assay, 1721
Chloral hydrate–quinaldine ethiodide complex—automated colorimetric assay of chloral betaine tablets, 1721
Chloramphenicol—degradation products determined, 786
serum levels—following chloramphenicol palmitate suspension administration, in children, rhesus monkeys, cats, 153
—six photodegradation products in aqueous solution isolated and identified, 1889
Chloramphenicol–urea solid dispersion system—mechanism of increased dissolution, absorption rates of chloramphenicol, 1406
Chlordiazepoxide metabolite—demoxepam, 438
metabolites—plasma levels, half-life, man, 1500
Chloride determination—aluminum hydroxide gels, 748
Chloride-selective electrode—chloride determination in aluminum hydroxide gels, 748
Chlormadinone acetate release mechanism—silicone elastomer matrix, 541
3-(Chloroalkyl) - 2 - benzoxazolinones—reactions with amines, 1370
1 - (*p* - Chlorobenzoyl) - 5 - dimethylamino-2 - methylindole - 3 - acetic acid—physiologic disposition and metabolites, animals, man, 1053
1 - *p* - Chlorobenzylidenyl - 5 - methoxy - 2-methylindene - 3 - acetic acid—physiologic disposition and metabolites, dogs, rats, 1049
Chlorocitramalic acid—synthesis from itaconic acid, 930
4′ - Chloro - 2 - (ethylamino) - propiophenone—reduction of side effects using timed-release form, 1900
1 - *p* - Chlorophenyl - 1 - hydroxy - 2 - propanone—enolization followed by NMR, characterization of equilibrium mixture, 801
2 - (*p* - Chlorophenyl) - 2 - (4 - piperidyl)-tetrahydrofuran — structure – antimalarial activity relationships, 1596
3 - (*p* - Chlorophenyl) - 2,3,4,5 - tetrahydro-1 - [(2 - imidazolin - 2 - yl) - methyl] - 1-benzazepine—GLC method of microgram quantification, 627
Chlorphenesin carbamate—pharmacokinetic parameters, compared to methocarbamol, man, 1686
Chlorpromazine and sulfoxide—urinary excretion, human, 953
permeation—dimethylpolysiloxane membrane, 571
Cholesterol–lecithin film competitive interaction effect—3-methylcholanthrene–film interaction, 425
Cholesteryl nitrate, inhibitory effect—nitrogen dioxide–cholesterol interaction, monomolecular films, 933
Choline—eliminated as interference in inositol microbiological assay, 1856
Chromatographic systems (TLC)—sulfonamide identification, 448
Chromatography, column, thin layer—isolation, 826
TLC, GLC, column—analysis, 381
Cinchona alkaloids on ion-exchange resins—resin particle-size effect on equilibrium exchange, column studies, 319
Cinnamaldehydes, substituted—synthesis, antitumor activity evaluation, 1188
Cinnamylphenols and hydrogenation products—synthesized as possible antimicrobial agents, screened, 1753
Circular dichroism—analysis, 602
—determination, penicillin activity, 1608
—structure, 180
—sulfaethidole binding to bovine serum albumin, determination, 1658
Citrus sinensis*, *C. aurantium—peel oil comparison, 381
CL-912, a 1,3-dioxalane, in urological jelly—migration to collapsible tube liner, attenuated total internal reflection, 1264
Clindamycin, transfer—in cannulated-everted rat gut, 946
Clitocybe subilludens—occurrence of atromentin and thelephoric acid in cultures, 1727
CNS activity—*B. quitensis* extract, mice, 1221
activity—indole alkaloids in *B. argentea*, 1209
depressant activity—anthranilamides, 703
depressants, potential—3-(aminoalkyl)-2-benzoxazolinones, preparation, 1370
depressants, stimulants—medium ring lactams, mice, dogs, 1058
depression—3,4 - dimethoxyphenylacetamide from *Catharanthus lanceus*, 1240
depression, Parkinsonism-like syndrome—chronic reserpine, dogs, 1134
$^{14}CO_2$-evolution, 1-^{14}C-octanoate—adenine nucleotide enhancement, 77
Coacervates, complex—drug partitioning of antimicrobial agents, 1825
Cobaltous chloride—enzyme inhibition of cortisone-induced cleft palate and methylcholanthrene tumorigenesis, albino mice, mode of action, 1878
sodium cobaltinitrite—effect on growth of methylcholanthrene-induced tumors, 473
Coenzyme A, acylation—mechanism, anhydride intermediate, 1276
Coenzyme Q_4 homologs—evaluated in muscular dystrophy treatment, 640
Cold-stress effect—urinary excretion, 2,3,5-triiodobenzoic acid-^{14}C, 695
Colorimetric analysis—spectrophotometer, 107, 215, 287, 451, 463, 541, 596, 918, 920
Colorimetry—analysis, *m*-aminophenol, 1853
—analysis, 3-hydroxy-$\Delta^{1,5}$-diene steroids, 1542
—analysis, physostigmine, 1387
—analysis, prednisone with 2,4-dinitrophenylhydrazine, 1538
—automated assay, chloral hydrate in chloral betaine tablets, 1721
—determination, acetyl sulfisoxazole, 1696
—meprobamate analysis in dissolution studies, compared to compendial methods, 1850
Column chromatography—separation, 184, 479, 596
—separation, furazolidone–nifuroxime suppositories, 1385
—separation of *Cudrania javanensis* constituents, 1729
—separation, quingestanol acetate in capsules, 1388
Compaction effect—flow indexes accuracy, 161
—effect of particle size and speed of compaction on lactose tablet density, 1866
process—role of moisture, ideal particulate system, 1704
Complex formation—bishydroxycoumarin, polyvinylpyrrolidone, 720
formation—effect on membrane transport, kinetic theory, 886
formation—thiouracils–cupric, cadmium, ferric ions, 845
Complexes, drug—in mixed solvent systems, effect on solubility, 1617
sulfathiazole with sulfanilamide and theophylline—crystal structure, 282
Compressed powder compacts—impact–rebound hardness test, 758
Compression changes—lubricant efficiency assessment, ideal particulate system, 1704
force effect—quinazolinone compound, tablet dissolution, 445
properties—powders, tablets, 1428
Compressive strength—granules, 922
Computer interpolation of potency data—use with automated microbiological methods, 1858
methods—kinetic analysis, simulated, 1079
Computer-simulated data—determination, significance of biologic half-life, 624
Concentration converter—absorbance–time curves, 300
tetracyclines—*E. coli* inhibition, 33
Conductivity—urea degradation monitoring, 1212
Configuration assignment—mitotane isomers, correction, 484
Conformation—acetylcholine analogs, 67
analysis—related to antihistamine activity, 1764
isomerism relationship—biological activity, 806
Conformational analysis, NMR spectroscopy—dimethoxyamphetamine rotamers, 1232
Contact angles and wettability—liquids on

human skin, critical surface tension determined, 1893
Containers, plastic—liquids–nylon sorption, 1317
Contaminants, in nonsterile antibiotics—survey of market samples, 1099
Contamination, *Pseudomonas aeruginosa*—in liquid antacids, 604
Content uniformity, tablets—USP XVIII requirements, probability equations, 955
Copolymers, graft—surface properties of polyvinylpyrrolidone and vinyl acetate monolayers, 1731
Coreximine production from (±)-reticuline-(3-^{14}C)—*P. somniferum*, 873
Corneal anesthesia—bicyclic aminoalcohol esters, 411
Corticosteroids—partition coefficients, 345
Cortisol, corticosterone in human plasma—determination, competitive protein-binding radioassay, 1476
Coulometry—analysis, procarbazine hydrochloride, 1851
controlled potential—quantitative analysis of amine-oxides, 798
standardization—iodine titrant, echothiophate iodide analysis, 1548
Coumarin hydrolysis—kinetics, mechanism, 1019
Coumarinic acids—lactonization, 396
Coumarins—hydrolysis, 396
natural—isolation of umbelliprenin from *Ammi majus* L. fruits, 788
Creams, ointments, semisolid—viscoelastic properties, 1351, 1356
Critical drug concentration—4-aminoantipyrine-induced overturn, goldfish, 1762
Cromolyn sodium—crystallography, 1458
Crude drugs—extraction procedures, effect on GLC analysis, 1417
Cryogenine—ganglionic activity, rats, 952
Cryptenamine, methyclothiazide, reserpine combinations—hypotensive effects and side effects, 1139
Cryptenamine–pentobarbital—cardiovascular effects, dogs, 488
Crystal structure—1:1 aminopyrine–barbital complex, 699
structures — sulfathiazole – sulfanilamide, sulfathiazole–theophylline complexes, 282
Crystallization, rheology—pharmaceutical applications, 959
—saturated aspirin from ethanol, 1420
Crystallography—cromolyn sodium (disodium cromoglycate), 1458
Crystals, diethylstilbestrol—dissolution rates, dye inhibition, 1818
sulfathiazole, diethylstilbestrol—dissolution rates, dye effect, 59
Cudrania javanensis—isolation and identification of osajaxanthone, vanillic acid, monomethyl fumarate, *p*-hydroxybenzoic acid, (−)-(*S*)-stachydrine, 1729
Cultures, plate—antibiotic detection, 63
Cyanamide—separation, IR analysis, particularly in guanidine sulfate, 1699
Cyanocobalamin-^{57}Co—stomach and GI absorption, surfactant effect, rats, 1651
Cyclamate interference—lincomycin therapy, 497
labeled—conversion to cyclohexylamine and other metabolites, *in vivo*, rats, 1341
Cycloheptaamylose inclusion complexes—barbiturates, 652
Cystinyl-tyrosyl-tyrosine derivatives—synthesis, oxytocin antagonists, 896

D

Degradation—germine-3,16-diacetate in aqueous solution, 193
products presence—pyrantel determination, 111
Dehydration, chemical—cream analysis, 295
1′ - Demethyl - 4′ - depropyl - 4′ - pentylclindamycin transfer—in cannulated-everted rat gut, 946
Demoxepam and demoxepam-2-^{14}C—metabolism, dog, 438
—chlordiazepoxide metabolite, half-life, man, 1500
Density, lactose tablets—effect of particle size and speed of compaction, 1866
Deoxygenation of water—by gas permeation, 1906
Depot tablets—*in vitro* drug availability, 1683
Depressants, new potential—structure–activity relationships, synthesis, evaluation, 3,4,5-trimethoxybenzamides, 1409
Derivative formation, antiarrhythmic drug—isolation, identification, mechanism, 627
Dermal, intradermal, ocular toxicity—ethylene chlorohydrin, 568
Design consideration—automated microbiological assay, 764
Desmethylchlordiazepoxide — chlordiazepoxide metabolite, half-life, man, 1500
Desmethyltylophorine—isolated and identified from *Tylophora indica*, 1725
Desmethyltylophorinine—isolated and identified from *Tylophora indica* and *Tylophora dalzellii*, 1725
Desoxypodophyllotoxin—isolation from *Callitris columellaris*, cytotoxicity evaluation, 121
Detoxication activity—steroids, 1
Deuteration, benzylpenicillin—*P. chrysogenum* cultures, ^{2}H-substrates, 1661
Deuterium isotope solvent effects—alkaline hydrolysis rates, esters, 736
Diagnostic meals, barium sulfate—barium determination, 458
Diagram—analog computer program, 205
—automated analyzer, esterified estrogen tablets, 467
computer program—kinetic simulation, 1079
—granule strength testing instrument, 922
—pendulum impact device, 758
3-(*N,N*-Dialkylamino)propionic esters and hydroxamic acids—synthesis, 28
Dialysis, closed loop—solute–protein binding levels, hemodialysis removal rates, 1471
equilibrium—bishydroxycoumarin, polyvinylpyrrolidone complex, 720
peritoneal—statistical analysis of effects of procedure variables, 1520
—preservative distribution determination, emulsions, comparison with mathematical models, 1422
rates—drug in simulated and human saliva, 429
—sulfaethidole binding to bovine serum albumin, determination, 1658
Diazomethane–thyroxine reaction—thyroxine analysis, 493
Diazopyrazole esters—antimicrobial activity, 554
Dicioxacillin, sodium—pharmacokinetics, 715
Dicyandiamide—separation, IR analysis, particularly in guanidine sulfate, 1699
Dielectric constant effect—amino acid solubility, 258
constant—role in rectal absorption of acetaminophen in different vehicles, 600
constants, parabens—solubility relationship, 56
Dietary considerations—GI absorption of acetaminophen tablets in man, 1646
4(or 2)-(β-Diethylaminoethylamino)-1,2(or 3,4)-cyclohexenothiaxanthone hydrochloride—synthesis as potential schistosomicidal and carcinostatic agents, 1747
Di-(2-ethylhexyl) sodium sulfosuccinate, related esters—determination, 920
Diethylstilbestrol microcrystals—dissolution rates, dye inhibition, 1818
Die wall effects—studied using ideal particulate system of sodium chloride and water, decahydronaphthalene, or paraffin, 1704
Differential absorption—analysis, 602
scanning calorimetry—identification, fluprednisolone solid phase, 1485
thermal analysis—heat of fusion, sulfonamides, 238
thermal analysis—monitoring, aging sulfathiazole–urea solid dispersions, 1333
Diffusion cell—chlorpromazine membrane permeation determination, 571
coefficients, salicylamide–micelle species—calculated from dissolution, solubility data, 1105
equation, first order—dilution correction, 1278
membrane—physical adsorption influence on molecular flux, heterogeneous dimethylpolysiloxane barriers, equations, 1788
system—development of a vertical membrane equicompartment diffusion cell with high area to volume ratio, 1713
4,4′ - Diformamidodiphenylsulfone—pH - dependent hydrolysis, 606
Digital computer programs—subroutine NONLIN, 1393
Digitoxin, digoxin tablets—gitoxin identification, 298
Digitoxin–polyethylene glycol 6000 solid dispersion—dissolution rate, 1569
Diglycerides—acyl migration, using NMR, 307
1,4-Dihydro-2*H*-3,1-benzoxazin-2-one derivatives—synthesis as possible anticonvulsants, screened for pharmacological activity, structure–activity relationships, 1757
10,11 - Dihydro - 5*H* - dibenzo[a,d]cycloheptene and related compounds—synthesis of 4-azaketones and derivatives, 1586
Dihydrofolate reductase binding—methotrexate, 1128
7,8-Dihydro-14-hydroxynormorphinone, naloxone, and *N*-allyl-7,8-dihydro-14-hydroxynormorphine—isolated and identified as metabolites of naloxone in human urine, 1567
3,3′ - Dihydroxyazoxybenzene — identification as a major chromogen in *p*-aminosalicylic acid, sodium *p*-aminosalicylate dosage form, synthesis, photosynthesis, 1886
2,4-Dihydroxy-3,3-dimethylbutyric acid γ-lactone—determination in pantothenyl alcohol, 163
13,-Dihydroxy-2-propanone carbonates—synthesis, insect repellents, potential, 1083
3′,5′-Diiodo-4′-hydroxydiphenylether system—role in color formation of thyroxine and nitrous acid, 1259
Dilution effect correction—first-order diffusion equation, 1278
Dimenhydrinate—isolation, identification of 8 - (2 - diphenylmethoxy - *N* - methylethylamine)-1,3-dimethylxanthine, 791
Dimers, theophylline—in aqueous solution, NMR spectroscopy, 1267
Dimethoxyamphetamine rotamers—NMR spectroscopy, analysis, *ABX* pattern, 1232
3,4 - Dimethoxyphenylacetamide — pharmacologically evaluated for CNS depression, hypocholesterolemic activity, 1240
3(a) - Dimethylamino - 2(a) - acetoxy - *trans* - decalin methiodide—conformational X-ray analysis, muscarinic potency, 1364
4-Dimethylamino-3-tetrahydrofuranol, esters—synthesis as possible anticholinergic agents, pharmacological evaluation, 1107
4,17α - Dimethyl - 4 - aza - 5α - androstan-17β-ol acetate, related compounds—synthesis, screening as antimicrobial agents, 1234
Dimethyl *N,N′*-bis(2-amino-3-oxophenoxazine - 4,6 - dimethyl - 1,9 - dicarbonyl)-*dl*-dialaninate—synthesis, 1904
N^{α},N^{α}-Dimethylhistamine—isolation, identification, 495
Dimethylpolysiloxane barriers, heterogeneous—influence of physical adsorption on molecular flux, equations, 1788
Dimethyl sulfate–probenecid reaction—probenecid analysis, 745
2,4-Dinitrobenzenesulfenamide derivatives—compilation and description of 72 amines, 803
2,4 - Dinitrophenylhydrazine — colorimetric reagent, analysis of prednisone, 1538
1 - Dioxanoalkylnormeperidines — synthesis as possible analgesics, 1250
1 - Dioxolanoalkylnormeperidines—synthesis as possible analgesics, 1250
Diphenylhydantoin and methyl derivatives, analysis in biological material—GLC and mass spectroscopy, 1216
5 - (*p* - hydroxyphenyl) - 5 - phenylhydantoin—determination, 327
metabolite—plasma protein binding, rats, man, 1642
8 - (2 - Diphenylmethoxy - *N* - methylethylamine) - 1,3 - dimethylxanthine — isolation, identification from dimenhydrinate, 791
α,α′-Dipyridyl—color formation, Fe (II) determination, 918
Disintegration, dissolution times, hydrochlorothiazide tablets—effect of dissolution media, 795
tablets—medicaments, disintegrant effects on mean pore diameter and porosity, 1325
Disodium cromoglycate—crystallography, 1458

Dispersions, solid systems—review, 1281
solid, using polyethylene glycol 6000—in formulating organic liquid drugs, 125
Dissociation constants—aminoquinolines, 371
—sparingly soluble substances, 1155
Dissolution, absorption, chloramphenicol solid dispersed in urea—mechanism of increased rates, 1406
absorption-rate correlation—warfarin tablets, 666
aspirin crystals—kinetic, thermodynamic parameters, 267
griseofulvin powders—sink conditions, 230
media, hydrochlorothiazide tablets—effect on disintegration, dissolution, 795
monitoring tablets—use of sodium ion-selective electrode, 1756
poorly water-soluble drug—parameters affecting, 445
rate testing—automated, multiple system, 1556
rates—automated procedure, 300
rates, crystals—water-soluble dye effect, 59
rates—diethylstilbestrol microcrystals, inhibition by water-soluble dyes, 1818
rates—digitoxin, 1/-methyltestosterone, hydrocortisone acetate, prednisolone acetate solid dispersions, 1569
rates—effect of fluid motion and activation energy, Turbula shaker mixer and rotating-disk methods compared, 1874
rates, fluprednisolone phases—*in vivo, in vitro* comparison, 1488
rates, *in vitro*, anagestone acetate—correlated to *in vivo* bioavailability, rabbits, 1591
rates under sink conditions—equations presented considering back transfer, 1575
slightly soluble powders—sink conditions, 1496
studies, meprobamate—development of applicable colorimetric method, 1850
test—rotating-basket method, 496
Distribution coefficient correlation—hydrophilic–lipophilic balance, nonionic surfactants, 648
coefficients—salicylic acid, erythromycin, two-phase system, 52
rabbit—anhydrous, trihydrate, and metampicillins, 805
Distribution-rate constants, volumes, human—phosphonomycin, 678
Dog, quantitative model—nondisintegrating sustained-release tablet evaluation, 132
Dosage forms, fast release—solid dispersion systems, review, 1281
Dose–effect relationships—cyclophosphamide on cell systems of mice, 892
Dose-independent symptoms—toxogonin, 860
Dose–pharmacological effect relationship determination—pharmacological data, 96
Dose–response interpolation in automated microbiological methods—computer interpolation of potency, 1858
Dosing calculations—asymptotic minimum drug level, 406
Drug absorption, GI, pH effect—sulfaethidole and barbital, rats, 1160
assay, multicomponent suppositories—GLC method, 1074
concentration, goldfish—overturn as a function of bathing fluid concentration, 1762
displacement from plasma protein binding sites—peritoneal dialysis accelerators, 1065
dissolution—equations developed considering back transfer, 1575
distribution, *in vivo*—computerized simulation, 1079
partitioning—microbiological determination, gelatin–acacia coacervate system, 1825
poisoning—treatment with peritoneal dialysis, 1767
release—methyl acrylate–methyl methacrylate matrix, 209, 212
safety—skeleton matrix depot tablets, nitroglycerin, 1683
solubility—multicomponent systems capable of interacting in solution, deviation from individual solubility profiles, 1617
transfer, passive—everted rat intestine, 326
transport, everted rat intestine—monosaccharide effect, 225
transport, everted rat intestine—potassium-ion inhibition, 1813
transport, screens, membrane barriers—effect of impeller, agitation, temperature, polysorbate 80, 1496
Drug-absorption analysis—pharmacological data, 96
Drug–plasma protein binding—determination, fluorescent probe technique, 1821
protein binding—quantitation of nonlinear equations, 1623
Drug–protein binding—determination, fluorescent probe indicators, 1430
Drug-release rates—lipase–lipid–sulfamethizole systems, 1709
tests, *in vitro*—optimization, 878
Drug-transfer rates, *in vitro*—effect of intestinal musculature, rat, 1508
Dyes, water soluble—drug crystal dissolution, inhibition, 59, 1818

E

Echothiophate iodide—analysis, iodimetric titration of thiocholine, 1548
Edetic acid—treatment of rat intestinal musculature, effect on drug transfer, 1508
Editorials
Advancing with Caution (July)
20th Century Plague (September)
Guidelines or Draglines? (May)
The Metric Move (October)
"Patent" Medicines vis-à-vis An Enlightened Society (February)
The People's Right to Know (November)
Prepackaged Prescriptions (August)
Readers' Opinions Solicited (January)
Restraints on Abbreviations (December)
Reviewer's Guidelines (June)
Tapping Our Resources (April)
Toward a World View (March)
Electrolyses, controlled potential—quantitative analysis of amine-oxides, 798
Electron microscopy—detection of liver damage induced by *N*-γ-phenylpropyl-*N*-benzyloxyacetamide, 1576
Emepronium bromide, determination in human urine—by ion-pair extraction method, 475
Emulsifier–water interaction—role in phase equilibria of water–emulsifier–propellant systems, 1883
Emulsion—analysis, 295
Emulsions, oil/water—flocculation, coalescence kinetics, 690
Enamine derivatives of phenylpropanolamine—prodrugs, pharmacological evaluation, 1810
Enterochromaffin cell system, guinea pig—vagal adrenergic degranulation, 81
Entropic factor—small particle solubility, 130
Enzymatic hydrolysis—bicyclic aminoalcohol esters, 411
Enzyme activity—human liver, normal, cirrhotic, noncirrhotic abnormal, comparison, 611
catalysis—formation of acyl coenzymes A, 1276
inhibition—cobalt compounds, possible mode of action, 1878
inhibitors—single binding site–hydrophobic–hydrophilic bridging, theoretical, 1204
irreversible site-directed inhibitors—9-(substituted aralkyl)-6-substituted purines, 1184
Ephedrine—cerebral metabolism effect, dogs, 1320
release rates—effect of surfactant HLB values, oil and water emulsified systems, dialysis technique, 1830
sodium pentobarbital—dialysis rates, saliva, 429
sulfate—oral commercial preparations, urinary excretion rates without pH control, man, 1629
Epidermis, electrical response specificity—hexachlorophene-induced changes and its mechanism of action, 1745
Epifriedelanol—isolated and identified from *Cannabis sativa*, 1891
Epinephrine binding—bovine serum albumin, 89
Equilibrium dialysis—analysis, 196
dialysis—drug–plasma protein binding, 1642
Ergot alkaloids, radioactive peptides—biosynthesis, degradation, isotope distribution, 949
Eriodictyol, eriocitrin—determination, 451
Erythrocytes, hemolysis—phosphate buffer solutions, 1033
Erythromycin transfer rate—two-phase system, 52
Estradiol benzoate—GLC internal standard, 493
Estrogen (esterified) tablets—content uniformity test, 467
Ethacrynic acid—polarographic assay, dosage forms, 1702
Ethchlorvynol levels—urine, serum, 261
Ethylene chlorohydrin—acute toxicity studies, 568
chlorohydrin—determination, 545
chlorohydrin—subacute toxicity, cardiovascular, respiratory, neuromuscular, sensitizing potential, sleeping time effects, 1163
oxide, chlorohydrin, and glycol—determination, 271
oxide in plastics—determination, 222
oxide sterilization—ethylene chlorohydrin toxicity evaluation, 1163
oxide-sterilized materials—ethylene chlorohydrin extraction, determination, 545
propylene glycol dinitrates—metabolism, pharmacology, 1599
***N,N'*-Ethylenediaminetetraacetic acid**—ferrous-ion complexing, pyridoxine bioassay, 1481
***N*-Ethyltryptamine** derivatives—synthesized, screened for reserpine-like, LSD-like activity, 304
Everted rat intestine—passive drug transfer, 326
Excipient–drug ratio—tablet dissolution effect, 445
Excretion kinetics—bunolol-^{14}C, dogs, 1512
kinetics, labeled levodopa—oral, intravenous administration, 1014
rates, urinary—ephedrine sulfate, without pH control, 1629
urinary—^{14}C-cyclamate, cyclohexylamine and other metabolites, rats, 1341
Expiration dating—guides for determining standard temperatures, 927
Extraction, Co-sweep—ethylene chlorohydrin, 545

F

Fe (II), Fe (III), total Fe in aqueous solution—determination, 918
Fecal excretion—7-hydroxyfluphenazine, 826
Fenclozic and ^{14}C-fenclozic acids—pharmacokinetic properties, 366
Fenoprofen—absorption, distribution, calcium and sodium salts bioavailability, man, 1797
—GLC analysis in human plasma, 1062
Fermentation beers—spectrophotometric determination of antibiotic, anthramycin, 781
Ferric acetohydroxamate—formation in the colorimetric determination of acetyl sulfisoxazole, 1696
hydroxamate procedures—analysis, 920
Fetal malformation, morphine induced—histamine, diphenhydramine effects, 420
maternal levels—2,3,5-triiodobenzoic acid-^{14}C, metabolites, 695
Films, cellulose acetate phthalate—effect of plasticizers on physical properties, 312
Fines concentration in granules—flow effect, 752
—maximum flow rate, 548
Flame photometry—analysis, 907
Flocculation, coalescence behavior—diluted o/w emulsions, 690
Flow property indexes—compaction effect, 161
rates—diameter of particles, orifice, 548
rates, granules—optimum lubricant size, concentration, 752
Flowometer—granulation flow rates, 548
Fluid motion—effect on dissolution rates, 1874
Fluidized bed granulation—effects of process variables on granule and tablet physical properties, 1869
Fluocinolone acetonide, fluocinonide topical gels—skin penetration, 1175
Fluorescence, estimation—UV light, 298
pH dependence—riboflavin, related isoalloxazine derivatives, 628
Fluorescent probe technique—parabens–

bovine serum albumin binding determination, 1821
Fluoride-specific ion electrode—organically bound fluorine determination, 1036
Fluorine, organically bound—determination, 1036
Fluorometry—analysis, 114, 461, 728
—analysis, biological fluids, 833
—analysis, reserpine and rauwolfia alkaloids, 1862
—determination, drug–protein binding, 1430
—determination of aspirin without interference of salicylic acid, 1898
—formation, analysis lithium–8-quinolinol complex, 1762
quenching TLC—analysis, 255
Fluphenazine-^{14}C dihydrochloride—metabolic fate, dog, monkey, 821
enanthate—metabolism, excretion, 829
metabolite—identification, 826
Fluprednisolone, crystalline phases—dissolution rates comparison, *in vivo*, *in vitro*, 1488
solid phases—isolation, characterization, 1485
Flurazepam and metabolites—spectrophotofluorometric assay, blood, urine, dog, human, 1303
Folic acid activity—3′-aminopteroic acid effect, 533
Foods—effect of high carbohydrate, high protein, high lipid test meals on GI absorption of acetaminophen tablets, man, 1646
Formic acid–chloroform solution—salicylic acid fluorescence, 114
Formulation, effect on progestational proliferation, rabbit uterus—preliminary tablet screening of anagestone acetate, 1591
Friedelin—isolated and identified from *Cannabis sativa*, 1891
Furazolidone–nifuroxime suppositories—separation, analysis, 1385

G

Ganglionic activity—cryogenine effect, rats, 952
Gas permeation—utilized for reducing oxygen levels in water, 1906
Gastric mucosae—effect of aspirin, albino rat, Mongolian gerbil, 790
mucosa injury—multidrug simultaneous evaluation, animals, 1314
Gastrointestinal serotonin, reduction—response to autonomic nerve stimulation, 471
GC—analysis, 454
Gelatin–acacia complex coacervate system—microbiological determination of drug partitioning, 1825
Germine-3,16-diacetate reactions—aqueous solution, 193
Gerontology, experimental—review of literature, 167
Gingival hyperplasia—effect of drug–plasma protein binding, 1642
Gitoxin—identification, estimation, 298
GLC—analysis, 163, 222, 255, 271, 375, 493, 545, 595, 645, 708, 799, 909, 913, 946, 1074
—analysis, bufexamac, 1368
—analysis, diphenylhydantoin and methyl derivatives, 1216
—analysis, methamphetamine and pentobarbital in blood, 1492
—analysis of crude drugs, effect of extraction procedures, 1417
—analysis, *dl*-2-(3-phenoxyphenyl)propionic acid (fenoprofen) in human plasma, 1062
—analysis, tetrahydrocannabinol, 1246
—analysis, tolazamide in plasma, 1669
—assay, iodoamino acids, 1270
—assay method, neomycin, 1068
—determination, 1049, 1053
—determination, antiarrhythmic drug, 627
—determination, ephedrine sulfate in urine, 1629
electron-capture detection—analysis, 261
flash methylation—analysis, 327
—identification, 411, 873
–mass spectroscopy, combined—analysis, 745
—thermolysis, rearrangement of 1,4-benzodiazepines, on column, 135
Glucose metabolism—vanadium effect, rat, 482
xylose—passive-transport inhibition, 225
Glycerol trinitrate—metabolism, pharmacology, 1599
Glyceryl monostearate—as lipase accelerator, effect on drug release from timed-release tablets, 1709
Goldfish, overturn—4-aminoantipyrine absorption–exsorption kinetics, 1360
overturn—relationship between bathing fluid and body drug concentrations, 1762
Granulating agents effect—physical stability, tablets, 263
Granulation, fluidized bed—effects of process variables on granule and tablet physical properties, 1869
Granule flow rates—lubricant size, concentration effects, 752
strength determination—instrumentation, 922
Griseofulvin, crystalline, microcrystalline—Van't Hoff plot of relative solubilities, 130
powders—dissolution, 230
solid dispersion—absorption kinetics, man, 1376
Guanidine sulfate—separation, analysis of dicyandiamide and cyanamide, 1699
Gymnema sylvestre leaves—constituents, 190
Gymnestrogenin, gymnemagenin—isolation, identification, 190

H

Half-life, drug biologic—theoretical considerations for correct interpretation, 624
Halogens—neutron activation analysis, drugs, 1550
Helical conformation—polyamino acid, 583
Hematinic salts—determination of iron content, 918
Hemodialysis removal rates—dynamic closed-loop dialysis, 1471
Hemolysis curves—phosphate buffer solutions, 1033
Heparin light scattering—effect of calcium $^{+2}$, 1109
lung, mucosal derived—comparison of neutralization by protamine sulfate, *in vivo*, *in vitro*, 638
Hepatic lipid accumulation—induced by W-1372, detected by electron microscopy, 1576
Hexachlorophene—role in changes in electrical response specificity for sodium and potassium ions, human finger epidermis, mechanism of action, 1745
Hexahydrocoenzyme Q_6—evaluation of use in pseudohypertrophic muscular dystrophy, 640
Hexamethonium congeners—bicyclo[2.2.2]-octane, hypotensive activity, 1534
Hippuric acid formation—intestinal metabolism, benzoic acid, 278
***N*^{1} - Hippuryl - 4 - arylazo - 3,5 - dimethylpyrazole** derivatives—synthesis and biological evaluation as antimicrobial agents, 1738
Histamine, diphenhydramine effects—morphine-induced teratogenesis, 420
HLB values, surfactants—influence on ephedrine release characteristics from emulsified liquid systems, dialysis technique, 1830
Homatropine, solubilization, hydrolysis—temperature effect, 901
Hordenine—isolation from *Ariocarpus kotschoubeyanus*, 477
Hormones and resistance—literature review, 1
Human platelet lysate—evaluation of influence of nonsteroidal anti-inflammatory drugs on nicotinate phosphoribosyl transferase, mechanism of action, 1887
Hydrazones of 1-phenyl-, 1-benzyl-, and 1-benzhydryl - 4 - aminopiperazines—synthesis, 386
Hydroalcoholic solvent systems—amino acid solubility, 258
Hydrochlorothiazide, 3- and 2-ethyl analogs—hydrolysis, mechanism, pH–rate profiles, 1380
tablets—age effect, 263
tablets, disintegration, dissolution—effect of dissolution media, 795
Hydrocinnamaldehydes, substituted—synthesis, antitumor activity evaluation, 1188
Hydrocortisone acetate–polyethylene glycol 6000 solid dispersion—dissolution rate, 1569
Hydrogenic orbitals—octahedral hybridization, 647
Hydrogen peroxide solution—analysis, 460
Hydrolysis—canrenone, 1801
—itobarbital, 40
kinetics, parameters—barbituric acid and derivatives, 1145
pH dependent—4,4′-diformamidodiphenylsulfone, 606
products—ampicillin, 728
rates and mechanism—benzothiadiazines, 1380
rates, *in vivo* enzymatic—lincomycin esters, 1414
rates—*p*-substituted benzoate esters, 736
Hydrophilic–lipophilic balance—effect of polysorbate 60 and sorbitan monostearate values on ephedrine release rates in emulsified systems, 1830
nonionic surfactants—distribution coefficient correlation, 648
Hydroxamic acid derivative—vasomotor, α-block negating action, 839
formation—lactate analysis, 596
9 - (1 - Hydroxy - 2 - alkyl)adenines—synthesis, adenosine deaminase inhibitors, 1204
3 - Hydroxyazobenzene - 4′ - carboxylic acid—formation, colorimetric analysis of *m*-aminophenol with *p*-nitrosobenzoic acid, 1853
3-Hydroxy-$\Delta^{1,5}$-diene steroids—reaction with aluminum chloride in benzene–nitrobenzene, colorimetric analysis, 1542
β-Hydroxy-2,4-dimethoxybenzylpiperazine—synthesis, structure determination, 1257
7-Hydroxyfluphenazine—fluphenazine metabolite, 826
Hydroxyindole - *O* - methyltransferase—substituted *N*-acyltryptamines, effect on hydrolysis, rats, 634
—tryptamines, benzoyl, benzenesulfonyl substituted, synthesis, inhibitory activities, 636
β-Hydroxylamine cinnamonyl hydroxamic acid—hypotensive, α-block negating action, 839
Hydroxylamines, *O*-substituted—synthesis of Schiff-base derivatives, pharmacological screening, 925
β - Hydroxy - β - methylglutaryl - CoA reductase inhibitors—3-methyl-4-phenylbutenoic acid isomers tested, 614
10 - Hydroxynortriptyline—identification as major metabolite of nortriptyline in human urine, GLC, 1403
***N* - (*p* - Hydroxy - β - phenylethyl) - β - hydroxy - *trans* - cinnamamide**—isolated and identified from *Cannabis sativa*, 1891
5 - (*p* - Hydroxyphenyl) - 5 - phenylhydantoin—plasma protein binding, rats, man, 1642
17α - Hydroxyprogesterone ω - substituted esters—synthesis, Clauberg activity, 1089
7 - (2 - Hydroxypropyl)theophylline solutions—pKa determinations, 309
5-Hydroxytryptamine cardiovascular activity—bulbocapnine effect, 1045
Hypobranchial glands, *Thais haemastoma*—pharmacology, toxicity, 1842
Hypocholesterolemic activity—3,4-dimethoxyphenylacetamide from *Catharanthus lanceus*, 1240
Hypoglycemic activity—tecomine, stability evaluation, 1142
agents—pyrazole congeners synthesized, screened, 323
Hypotensive activity—3-(*N*-alkylamino)propionic esters and 3-(*N*,*N*-dialkylamino)-propionic esters, hydroxamic acids, 28
activity—bis-quaternary ammonium compounds of bicyclo[2.2.2]octane, 1534
activity—N^{α},N^{α}-dimethylhistamine, 495
Hypotonic, hypertonic solutions effect—passive drug transfer, 326
Hyptis verticillata—cytotoxic principles, 649

I

Ianthella sp.—hypotensive constituent, 495
Immunochemical properties—linear polypeptide, known sequence of amino acids, 330
Impurity interference—zinc determination, 592

of dimenhydrinate—isolation, identification of 8-(2-diphenylmethoxy-*N*-methylethylamine) - 1,3 - dimethylxanthine, 791
Incompatibilities, dosage forms—determination, 335
Indentation volume measurement—compressed powder compacts, 758
Indolizine Mannich base derivatives—TLC requirements, characterization, 486
Indomethacin, indene analogs—physiologic disposition and metabolites, animals, man, 1053
indene analogs—physiologic disposition and metabolites, dogs, rats, 1049
Inhalation toxicity—ethylene chlorohydrin, 568
Inhaler, portable—aerosol powder drugs, 1559
Inhibitory activities—substituted tryptamines, 636
Inositol—microbiological assay in the presence of choline without interference, using *Schizosaccharomyces pombe* as test organism, 1856
Instrumentation—granule strength testing, 922
—pilot plant lyophilizer, 774
Interactions—possible potentiation of reserpine acetate by deoxycholic acid, 140
Interelemental interferences—sodium, potassium, calcium determination, 907
Interfacial area, phase volume, stirring rate, effects—transfer-rate constants, 52
Intestine, everted, noneverted—absorption kinetics, 234
Iodimetric titration—thiocholine, echothiophate iodide analysis, 1548
Iodine—oxidation of procarbazine hydrochloride, coulometric titration, 1851
Iodoamino acids—GLC analysis, thyroid extracts, 1270
1 - (*p* - Iodobenzenesulfonyl) - 3 - *n* - propylurea-^{126}I—synthesis, 390
Ion, radii—sodium salicylate, 432
Ion-exchange chromatography—determination of *p*-aminosalicylic acid in *m*-aminophenol mixtures, 1694
resins–cinchona alkaloids—resin particle-size effect on equilibrium exchange, column studies, 319
resins, polycarboxylic acid—taste coverage, chewable tablets, 1523
Ionization-constant determination—using 7-(2-hydroxypropyl)theophylline, potentiometric titrimetry, 309
Ion-pair extraction method—determination of emepronium bromide in human urine, 475
IR and visible spectrophotometry—identification, 144
IR spectrophotometry—analysis, 67, 469, 622
—analysis, trace dicyandiamide and cyanamide, 1699
—automated analysis procedure, 755
—identification, 28, 104, 148, 180, 193, 201, 381, 390, 411, 533, 649, 873, 1895
—identification, 3-(aminoalkyl)-2-benzoxazolinones, 1370
—identification, fluprednisolone solid phase, 1485
—structure, 74, 184, 190, 386, 618, 685, 930, 1089, 1257
—structure, identification, 122, 156, 158, 793
—structure, work softening of soft paraffins, 1198
Isoelectric pH—amino acid minimum solubility, 565
***N* - Isopropyl - α - (2 - methylhydrazino) - *p*-toluamide hydrochloride**—analysis, coulometric titration, 1851
Isoteniscopic method—solvent vapor pressure determination, 238
9-Isothiocyanatoacridine reagent—fluorescent analysis, primary aliphatic amines, 141
Isotonic coefficients, phosphate buffer solutions—erythrocytes hemolysis, 1033
Itobarbital—hydrolytic degradation, 40

J

K

Kaolin—identification, 916
Ketimines, potential antianxiety agents—synthesis, preliminary pharmacological screening, 1903
Kinetic analysis—pilocarpine and pilocarpic acid aqueous solutions, 1465
parameters, Michaelis–Menten—renal tubular secretion, *p*-alkylated mandelic acids, 375
Kinetics—complex formation, membrane transport, theoretical, 886
drug release—copolymer matrix, 209
—ethchlorvynol absorption, excretion, 261
mechanisms—coumarinic acid lactonization, coumarin hydrolysis, 396
—multiple-dosing drugs, 406
—o/w emulsion flocculation, coalescence, 690

L

Labile functional group assays—stability indicating, 335
Laboratory contamination—antibiotics, airborne, 63
β-Lactam antibiotics—physical, chemical properties, 503
unfused, and linear amides—solvolysis mechanism, substituent effects, 1168
Lactams, medium ring derivatives—CNS activities, mice, dogs, 1058
Lactate determination—parenterals containing reducing sugars, 596
Lactonization—canrenoic acid, 1801
coumarinic acids—kinetics, mechanism, 1019
Lactose, crystalline and spray dried—tablet density changes related to particle size and compaction speed, 1866
Laplace transforms, inverse—use of general partial fraction theorem, 1593
Lecithin–cholesterol mixed films—competitive interaction, 425
Lemon bioflavonoid complex—eriodictyol, eriocitrin determination, 451
Leukemia L-1210 inhibition—triazenopyrazoles, 554
Levodopa, absorption and excretion, dogs—pharmacokinetics, 1014
Lidocaine analogs—synthesis, 1-azulyl amides, 1-amido-3-acetyl azulenes, 479
Ligand conformational free energy—receptor activation, 806
Light stability, chloramphenicol—using sunlight, UV, and tungsten light, in three solvents, six photodegradation products isolated and identified, 1889
Lincomycin cyclamate—synthesis, characterization, 497
esters, dog serum, simulated intestinal fluid—enzymatic hydrolysis rates, 1414
Linear nonisothermal stability studies—simulation, 205
Linearity—drug release from matrix *versus* square root of time, 209
Lipase–lipid–drug system—effect of lipase accelerators on drug-release rates, 1709
Lipopolysaccharide, pyrogens—isolation, purification, characterization, activity, 1578
Liquid scintillation counting—analysis, 482
Lithium carbonate pharmacokinetics—two-compartment model, 882
Lithium–8-quinolinol coordinate covalent complex—formation, fluorescence, 1762
Liver, human, normal, cirrhotic, noncirrhotic abnormal—determination, comparison of MAO activity, 611
Lossen rearrangement—4-butoxyphenylacetohydroxamic acid (bufexamac), 1368
LSD-like activity—*N*-ethyltryptamine derivatives synthesized, screened, 304
Lubricant size, concentration effects—granule flow rates, 752
Lyophilizer, instrumented—pilot plant, 774
Lysergic acid structural analogs—literature review, 809
Lysergide—cerebral metabolism effect, dogs, 1320
Lysicamine—metabolic and photolytic conversion from nornuciferines, identification, 1654

M

Mannich bases—antimicrobial activity testing, *Staphylococcus aureus, Escherichia coli,* structure–activity relationships, mode of action proposed, 316
from indolizines—TLC studies, 486
MAO activity—human liver, normal, cirrhotic, noncirrhotic abnormal, comparison, 611
Marijuana—chemistry and pharmacology review, 1433
effects—6-week pharmacological and toxicity study, rats, 1761
Mass spectroscopy—analysis, 135
—analysis, diphenylhydantoin and methyl derivatives, 1216
—identification, 28, 649, 826, 1516
—identification, lysicamine, 1654
—identification, structure, 533, 1209
—structure, 438
Maytenonic acid, triterpene from *Maytenus senegalensis*—structure elucidation, 1085
Maytenus senegalensis (Celastraceae)–structure elucidation of maytenonic acid, 1085
Mebutamate—preparation of microcrystalline form, 1572
Medicinals, liquid—solid dispersed using polyethylene glycol 6000 as carrier, 125
Membrane diffusion—physical adsorption effects on flux, using heterogeneous dimethylpolysiloxane barriers, 1788
filtration sterility testing—collaborative study on soybean-casein digest medium, 1087
permeability coefficients—effect of edetic acid treatment, 1508
permeability, fluocinolone acetonide and fluocinonide topical gels—predicting optimal vehicle composition, 1180
permeation—atropine from ointments, 48
permeation, benzoic acids—*in vitro* transfer, *in vivo* absorption, physicochemical parameters, 1666
transport—complex formation effect, theoretical, 886
transport, GI drug absorption—ionized and unionized sulfaethidole rate constants, pH effect, 1160
transport, *in vitro*—development of a diffusion cell with high area to volume ratio, 1713
Membranes, silicone elastomer—steroid transport rates, 541
Meprobamate—colorimetric analysis for dissolution studies, compared to compendial methods, 1850
Metabolism, apomorphine—self-induced, 93
cerebral—lysergide, ephedrine, nimergoline effects, *in situ,* dogs, 1320
methocarbamol, ^{14}C and unlabeled—rat, dog, human, 104
—nitrate esters, 1599
pentylenetetrazol - 10 - ^{14}C—rats, humans, 725
transfer, intestinal—everted sac, tissue incubation methods, 278
Metabolite—7-hydroxyfluphenazine glucuronide, 829
Metabolites, acetaminophen, salicylamide—isolation, identification, 215
demoxepam—separation, identification, 438
fluphenazine-^{14}C—isolation, identification, 821
potassium canrenoate-^{3}H—identification, 708
taurinophenetidine and derivatives—determination, 249
taurinopyrine, aminopyrine in urine—separation, analysis, 245
urinary, fecal—morphine, cats, 469
Metal binding abilities, radioprotective organic thiosulfates—with Cu (II), Al (III) Fe (III), ionization, stability constants calculated, 151
Methamphetamine—GLC analysis, blood, 1492
HCl sustained-release dosage form—analysis, 595
Methanesulfonamides—synthesis, pharmacological screening as antihypertensives, 1095
Methocarbamol—pharmacokinetic parameters, compared to chlorphenesin carbamate, man, 1686
Methocarbamol-^{14}C—synthesis, 104
Methotrexate pharmacokinetics—model, mammals, 1128
2 - *p* - Methoxyphenylglutarimide—synthesis of 2-ethoxy, 2-carbethoxy derivatives, 618

N^1 - (4 - Methoxyphenylsulfinyl) - 3,5 - dimethyl - 4 - arylazopyrazole derivatives—synthesis and biological evaluation as antimicrobial agents, 1738
5-Methoxytetrahydro - β - carboline alkaloid—occurrence in nature, *B. argentea*, 1209
Methyclothiazide, cryptenamine, reserpine combinations—hypotensive effects and side effects, 1139
Methyl acrylate–methyl methacrylate matrix—methamphetamine HCl dosage form, 595
2 - Methyl- and 2 - benzyl - 4,4 - dimethyl-2-aminotetralins, substituted—synthesis, 201
D-(−)-*p*-Methyl and D-(−)-*p*-ethyl mandelic acids—renal tubular secretion, 375
***N* - Methyl - 3 - benzoyl - 3 - hydroxypiperidine**—novel behavior, Von Braun demethylation, 1905
Methylcholanthrene induced tumors—effect of cobalt chloride and sodium cobaltinitrite on growth, 473
interaction—lecithin–cholesterol mixed films, 425
α-, β - Methylcholine—conformational analysis, 67
***N* - Methylethanolamines,** tertiary—Von Braun demethylation, novel reaction with cyanogen bromide, 1905
Methyl *o*-methoxybenzoate—internal standard, GC, 454
Methylphenidate HCl tablets—automated analysis, 755
3-Methyl-4-phenylbutenoic acid isomers—tested as β-hydroxy-β-methylglutaryl-CoA reductase inhibitors, 614
17-Methyltestosterone–polyethylene glycol 6000 solid dispersion—dissolution rate, 1569
***N*b - Methyltetrahydroharman** — isolation, identification from *B. argentea*, 1209
***N*-Methyltyramine**—isolation from *Ariocarpus kotschoubeyanus*, 477
Micelle formation, phenothiazine derivatives—effect on NMR spectra, 329
—effect of solubilizates on monomer-micelle equilibrium, 1531
—nonspherical shape surfactants, 1595
Microbial contamination—survey of nonsterile antibiotic market samples, 1099
Microbiological assay—automated, 767
assay, automated—theory, 764
assays—guide to antibiotics, 1689
Microbiological–fluorometric analysis—ampicillin, 728
Microbiology, analytical—computer interpolation of potency with automated systems, 1858
Microcrystalline drugs—method of preparing aspirin, mebutamate, quinine sulfate, effect of particle size, 1572
Microcrystallization methods—aspirin, mebutamate, quinine sulfate, 1572
Mitotane—separation, characterization, configuration assignment of dehydrochlorination products, 484
Mixed solvent system—effect on drug solubility, drug–drug interactions, 1617
Model, one compartment—tropicamide dose–effect relationship, 96
methotrexate distribution, mammals—one, two compartments, 1128
Moisture isotherm—montmorillonite, 733
Molecular complexes—crystal structures, 282
orbital, ligand field calculations—octahedral hybridization of hydrogenic orbitals, 647
orbital perturbation theory—tetracycline activity, 576
structure—aminopyrine, barbital, 699
weight determination—sulfated heparin, 1109
weight determinations, micellar—sodium taurodeoxycholate and sodium taurocholate with salicylamide, 1105
Molluscicidal agents—pentachlorophenol enzymatic peroxidation, structure–activity relationships, 1242
Monoamine oxidase inhibitors—azetidines, synthesis, evaluated *in vitro*, 156
Monomolecular films, nitrogen dioxide–cholesterol interaction—inhibitory effect of cholesteryl nitrate, 933
Montmorillonite adsorbates—bonding nature, 733
Morphine induced—fetal malformation, 420
—metabolism, metabolites, cats, 469
–sodium bisulfite interaction product—isolation of 8-sulfonic acid-dihydromorphinone, 793
Mosquito repellents, topical—synthesis, 84
Multivitamin combinations—pyridoxine bioassay, 1481
preparations—semiautomated, simultaneous analysis, 1717
products—riboflavin, thiamine HCl, niacinamide determination, 1070
Muscarinic potency—acetylcholine–decalin analog conformation, 1364
Muscular dystrophy, pseudohypertrophic—treatment with hexahydrocoenzyme Q_4, evaluation, 640
Mydriatic drug—bioavailability, biokinetic behavior, 354
response behavior, tropicamide—vehicle pH influence, rabbits, 1039
Myocardial effect—chronic reserpine, dogs, 1134
***N*-Myristyl-β-aminopropionic acid**—peritoneal dialysis acceleration, 1065

N

Nalorphine, urinary metabolites—isolation, characterization, dogs, cats, 148
Naloxone, metabolites—determination in human urine, 1567
Neomycin, in petrolatum-based ointments—GLC analysis, 1068
sulfate aqueous gels—preparation, polymer–drug interaction, viscosity and drug activity, 1343
Neuromuscular blockage—nicotine effects studied, compared to other agents, classified, using rat sciatic-gastrocnemius preparation, 1740
Neutron activation analysis—halogens in drugs, 1550
—zinc, 592
Nicotinate phosphoribosyl transferase—inhibition by nonsteroidal anti-inflammatory drugs, mechanism of action, using radiolabeled nicotinic acid, 1887
Nicotine—effect on electrical threshold, neuromuscular junction, rat sciatic-gastrocnemius preparation, classified as neuromuscular blocking agent of pseudocurare type, 1740
Nicotinic acid, radiolabeled—used to evaluate influence of nonsteroidal anti-inflammatory drugs on nicotinate phosphoribosyl transferase, 1887
Nifuroxime–furazolidone suppositories—separation, analysis, 1385
Nimergoline—cerebral metabolism effect, dogs, 1320
Nitrate esters—review, 1599
***p*-Nitrobenzaldehyde**—determined as degradation product in chloramphenicol, 786
5-Nitro-2-furaldehyde phenylhydrazones—synthesis, 650
5-Nitrofuramides—photolysis in methanol, 1425
Nitrofurazone cream—analysis, 295
Nitroglycerin—with proxyphylline, formulating timed-release tablets, absorption, 1683
3 - Nitroso - 2 - arylimidazo(1,2 - *a*)pyrimidines—synthesis, 74
***p*-Nitrosobenzoic acid**—colorimetric analysis, *m*-aminophenol, 1853
Nitrous acid fluorometry—analysis, reserpine and rauwolfia alkaloids, 1862
Nitrous acid–acetaminophen reaction—analysis method, 463
NMR spectroscopy—analysis, 45, 89, 622
—analysis, dimethoxyamphetamine rotamers, 1232
—analysis, structure, spiro-[androstane-17-yl-5′-oxazolidine] derivatives, 1677
—configuration, mitotane isomers, 484
—determination, parabens–bovine serum albumin binding, 1821
—determination, theophylline self-association, 1267
—enolization of 1-*p*-chlorophenyl-1-hydroxy-2-propanone, 801
—identification, 104, 180, 201, 390, 649, 826, 873, 1895
—identification, 3-(aminoalkyl)-2-benzoxazolinones, 1370
—micelle formation effect, 329
—structure, 74, 138, 411, 438, 491, 618, 632, 909, 930, 1089, 1257
—structure, identification, 156, 307
—structure, identification, (±)-bisnorargemonine, 1634
Nomographic method—multiple-dosing kinetics, 406
Nonelectrolytes, polar, solubility in nonpolar solvents—consideration of entropic, enthalpic, and specific interactions, 1782
Nonionic surfactants—hydrophilic–lipophilic balance and distribution coefficients, 648
NONLIN, subroutine—digital computer program, 1393
Non-Newtonian flow systems—application of nonlinear regression analysis, 1393
Norepinephrine responses—antagonism by sulfur-containing aliphatic amines, rabbit aorta, 1743
Nornuciferines—*in vitro* metabolic and photolytic conversions to lysicamine, 1654
Nortriptyline—identification of 10-hydroxynortriptyline as major metabolite in human urine, 1403
Nylon–liquid sorption equilibrium—thermal gravimetric analysis, 1317

O

Oils, *C. sinesis*, *C. aurantium*—partial component identification, 381
Ointments, atropine diffusion—water, alcohol, dimethyl sulfoxide effects, 48
creams, semisolid—viscoelastic properties, 1351, 1356
neomycin in petrolatum—GLC analysis, 1068
—paraffin effect on rheological properties, 814
Ophthalmic, oral administration—mydriatic drug bioavailability, biokinetics, 354
Opium alkaloids—aporphine biosynthetic pathways in *Papaver somniferum*, 1880
alkaloids—proposed biosynthesis of 1-benzylisoquinolines, 1672
Optical rotatory dispersion—structure, 180
Organic cations—spectrophotometric determination by solvent extraction with tetrabromophenolphthalein ethyl ester, 943
Organosilicon compounds—review of literature, 1113
Oscillatory shear—semisolid breakdown parameters, 1356
testing, nondestructive—semisolid rheological parameters, 1351
Oscillometry—dielectric constant determination, 56
Osmometer, thermoelectric—improved design, 117
Osmotic fragility, erythrocytes—low pH effect, 1033
Oxazolidine, steroidal derivatives—synthesis, NMR characterization, potential aldosterone antagonists, 1677
Oxidation with hydrogen peroxide—fluorine analysis, 1036
Oxime esters—synthesis from 1-azabicyclo-[4.4.0]decane-4-one, pharmacological evaluation as anticholinergic agents, 1266
Oxygen levels in water—technique for reduction, gas permeation, 1906
Oxygen-uptake enhancement, rat heart homogenates—adenine nucleotides, 77
Oxytetracycline—separation, analysis from degradation products, urea-impregnated chromatographic paper, 1544
(5-Oxytetralonyl)acetic acid—isolation, identification, bunolol metabolite, dogs, 1516
β-(5-Oxytetralonyl)lactic acid—isolation, identification, bunolol metabolite, dogs, 1516
Oxytocin activity antagonists—peptides, 896

P

Palladium - on - poly - *S* - leucine — α - acetamidocinnamic acid, α-methylcinnamic acid hydrogenation rates, 583
Pantothenyl alcohol—analysis, 163
pantothenates—analysis, 909
Papaver somniferum—biosynthesis of aporphines, 1880
—coreximine detection, 873
—proposed biosynthesis of 1-benzylisoquinolines, 1672

XUM

Paper chromatography—identification, 144
—separation, 148
—separation, analysis, oxytetracycline, 1544
Parabens—mutual solubilizing effect, 56
solubility—theoretical aspects, 622
Parabens–bovine serum albumin binding—determination, fluorescent probe technique, 1821
Paraffin, soft—rheological effect, ointments, 814
Particle-size analysis—emulsions, 690
determination—montmorillonite, 733
drugs—effect on intramuscular administration of phenobarbital, beagle dogs, 1733
effect—griseofulvin dissolution, 230
effect—steroid release from silicone matrix, 541
—solubility dependence, 130
styrene divinylbenzene copolymer-based sulfonic acid cation-exchange resins—effect on equilibrium exchange, column studies, 319
Particulate solids—flow rates, 548
Partition coefficients—ether–water partitioning, steroids, 345
—1-phenyl-2-propanols, 1-phenyl-2-propanones, derivatives, 799
—sotalol · HCl, 833
Paxillus atrotomentosus, *P. panuoides*—pigment comparison, 1503
β-Peltatin, 4′-demethyldesoxypodophyllotoxin—isolation, identification, *H. verticillata*, 649
Penicillin, activity—determination using spectropolarimetry and circular dichroism, 1608
binding—bovine serum albumin, 45
cephalosporins, inactivation—bacterial enzymes, 503
to penicillenic acid isomerization—metastable intermediate demonstrated, 1273
Penicillium chrysogenum cultures—benzylpenicillin deuteration, 1661
Pentachlorophenol—enzymatic peroxidation, structure–activity relationships of molluscicides, 1242
Pentaerythritol tetranitrate and ^{14}C-substituted—human pharmacodynamics, biotransformation, 274
—metabolism, pharmacology, 1599
Pentobarbital—GLC analysis, blood, 1492
sleeping time—apomorphine metabolism determination, 93
Pentobarbital–cryptenamine—cardiovascular effects, dogs, 488
Pentylenetetrazol-10-^{14}C—biological disposition, 725
Pentylenetetrazol-induced seizures—evaluation of substituted 2-thioquinazolin-4-ones anticonvulsant activity, 127
Peptide—as oxytocin antagonists, 896
ergot alkaloids, radiolabeled—degradation, distribution, 949
esterase models, catalytic activity—aspartic acid residue influence, 956
Periodate oxidation—assay, separation of phenylethanolamines, 1229
oxidation—phenalkanolamines to benzaldehydes, 291
Peritoneal dialysis, acceleration—barbiturates, diphenylhydantoin, and salicylate, 1065
of urea—effects of dwell time, volume of dialysis fluid, added accelerators, statistical analysis, 1520
—review, 1767
Permeability, membrane—propylene glycol solvent effects, 1180
pH, aluminum hydroxide content, effects—chloride-selective electrode response, 748
dependence—fluorescence of riboflavin, related isoalloxazine derivatives
effect—ampicillin product fluorescence, 728
–hydrolysis rate profile—itobarbital, 40
time, effects—thorium nitrate–tetracycline complex, 107
pH-partition coefficients—GI drug absorption *in situ*, rats, 1160
hypothesis–salicylic acid absorption—correlation, 393
Pharmaceutical sciences—1970 literature review of pharmaceutics, 959
Pharmacodynamics—dose–time–response relationships, phase-nonspecific agents, 892
Pharmacokinetic, chemical kinetic simulation—graphic display method, 1079
models—analysis problems, 882
parameters, biophase—transcorneal tropicamide mydriasis, vehicle pH influence, 1039
parameters—comparative, chlorphenesin carbamate and methocarbamol, man, 1686
parameters—fenclozic acid in animals, humans, 366
parameters—methotrexate absorption, distribution, excretion, 1128
parameters—potassium canrenoate-^2H in human, 708
theory—inverse Laplace transforms, use of general partial fractions, 1593
Pharmacokinetics, 4-aminoantipyrine absorption–exsorption—goldfish, 1360
bioavailability—4 - (3′ - pyridyl)bicyclo-[2.2.2]octane-1-amine maleate tablets, rats, 1111
—canrenone hydrolysis, canrenoic acid lactonization, pH effect, 1801
GI absorption, pH effect—sulfaethidole and barbital, ats, 1160
—labeled levodopa absorption and excretion, dogs, 1014
—phosphonomycin, intravenous administration, 678
—quantitation of nonlinear equations, effect of plasma protein binding on drug distribution and elimination, 1623
skin penetration—fluocinolone acetonide, fluocinonide topical gels, drug efficacy, vehicle and drug physical properties, effects, 1175
—warfarin absorption, 666
Pharmacological activity—lysergic acid analogs, 809
biological screening—substituted α-phenylcinnamonitriles, 1244
response data—biokinetics, mydriatic drug, 354
response intensity—biophasic drug level relationship, 96
response intensity correlation—*in vivo* drug availability, 878
screening — 1 - alkyl - 3 - benzoyl - 3 - acyloxypiperidines, 685
screening—taurinopyrine, 245
Phase change, solvent mediated—aspirin crystal dissolution, 267
diagram, chloramphenicol–urea binary system—reexamined using differential thermal analysis, X-ray diffraction, 1406
diagrams, ternary—algebraic extrapolation of tie lines, 160
equilibria, determination—water–emulsifier–propellant systems, by visual observation, 1883
Phenalkanolamines—determination, 291
Phenethylamines, psychotomimetics—biological, chemical properties, 655
sulfur-containing—synthesis, pharmacological evaluation, 1095
Phenobarbital—effect of food on oral absorption, rats, 1639
intramuscular administration—effect of particle size on blood levels and bioavailability, beagle dogs, 1733
Phenols, cinnamylated and hydrogenation products—synthesized as possible antimicrobial agents, screened, 1753
Phenothiazine, cobalt (III) oxidation products—UV spectrophotometric determination, 1346
derivatives and dosage forms—analysis, 588
derivatives—micelle formation, 329
derivatives, quaternary ammonium salts—synthesis, physical properties, 1895
oximes—synthesis, pharmacological screening as possible anticholinergic agents, 1262
Phenotypes, chemical—drug and fiber *Cannabis sativa*, 1246
Phenoxazine ring system analogs—synthesis of dimethyl *N,N′*-bis(2-amino-3-oxophenoxazine - 4,6 - dimethyl - 1,9 - dicarbonyl)-*dl*-dialaninate, 1904
Phenoxazinone pigments—separation, identification from *Pycnoporus* genus, 1097
***dl*-2-(3-Phenoxyphenyl)propionic acid**—absorption, distribution, calcium and sodium salts bioavailability, man, 1797
—GLC analysis in human plasma, 1062
Phenylacetaldehydes, substituted—synthesis, antitumor activity evaluation, 1188
***N*-Phenylacetylsulfamide**—synthesis, three methods, 620
Phenylbutazone—gastrotoxic effects, cats, 1314
α-Phenylcinnamonitriles, substituted—synthesis, biological evaluation, 1244
Phenylephrine—isolation from syrups, 314
–phenylpropanolamine combination—assay in aspirin mixture, 1229
Phenylmercuric nitrate—microbiological determination of partitioning in coacervate systems, 1825
Phenyl - *N* - methyl - 2 - pyridiniumketoximes (*syn* and *anti*)—acetylcholinesterase reactivators, synthesis, potency relationship, 138
Phenylpropanolamine, enamine derivatives—amine prodrugs, pharmacological evaluation, 1810
–phenylephrine combination—assay in aspirin mixture, 1229
1-Phenyl-2-propanols, 1-phenyl-2-propanones, derivatives—synthesis, pharmacological evaluation as psychotomimetic agents, 799
***N* - γ - Phenylpropyl - *N* - benzyloxyacetamide**—hepatic injury, detection by light and electron microscopic study, 1576
Phlorizin inhibition—glucose-retarded riboflavin transport, 225
Phosphate, borate buffers, effect—itobarbital hydrolysis, 40
Phosphonomycin—pharmacokinetics, 678
Photodegradation products, chloramphenicol—isolated and identified, from water, ethanol, and benzene, using sunlight, UV, and tungsten light, 1889
Photolysis—conversion of nornuciferines to lysicamine, 1654
—5-nitrofuramides in methanol, 1425
Photomicrographs—aspirin spherulites, 1420
Physical pharmacy—dissolution, solubility, complexation, 959
Physostigmine, analysis—colorimetric measurement of physostigmine dithiocarbamate–copper complex, 1387
Pilocarpic acid and pilocarpine—kinetic analysis, hydrolysis of 2,4-dinitrophenyl acetate, 1465
Pilocarpine and pilocarpic acid—kinetic analysis, hydrolysis of 2,4-dinitrophenyl acetate, 1465
pKa determination—sotalol · HCl, 833
determinations — 7 - (2 - hydroxypropyl)-theophylline solutions, 309
pKa′ values, apparent—coumarins, coumarinic acids, 1019
values—coumarinic acid, 396
Placental transfer, 2,3,5-triiodobenzoic acid-^{14}C—rats, 695
Plasma levels—comparative, chlorphenesin carbamate and methocarbamol, man, 1686
levels—fenoprofen, GLC analysis, 1062
levels—fenoprofen, man, 1797
levels, half-life—chlordiazepoxide, metabolites, man, 1500
levels—prednisolone phosphate sustained-release, nonsustained-release tablets, 1028
levels—warfarin, assay, 1271
levels—warfarin, small oral dosage, 1272
protein binding—5,5-diphenylhydantoin and metabolite, rats, man, 1642
protein, drug displacement—anthranilic acid peritoneal dialysis effect, 1065
urine—diphenylhydantoin and metabolites, determination, 327
Plasticizers—effect on cellulose acetate phthalate films, physical properties, 312
PMR spectroscopy—analysis, 652
—analysis, structure, deuterated benzylpenicillin, 1661
—identification, 28
—structure, 67
—structure, conformation, antihistamines, 1764
Poisons, endogenous and exogenous—removal by peritoneal dialysis, 1767
Polarimetry—conformation, 685
Polarography—analysis, ethacrynic acid, 1702
cathode ray fast sweep—analysis, 1070
Polyestradiol phosphate—apomorphine glucuronidation inhibition, 93
Polyethylene glycol 6000—carrier for solid dispersion of benzonatate, clofibrate,

methyl salicylate, benzyl benzoate, *dl*-α-tocopheryl acetate, 125
dispersions—increased dissolution rates of water-insoluble glycosides, steroids, 1569
Polymer–drug interaction—neomycin sulfate gels, 1343
Polymorphism—fluprednisolone, 1485
Polypeptides, linear, antigenic—immunochemical properties, 332
linear—known sequence of amino acids, 330
Poly - (L - phenylalanyl - L - glutamyl - L-alanylglycyl)glycine methyl ester—synthesis, 330
Polysorbate 80—effects on absorption of chloramphenicol palmitate (amorphous and polymorph A forms), cats, 153
Polyvinyl chloride matrix—prednisolone phosphate tablets, 1028
Polyvinylpyrrolidone and vinyl acetate copolymers—surface properties of monolayers, 1731
Portal vein sampling—intestinal drug absorption, 331
Potassium ion—mechanism of passive-transport inhibition, 1813
Potency determination, automated microbiological methods—computer interpolation of data, 1858
heparin—correlation with neutralization values, 638
Potentiation—reserpine by deoxycholic acid, 140
Potentiometric measurement of sodium—monitoring tablet dissolution, 1756
titration—aminoquinolines dissociation constants, 371
titration, automated—determination, *in vitro* tablet dissolution rates, 1564
titration—determinations, 151
titration—dissociation constant determination, 1155
titration—stability constant analysis, complexes, 845
Powder compacts, compressed—impact test, 758
—compression characteristics, 1428
slightly soluble—dissolution, sink conditions, 1496
Prednisolone acetate–polyethylene glycol 6000 solid dispersion—dissolution rate, 1569
Prednisolone phosphate sustained-release tablets—formulation, 1028
Prednisone—separation from analgesic mixtures, colorimetric analysis, 1538
Preservative distribution, emulsions—determination, dialysis method, 1422
effects, acacia solutions—rheological properties, 863
Probenecid determination—biological fluids, 745
Procainamide azulene analogs—synthesis, 184
Procarbazine hydrochloride—analysis, coulometric titration, 1851
Prodrugs, amine—enamine derivatives of phenylpropanolamine, 1810
Product stability testing—simulation of worldwide virtual temperatures, 927
Production cycle development—instrumented pilot plant lyophilizer, 774
Progestational activity—17α-hydroxyprogesterone-substituted esters, 1089
Propellant composition—determination of phase equilibria, 1883
Prophylactic agents, potential—organosilicon compounds, 1113
Protamine sulfate, neutralization of heparin—comparison, lung, mucosal derived, *in vivo*, *in vitro*, 638
Protective steroids—identification, assessment, 1
Protein, nucleic acid syntheses, *E. coli*—tetracycline effect, 33
Protein–drug binding—determination, fluorescent probe indicators, 1430
Protein–solute binding—determination, *in vitro* dialysis, 1471
Proteolytic enzyme active sites—peptide catalytic activity determination, 956
Pseudomonas aeruginosa contamination—liquid antacids, survey, 604
Psychotomimetic agents—marijuana, review, 1433
phenethylamines—review, 655
Psychotropic activity—dimethoxyamphetamine conformational behavior, 1232
Purines, 9-(substituted aralkyl)-6-substituted—synthesis, adenosine deaminase irreversible inhibitors, 1184
Pycnoporus genus—occurrence, distribution of phenoxazinone pigments, 1097
Pyrantel pamoate, bulk, dosage forms—analysis, 111
Pyrazole congeners—synthesis, screened for antidiabetic activity, 323
2-Pyridinium aldoxime methochloride—intramuscular, intravenous administration, man, 1224
Pyridoxine, multivitamin combinations—bioassay, ferrous-ion removal with *N,N'*-ethylenediaminetetraacetic acid, 1481
4-(3′-Pyridyl)bicyclo[2.2.2]octane-1-amine maleate—tablet absorption, rats, 1111
Pyrogenic lipopolysaccharide from *Klebsiella pneumoniae*—isolation, purification, and characterization, pyrogenic activity tested, 1578

Q

Quantitative recovery from fabric—ethylene oxide, chlorohydrin, and glycol, 271
Quantum chemical approach—structure–activity relationships, tetracyclines, 576
Quaternary ammonium salts of phenothiazine derivatives—synthesis, physical properties, 1895
phenothiazine oximes—anticholinergic activity, 1262
Quingestanol acetate capsules, combinations with ethinyl estradiol or quinestrol—separation, analysis, 1388
Quinine sulfate—preparation of microcrystalline form, 1572
—standard fluorescent species, 114
8-Quinolinol–lithium coordinate covalent complex—formation, fluorescence, 1762

R

Radioassay, protein-binding—determination of cortisol, corticosterone in plasma, 1476
Radiolabeling—norreticuline, biosynthesis in *P. somniferum*, 1672
—synthesis of triammonium ^{35}S-2-dithiocarbamyl - 3 - dithiocarbonylthiopropanoate for metabolism study, 1839
Radionuclides, halogen—neutron activation analysis, drugs, 1550
Radioprotective agents—metabolism, metabolic products of triammonium 2-dithiocarbamyl - 3 - dithiocarbonylthiopropanoate determined, mice, 1839
Radiorespirometry—determination, 482
Rate constants—aqueous urea degradation, 1212
E. coli cell division—tetracyclines, 33
Rauwolfia alkaloids—semiautomated fluorometric analysis, 1862
Reaction, concentration-rate profiles, inhomogeneous barrier region—calculation, 886
α,β-Receptors, blockade effect—β-hydroxylamine cinnamonyl hydroxamic acid action, 839
Rectal absorption, acetaminophen—effect of vehicle dielectric constant, 600
suppositories—salicylate availability, 867
Reflux extraction—preparation of crude drug extracts, 1417
Regression analysis, nonlinear—non-Newtonian flow systems, 1393
Release rate, drug–copolymer matrix—factors affecting, 209
Renal failure—applications of peritoneal dialysis, 1767
serum clearance, human—phosphonomycin, 678
tubular secretion—*p*-alkylated mandelic acids, 375
Renilla mulleri—toxicology, pharmacology, 1620
Repellency, mosquito—volatility relationship, 84
Repellents, insect, potential—1,3-dihydroxy-2-propanone carbonates, synthesis, 1083
Repose angle—flow rates, 548
Reserpine, chronic—clinicopathologic effects, dogs, 1134
cryptenamine, methyclothiazide combinations—hypotensive effects and side effects, 1139
–deoxycholic acid—potentiation, 140
—semiautomated fluorometric analysis, 1862
Reserpine-like activity—*N*-ethyltryptamine derivatives synthesized, screened, 304
Resonating structure, lactams—CNS activities, mice, dogs, 1058
Respiratory tract—action of tetracyclines, 321
(+)-Reticuline—incorporation into isoboldine, determination of aporphine biosynthetic pathways in *Papaver somniferum*, 1880
Reverse isotope dilution—analysis, 278
Review Articles
Aspects of Nitrate Ester Metabolism, 1599
Chemistry and Pharmacology of Marijuana, 1433
Experimental Modification of the Chemistry and Biology of the Aging Process, 167
Hormones and Resistance, I
β-Lactam Antibiotics: Their Physicochemical Properties and Biological Activities in Relation to Structure, 503
Organosilicon Entities as Prophylactic and Therapeutic Agents, 1113
Peritoneal Dialysis: A Review, 1767
Pharmaceutical Applications of Solid Dispersion Systems, 1281
Pharmaceutical Sciences—1970: Literature Review of Pharmaceutics, 959
Psychotomimetic Phenethylamines, 655
Stability-Indicating Assay Methods for Drugs and Their Dosage Forms, 335
Structural Analogs of Lysergic Acid, 809
Rhazya stricta alkaloids—identification and structure elucidation of sewarine, 1581
Rheological parameters, oscillatory method—semisolid systems, 1351
properties, acacia solutions—kinetics, 863
properties, white soft paraffin—continuous shear and creep viscometry, 1198
Rheology—ointments, emulsions, soft paraffin, 814
Riboflavin, related isoalloxazine derivatives—fluorescence pH dependence, 628
thiamine HCl, niacinamide in dosage forms—determination, 1070
viscosity—effect on absorption, man, 784
Ribosomes, aminoacyl site—tetracycline binding, 576
Ringer's solution—sodium, potassium, calcium determination, 907
Rotating basket dissolution test—vibration effect, 496
Rotating disk—aspirin dissolution, 267
method—compared with Turbula shaker mixer method, influence of flow velocity and activation energy on dissolution rates, 1874

S

Salicylamide—spectrophotofluorometric determination, in blood serum, urine, 1092
Salicylate absorption—rectal suppositories, 867
acetanilide transfer—rat intestine, *in vitro*, 234
sodium, solubility—mixed solvent systems, 432
Salicylic, acetylsalicylic acids—simultaneous determination, 454
Salicylic acid—effect on acetaminophen, man, 608
in buffered aspirin products—determination, 114
transfer rate—two-phase system, 52
transport—model biomembrane, 393
Salicylic acid–cetrimide system—stability in presence of additives, 939
Saliva, human, simulated—drug dialysis rates, 429
Schistosomicidal agents, oral—aromatic amines condensed with aminothiazoles, isatoic anhydride, 1251
agents, potential—synthesis of condensed *p*-toluidines, aminothiazoles, 1411
Schizosaccharomyces pombe—used as test organism to eliminate interference in inositol analysis, compared to *Saccharomyces carlsbergensis*, 1856
Scintillometry—analysis, 77, 104, 274, 278, 390, 438, 695, 708, 725, 829, 873
liquid—analysis, 821
Sea pansy—toxicology, pharmacology, 1620

Serotonin, duodenal—effect of vagal stimulation, guinea pig, 471
release—vagal stimulation effect, 81
Serum albumin, human—bishydroxycoumarin binding, 196
levels, chloramphenicol, amorphous *versus* polymorph A forms—comparison in children, rhesus monkeys, cats, 153
protein binding—taurinophenetidine and derivatives, 249
Sesame oil formulations—separation of quingestanol acetate, 1388
Sewarine, a phenolic akuammicine alkaloid from *Rhazya stricta*—identification, structure elucidation by NMR and mass spectroscopy, 1581
Shelflife prediction—kinetic parameters, 205
Silicon compounds, organic—properties, toxicology, potential prophylactic or therapeutic agents, 1113
Silicone elastomer—steroid release, *in vitro*, 541
Sink conditions, dissolution rates—role of back transfer from lipid phase, equations presented, 1575
Skin, human—measurement of contact angles of liquids before and after extraction of surface lipids, 1893
Sodium ion-selective glass electrode—monitoring tablet dissolution, 1756
Sodium *p*-aminosalicylate, *p*-aminosalicylic acid dosage form—identification of major chromogen, 3,3′-dihydroxyazoxybenzene, 1886
Sodium biphenyl reagent—bound fluorine liberation, 1036
Sodium cholate effect, dissolution—crystals–dyes, 59
Sodium cobaltinitrite—enzyme inhibition of cortisone-induced cleft palate and methylcholanthrene tumorigenesis, albino mice, mode of action, 1878
Solid dispersion systems—review, 1281
Solid–liquid system—solid determination, phase diagrams, 160
Solubility, alkyl *p*-hydroxybenzoates—theoretical aspects, 622
analysis—human serum albumin, 196
analysis—mixed solvent system–mixtures of drugs, difficulties encountered in using individual solubility profiles, 1617
analysis—thiouracil–metal complexes, 845
apparent—specific rate constant, benzocaine, homatropine, 901
nonelectrolytes, polar—in nonpolar solvents, consideration of entropic-enthalpic–specific interactions, 1782
sodium salicylate—dielectric constant relationship, 432
solubility parameter—sulfonamides, 238
—substituted alkyl benzoates, 56
Solubilization, benzoic acid derivatives—distribution in nonionic micelles, 1528
benzoic acid derivatives—in nonionic surfactants, 1531
Solute–protein binding—determination, *in vitro* dialysis, 1471
Solvation—polar organic solvents, stoichiometric species approach, 1782
Solvolysis (alkaline) mechanism, substituent effects—unfused β-lactams and linear amides, 1168
Sorption equilibria—liquids sorbed by nylon, 1317
Sotalol determination—blood, urine, 833
Soybean-casein digest medium—collaborative study of use in membrane filtration sterility tests, 1087
Spasmolytics, synthesis, evaluation—3-tropanyl 2,3-diarylacrylate derivatives, 1102
Specific conductivity—urea degradation monitoring, 1212
Specificity, periodate oxidation—phenalkanolamine determination, 291
Spectrofluorometry—analysis of submicrogram quantities of apomorphine in brain, 1736
Spectrophotofluorometry—analysis, 471
—assay, flurazepam, 1303
—identification, naloxone metabolites, 1567
—salicylamide determination, blood serum, urine, 1092
Spectrophotometry—analysis, 475
determination—organic cations–tetrabromophenolphthalein ethyl ester, solvent extraction, 943
IR, UV—analysis, 708
UV, visible—aminoquinolines, dissociation constants, 371
visible—analysis, 1097
Spectropolarimetry—determination, penicillin activity, 1608
Spectroscopy, IR, NMR, mass—structure elucidation of maytenonic acid from *Maytenus senegalensis*, 1085
Spiro - [androstane - 17 - yl - 5′ - oxazolidine] derivatives—synthesis, NMR characterization, potential aldosterone antagonists, 1677
Spiroethers, steroidal—synthesis, 491
Stability constants—amine–bromthymol blue complexes, in chloroform, 1584
profile and pH effect—germine-3,16-diacetate, 193
Stability-indicating assay methods—literature review, 335
procedure—methylphenidate HCl tablets, 755
Starch—mechanism as tablet disintegrant, 1325
Stereochemical aspects—local anesthetic activity, 685
Stereospecificity—antihistamine activity–*trans*-conformation relationships, 1764
Sterilization—migration of a 1,3-dioxalane from urological jelly to tube lining, 1264
Steroid hormone receptors—alkylating agents, synthesis of ω-diazoketones, activity, 1089
spiroethers—synthesis, 491
Steroids—protective spectrum, 1
—reaction with aluminum chloride in benzene–nitrobenzene, colorimetric analysis for 3-hydroxy-$\Delta^{1,5}$-diene group, 1542
Streptomyces refuineus var. *thermotolerans*—spectrophotometric determination of anthramycin in fermentation beers, 781
Structural group contribution—steroid partition coefficients, 345
Structure–activity relationships—hydrazones, 386
—lysergic acid analogs, 809
—molluscicidal agents, 1242
—1 - phenyl - 2 - propanols, 1 - phenyl - 2-propanones, derivatives, 799
—psychotomimetic phenethylamines, 655
tetracyclines—*E. coli* inhibition, 33
—3,4,5-trimethoxybenzamides, potential depressants, 1409
Substituent effect—coumarinic acid lactonization, coumarin hydrolysis, 1019
Sucrose standard—osmometer calibration, 117
Sulfadiazine—absorption, bile-flow effect, rats, 145
Sulfaethidole binding to crystalline and Fraction V bovine serum albumin—studied by dialysis and circular dichroism, 1658
Sulfathiazole–urea solid dispersions—phase diagrams, *in vitro* dissolution rates, aging effect, 1333
Sulfhydryl content alteration, liver—nonsteroids, 416
Sulfonamides binding—bovine serum albumin, 45
individual, mixed—identification procedure, 448
—solubility parameter, 238
8-Sulfonic acid-dihydromorphinone—identification, isolation as morphine–sodium bisulfite interaction product, 793
Sulfur-containing aliphatic amines—α-adrenergic blockage, antagonism of norepinephrine responses, rabbit aorta, 1743
Suppositories, commercial—GLC drug assay, 1074
furazolidone – nifuroxime — separation, analysis, 1385
Suppository bases—rectal absorption, 867
Surface phenomena—pharmaceutical applications, 959
pressure—lecithin–cholesterol mixed film, 425
properties—polyvinylpyrrolidone and vinyl acetate copolymer monolayers, 1731
tension, pH effects—surfactant absorption, toxicity, 854
tensions, critical—correlation to contact angles, human skin, 1893
Surface-active absorption promoters—influence on water-soluble antibiotics in stomach and intestine, rats, 1835
Surfactant determination—aqueous solutions, 920
distribution loci—benzoic acid solubilizates, 1528
Surfactants—formation of nonspherical micelles, 1595
HLB values—effect on ephedrine release rates, oil and water emulsified systems, 1830
nonionic, effect—solubilized benzocaine, homatropine hydrolysis, 901
nonionic—relative toxicity in planarian, 854
—role in enhancing antibiotic absorption, stomach, small intestine, and GI tract compared, rats, toxicity, 1835
Sustained-, nonsustained-release dosage form, rate, extent of absorption—studied, compared, man, dog, 132
Sustained-release dosage—solid-dispersion technique potential, 125
Sympathectomy, chemical, immunological—guinea pig, 81
Syrups—separation, isolation of phenylephrine, 314
Systemic availability, correlation—acetaminophen-precursor administration, 499

T

Tableting, lactose—effect of particle size and speed of compaction on density, 1866
Tablets, absorption—rats, 1111
chewable—improved palatability, coating-dependent release rates, 1523
—compression characteristics, 1428
content uniformity—probability equations, USP XVIII requirements, 955
disintegration—mean pore diameter, porosity, disintegration time parameters, 1325
dissolution-rate testing—automated, multiple system, 1556
hardness, disintegration, dissolution—aging effect, 263
in vitro dissolution rates—determination, automated potentiometric titration method, 1564
warfarin—plasma concentration comparison, 666
Tannin extract—identification of polymeric 5,7,3′,4′-tetrahydroxyflavin-3,4-diol, 144
Taste coverage, chewable tablets—ion-exchange resins, 1523
Taurinophenetidine and derivatives—distribution, animal organs, 249
Taurinopyrine—rabbit serum protein binding, 245
Technology, pharmaceutical—dosage forms, sterility, packaging equipment, 959
Tecomine—degradation rates, temperature and pH effects, hypoglycemic activity, 1142
Tecomine picrate—ion-exchange isolation of tecomine, 1142
Temperature, aging effects—acacia solutions, viscosity, 863
control system, osmometer—diagram, 117
effect—solubilized benzocaine, homatropine hydrolysis, 901
pH effects—epinephrine–bovine serum albumin relaxation rates, 89
pressure effects—acetone absorption, copolymer matrix, 212
Temperature–resistivity measurement, pilot plant lyophilizer—application to production equipment, 774
Teratogenic effects—morphine, high doses, 420
Tetraalkyl methanes, symmetrically substituted—synthesis, 1760
Tetrabromophenolphthalein ethyl ester, solvent extraction—spectrophotometric determination of organic cations, 943
Tetracyclines—action, mechanism in respiratory tract, time–action relationships, 321
antibiotics—structure–activity relationships, 576
dosage forms—analysis, 107
—structure–activity relationships, 33
5 - Substituted - 2,3,4,5 - tetrahydro - 1,5-benzoxazepines—preparation from 3-(chloroalkyl)-2-benzoxazolinones, 1370

Tetrahydrocannabinol, *Cannabis sativa*—content compared by age, sex, plant part, 1246
—chemistry and pharmacology review, 1433
Δ^9-Tetrahydrocannabinol, effects—6-week pharmacological and toxicity study, rats, 1761
5,7,3′,4′-Tetrahydroxyflavan-3,4-diol (polymeric)—identification, 144
Tetrakis(3-hydroxypropyl)methane, tetrakis(3-bromopropyl)methane, tetrakis(3-cyanopropyl)methane, and tetrakis(3-carboxypropyl)methane—synthesis, 1760
Tetramethylurea, solvent evaluation—nonaqueous titration of barbiturates, 1847
Tetronic acids—*P. atrotomentosus*, *P. panuoides*, 1503
Thais haemastoma—pharmacological properties of hypobranchial gland, toxicity, 1842
Thelephoric acid—occurrence in 30-, 45-, and 60-day-old *Clitocybe subilludens* cultures, 1727
Theophylline, association in aqueous solution—determination, NMR spectroscopy, 1267
association in aqueous solution—nonquantitation, 1269
Thermal gravimetric analysis—liquid–nylon sorption, 1317
Thermodynamics, nonideal solubilization—benzoic acid derivatives in nonionic surfactants, 1531
Thermoelectric osmometer, improved—diagram, 117
Thermolysis, 1,4-benzodiazepines—during GC, mass spectroscopy analysis, 135
Thiamine, viscosity—effect on absorption, man, 784
Thiaxanthone derivatives—synthesis as potential schistosomicidal and carcinostatic agents, 1747
Thioacridone—isolation, characterization as a reaction product, spectral properties, 1238
Thiocholine, iodimetric titration—analysis, echothiophate iodide, 1548
2-Thiohydrothymines, 3-substituted—synthesis, antitumor testing, 122
2-Thioquinazolin-4-ones, substituted—synthesis, anticonvulsant activity evaluation, 127
Thiosulfates, radioprotective organic—metal-binding abilities, ionization, stability constants calculated, 151
Thiouracil–metal complexes—solubility analyses, spectrophotometric investigation, 845
Thixotropy—semisolids, 1356
Thorium nitrate–tetracyclines, complex formation—tetracycline analysis, 107
Thyroid extracts—GLC analysis of iodoamino acids, 1270
Thyroxine, derivatives—chemical nature of color reaction with nitrous acid, 1259
sodium—analysis, 493
Tie lines—extrapolation, 160
Timed-release dosage forms—reduction of side effects of 4′-chloro-2-(ethylamino)-propiophenone, 1900
tablets—coated drug–carboxylic ion-exchange resin adsorbates, 1523
tablets—nitroglycerin and proxyphylline, 1683
tablets—spray-congealed, lipase–lipid–sulfamethizole systems, 1709
Tissue cultures—*in vitro* study, aging process, 167
distribution — pentylenetetrazol - 10 -^{14}C, 725
distribution—radioiodinated hypoglycemic agent, 390
drug levels—prediction errors, 882
fluid uptake relationship—drug transport, 225, 1813
levels—fluphenazine-^{14}C, metabolites, 829
Tissue/plasma distribution coefficients—methotrexate, mammals, 1128
Titration, nonaqueous—barbiturates in tetramethylurea, 1847
visual—phenothiazine derivatives, analysis, 588
TLC—analysis, 255, 278, 632, 645, 708, 829
—analysis, identification, 1097
—assay, warfarin, 1271, 1272
—characterization, Mannich bases derived from indolizines, 486
—degradation monitoring, 193
fluorimetry—analysis, 141
fluorimetry, reverse—analysis, nornucciferines, 1654
—identification, 799
—identification, estimation, 298
—identification, lysicamine, 1654
—identification, naloxone metabolites, 1567
—identification, phenothiazines, 1346
—isolation, identification, 1516
—isolation, tetronic acids, 1503
—monitoring, quingestanol acetate separation, 1388
—reaction monitoring, 606
—separation, 104, 148, 274, 411, 477, 634, 728
—separation, analysis, 949
—separation, identification, 121, 366, 390, 448, 788
—separation, identification, estimation, 438
—separation, isolation, *B. argentea* alkaloids, 1209
Tocopherols, vitamin A in dosage forms—vitamins D_2, D_3 determination, 913
Tolazamide—GLC analysis, guinea pig plasma, 1669
***p*-Toluidines,** 5-nitrothiazole—synthesis, potential schistosomicidal agents, 1411
(+)-*trans*-2-*o*-Tolyl-*trans*-5-hydroxycyclohexanol, urinary metabolite—absolute configuration, 302
Tonic-clonic convulsions—lactam derivatives, subcortical, supraspinal CNS effects, 1058
Topical formulations—viscoelastic properties, 1356
gels, fluocinolone acetonide, fluocinonide—release, penetration, *in vivo*, *in vitro* data, 1175
gels—optimal vehicle composition, theoretical, 1180
Tortuosity, copolymer matrix—drug release-rate relationship, 212
Toxicity—hypobranchial gland of *Thais haemastoma*, 1842
nonionic surfactants—polyoxyethylene chain-length effect, 854
subacute—ethylene chlorohydrin evaluation, rats, 1163
Toxicology—organosilicon compounds, 1113
—*Renilla mulleri* (sea pansy), 1620
Toxogonin, oral administration—dose-related blood, plasma levels, oxime, 860
Transcortin binding—cortisol–corticosterone separation, determination, 1476
Transfer rate constants—salicylic acid, erythromycin, two-phase systems, 52
rates—clindamycin, 1′-demethyl-4′-depropyl-4′-pentylclindamycin, in cannulated-everted rat gut, 946
rats, *in vitro*, benzoic acids—*in vivo* absorption and physicochemical correlations, 1666
Triammonium 2-dithiocarbamyl-3-dithiocarbonylthiopropanoate, radiolabeled—metabolism studied, metabolites determined, mice, 1839
Triazenes of phenylbutyric, hydrocinnamic, phenoxyacetic, and benzoylglutamic acid esters and hydrazides—synthesis, antileukemic activity, 1192
Triazenobenzamides—synthesis, light stability, antileukemic activity, 1426
Triazenoimidazoles, benzene analogs—synthesis, antileukemic activity, 1426
Triazenopyrazoles—synthesis, decomposition by light, 554
***n*-Tridecane**—GLC analysis standard, 595
Tridihexethyl chloride—bioavailability, biokinetics, 354
2,3,5-Triiodobenzoic acid-^{14}C—placental transfer, 695
Trimetazidine metabolites, in rabbits—synthesis of related compounds, 1257
3,4,5-Trimethoxybenzamides — synthesis, evaluation as potential depressants, structure–activity relationships, 1409
2-(3,4,5-Trimethoxyphenyl)cyclohexylamines, *cis* and *trans*—*N*-methyl and *N,N*-dimethyl derivatives, synthesis as potential psychotropic agents, 632
Trimethylsilyl esters, pantothenyl alcohol, pantothenates—synthesis, determination, 909
Trioctanoin—internal standard, 913
3-Tropanyl 2,3-diarylacrylates, azo and azoxy derivatives—synthesis, evaluation as potential spasmolytic prodrug forms, 1102
Tropicamide-produced mydriasis—drug-absorption analysis, 96
mydriasis—transcorneal biophase parameters, vehicle pH influence, rabbits, 1039
Tryptamines, benzoyl, benzenesulfonyl substituted, synthesis, inhibitory activities—hydroxyindole-*O*-methyltransferase, 636
Tumors, epithelial, induced by methylcholanthrene—effect of cobalt chloride and sodium cobaltinitrite on growth, 473
inhibitors—isolation, characterization of four aporphine alkaloids from *Annona purpurea*, 1254
localizing agents—radioiodinated hypoglycemic agents, 390
Turbidimetric analysis, microbiological—automated procedures, 767
Turbula shaker mixer—dissolution-rate determinations, compared to rotating-disk method, 1874
Tylophora dalzellii—desmethyltylophorinine determined as major constituent, 1725
Tylophora indica—isolation of three new alkaloids, 1725

U

Umbelliprenin, a nonfuranoid coumarin—isolation from *Ammi majus* L. fruits, 788
Urea complexes—separation, analysis of oxytetracycline, 1544
—degradation in concentrated aqueous solution, temperature control, 1212
inclusion compound—nitrofurazone cream analysis, 295
—peritoneal dialysis, effects of variables in procedure, statistical analysis, 1520
–sulfathiazole solid dispersions—phase diagrams, *in vitro* dissolution rates, aging effect, 1333
Urinary drug metabolism—bunolol-^{14}C, dogs, 1512
excretion, chlorpromazine—daily variations, 953
excretion—methocarbamol, 104
excretion—toxogonin, 860
fecal excretion—pentaerythritol tetranitrate, 274
metabolites—absolute configuration of (+)-*trans*-2-*o*-tolyl-*trans*-5-hydroxycyclohexanol, 302
UV photometric titration—phenothiazine derivatives, analysis, 588
UV spectrophotometry—analysis, 40, 48, 111, 196, 230, 234, 238, 291, 295, 300, 314, 366, 393, 396, 429, 445, 460, 469, 561, 720, 1028, 1155
—analysis, canrenone and canrenoic acid, 1801
—analysis, enzymatic hydrolysis, 411
—analysis, furazolidone–nifuroxime suppositories, 1385
—analysis, quingestanol acetate, 1388
—analysis, tecomine, 1142
—determination, phenothiazines in blood, urine, tissues, 1346
—determination, phenylethanolamines in aspirin mixture, 1229
—ester hydrolysis monitoring, 736
—identification, 104, 148, 533
—identification, oxytetracycline, 1544
—monitoring, automated dissolution-rate testing, 1556
—monitoring, barbituric acid hydrolysis, 1145
—stability constant analysis, complexes, 845
—structure, 184, 190
—structure, identification, 793
—structure, identification, (±)-bisnorargemonine, 1634

V

Vacuum extraction—ethylene oxide, 222
Vagal stimulation effect—enterochromaffin cells, 81
Vanadium—effect on glucose metabolism, rat, 482
Variability parameters—sotalol·HCl fluorometric analysis, 833
Vasodilators—nitrate esters, 1599

Vehicle composition, membrane permeability—steroidal topical gels, 1180
composition profiles, *in vivo*, *in vitro*—fluocinolone acetonide, fluocinonide topical gels, 1175
Veratrum alkaloids, cryptenamine—hypotensive effects, side effects, in combination with methyclothiazide and reserpine, 1139
Viable, total cell counts—*E. coli* division rates, 33
Virtual temperature—application to product stability testing, 927
Viscoelasticity, destructive oscillatory testing—semisolid formulations, 1356
nondestructive oscillatory testing—semisolid formulations, 1351
—ointments, soft paraffin, emulsions, 814
Viscometry—bishydroxycoumarin, polyvinylpyrrolidone complex, 720
—continuous shear, creep, oscillatory, 814
continuous shear, creep—white soft paraffin rheology, 1198
Viscosity—effect of additives on salicylic acid–cetrimide interaction, 939
—effect on riboflavin, thiamine absorption, in man, 784
Vitamin analysis—thiamine, riboflavin, pyridoxine, and niacinamide in multivitamin preparations, 1717
Vitamin A—biological availability from sterically hindered esters, 616
Vitamin B_{12}—stomach and GI absorption, surfactant effect, rats, 1651
Vitamins D_2, D_3, determination, differentiation—dosage forms, 913
Vitamin E derivatives—antioxidant, antihemolytic activities, relationship, 643
Von Braun demethylation—novel reaction of tertiary *N*-methylethanolamines with cyanogen bromide, 1905

W

Warfarin—plasma levels, TLC and spectrophotometric assays, 1271
—small, single oral dosage plasma levels, TLC and spectrophotometric assays, 1272
tablets—*in vitro*, *in vivo* availability, 666
Water as lubricant—with sodium chloride, role in compaction process, 1704
—deoxygenation by gas permeation, 1906
recovery from crude drugs—effect and comparison of extraction procedures, 1417
Wettability and contact angles—several liquids on human skin, critical surface tension determined, 1893
White soft paraffin, rheology—work softening and recovery effects, 1198

X

Xerocomic acid, *Paxillus* cultures—isolation, identification, 1503
X-ray analysis—aspirin crystals, 267
crystallography—conformation, 3(a)-dimethylamino-2(a)-acetoxy-*trans*-decalin methiodide, 1364
diffraction—analysis, 282
diffraction—monitoring, aging sulfathiazole–urea solid dispersions, 1333
diffractometry—analysis, 699
diffractometry—identification, kaolin, bentonite, 916
powder diffraction—identification, fluprednisolone solid phase, 1485

Y

Z

Zinc in pharmaceuticals—determination, 592